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Preeclampsia is a pregnancy complication, which can suddenly 
change from a relatively mild phenotype into a life-threatening 
situation. Hypertensive disorders represent a variety of conditions 
associated with hypertension during pregnancy, including 
preeclampsia. This thesis focuses on the renal pathophysiology of 
preeclampsia, and on the challenges regarding the prediction of 
preeclampsia.
Preeclampsia complicates 2-8% of pregnancies, and remains a 
significant cause of fetal and maternal morbidity and mortality, 
both in the Netherlands1, 2 and worldwide.3 This pregnancy specific 
disorder is defined as new onset hypertension (diastolic blood 
pressure >90 mmHg) and proteinuria (>300 mg in 24h) at or 
after 20 weeks’ gestation.4 Importantly, this condition may affect 
multiple organ systems causing varying clinical features in the 
mother, such as HELLP syndrome (Haemolysis, Elevated Liver 
enzymes, and Low Platelet count), and eclampsia. In addition, 
preeclampsia is also a major cause of adverse perinatal outcomes, 
such as prematurity and intrauterine growth restriction. Poor 
early placentation and generalized endothelial dysfunction are 
thought to contribute to the pathogenesis of preeclampsia.5 
Perhaps because the exact mechanisms causing preeclampsia 
have still not been fully elucidated, the only definitive cure for 
preeclampsia is removal of the placenta. In addition, although 
prediction models based on maternal factors and biophysical and 
biochemical markers during early pregnancy are continuously 
improving, prediction of preeclampsia remains challenging.6 In 
the long run, the effect of preeclampsia is not only restricted to 
pregnancy. Increasing evidence suggests that maternal health is 
affected decades after a pregnancy complicated by hypertensive 
disorders (including preeclampsia) by an increased prevalence 
of cardiovascular and metabolic disease.7, 8 The first part of this 
introductory chapter (Part 1 – Renal consequences of preeclampsia), 
focuses on the consequences of preeclampsia in one of the major 
target organs during this syndrome: the kidney. In particular, the 
role of endothelial dysfunction, and angiogenic imbalance will 
be discussed. In the second part (Part 2 – Placental dysfunction 
in preeclampsia), the disturbed development and function of the 
placenta, which underlie renal damage during preeclampsia, will be 
explained, as well as a putative role for the complement system in 
renal injury during preeclampsia. The third part (Part 3 – Prediction 
of preeclampsia) describes the challenges in the prediction of 
preeclampsia, and subsequently focuses on the promising use 
of urinary biomarkers. The fourth and last part of this chapter 
will focus on the research questions that form the basis for the 
experiments and the studies described in this thesis (Part 4 – This 
thesis), followed by an outline of the chapters.
Part 1 Renal consequences of preeclampsia
The kidney is one of the major target organs that are severely 
injured during pregnancies complicated by preeclampsia, as 
demonstrated by the presence of proteinuria and abnormalities in 
renal histology. Because a large part of this thesis deals with the 
renal consequences of preeclampsia, an introduction to the anatomy 
of the kidney is given below.
ANATOMY 
The kidneys are the main excretory organs of the human body. They 
control extracellular volume by regulating water and salt balance, 
and acid-base homeostasis. In addition, the kidneys have hormonal 
and metabolic functions. With these functions they regulate blood 
pressure, erythropoiesis, and calcium metabolism.9 The kidney is a 
bean-shaped organ that weighs approximately 150 grams in adults, 
and is situated in the retroperitoneum. Each kidney has three major 
components: the cortex, the medulla, and the collecting ducts. The 
outermost layer, the cortex, consists of glomeruli and convoluted 




tubules. The medulla is situated more towards the center, consisting 
of pyramidal structures of parallel arranged tubular formations 
with apical papillae. The collecting ducts merge in the medulla to 
form larger ducts. From these ducts, the urine goes from the minor 
calyces to the major calyces, and then flows down the ureter to the 












Figure 1: The kidney and a nephron.
Within the kidney, blood is filtered. The urine is then further modified through functional 
units, called nephrons. Each kidney contains around one million nephrons. A nephron consists 
of a glomerulus and its attached tubules. 
Blood is supplied to each kidney by a renal artery, which arises from 
the aorta and divides into two main branches in the hilum. Each of 
these gives rise to several interlobar arteries. These arteries ascend 
between the pyramids to the cortico-medullary junction and give 
rise to arcuate arteries. Eventually, afferent arterioles branch off, 
each directing to a single glomerulus. A glomerulus represents an 
anastomosing network of capillaries, arranged in several lobules. 
The efferent vessel draining blood from the glomerulus is called the 
efferent arteriole. The efferent arterioles give rise to another network 
of capillaries; the peritubular capillaries which surround the renal 
tubules.9 A nephron, the functional unit of the kidney, consists 
of a glomerulus with attached tubules. Each kidney contains 
approximately one million nephrons. The glomerulus consists 
of different cell types, namely mesangial cells, endothelial cells, 
visceral epithelial cells (called podocytes), and parietal epithelial 
cells. Mesangial cells, together with their mesangial matrix, form the 
mesangium. Mesangial cells have an important role in regulating 
glomerular function and blood pressure.9

















Figure 2: The glomerulus and the glomerular filtration barrier.
The glomerulus is a network of capillaries that performs the first step of filtering blood. 
The glomerulus consists of different cell-types, such as mesangial cells, endothelial cells, 
podocytes, and parietal epithelial cells. Within the glomerulus, the blood is filtered from 
the capillaries. The glomerular filtration barrier consists of endothelial cells, the glomerular 
basement membrane, slit diaphragms, and podocytes. This figure was modified from Kriz et al 
10, and  Deen11 with permission from authors and publishers. 
The glomerular filtration barrier consists of endothelial cells, the 
glomerular basement membrane, slit diaphragms, and podocytes. 
The endothelial cells in the glomerulus are thin and fenestrated. 
The glomerular basement membrane surrounds the glomerular 
capillaries. The outer aspects of the glomerular capillaries are 
covered with podocytes. Each podocyte has a large body with small 
foot-like processes that interdigitate with foot-processes of adjacent 
cells. The gaps between foot processes, called filtration slits, are 
bridged via slit diaphragms. The slit diaphragm is composed of 
specific proteins, including nephrin. Blood is filtered through these 
slits, and the slit diaphragm—together with endothelial cell layers 
and the glomerular basement membrane—restricts the passage of 
any large or negatively charged molecules. Water, the remaining 
small proteins, and electrolytes now enter Bowman’s space, which 
is aligned by visceral and parietal epithelial cells. As Bowman’s 
space is continuous with the lumen of the renal tubule, the pre-
urine now first enters the proximal tubules. The pre-urine is further 
concentrated after selective reabsorption of water and essential 
molecules in the loop of Henle and the distal tubule.
THE KIDNEY DURING PREECLAMPSIA: EFFECT OF ANGIOGENIC 
IMBALANCE
During preeclampsia, a characteristic glomerular lesion is observed 
called ‘glomerular endotheliosis’, which represents swelling of 
endothelial cells, and may result in a ‘bloodless’ appearance.12-14 
Electron microscopy shows loss of endothelial fenestration. 
Although glomerular endotheliosis can also be observed in 
healthy pregnancies,15  it is more prominent and widespread in 
preeclampsia.16 Endothelial swelling usually disappears within 
eight weeks following delivery, together with hypertension and 
proteinuria.17
Swelling of endothelial cells, similar to that seen in preeclampsia, 
develops in podocyte-specific vascular endothelial growth factor–A 
(VEGF-A) knockout mice, which suggests that VEGF-A—produced 




by podocytes—plays a role in the maintenance of the glomerular 
endothelium.18 Human preeclampsia is characterized by significantly 
decreased concentrations of VEGF-A,19, 20 which suggests that loss 
of VEGF-A is one of the major factors causing glomerular injury 
during this pregnancy complication. 
VEGF-A-signaling between podocytes and endothelial cells 
is thought to be crucial for the maintenance of the glomerular 
filtration barrier. VEGF-A has many physiological functions, 
including regulation of proliferation, angiogenesis, lymphogenesis, 
endothelial cell permeability, and vasodilation.21, 22 VEGF-A 
signaling is mediated via two receptors, namely VEGF-R1/ Flt-1 and 
VEGFR2/Flk-1.22 VEGF-A is expressed in practically every tissue in 
the human body. Tissues with fenestrated endothelium, such as the 
kidney, have the highest density of VEGF-A-expressing cells.21, 22 
Both VEGF-A and VEGF Receptors (VEGFRs) are abundantly present 
in the kidney. VEGFRs are expressed on endothelial, mesangial, and 
peritubular capillary cells.23
The anti-angiogenic factor soluble fms-like tyrokinase (sFlt-
1) is the soluble form of the vascular endothelial growth receptor 
1 (VEGF-R1), and the preeclamptic placenta releases excessive 
amounts of sFlt-1.19, 24, 25 Since sFlt-1 neutralizes VEGF-A, sFlt-1 
prevents VEGF-A from binding to its membrane-bound receptor. 
Adenoviral overexpression of sFlt-1 in mice causes proteinuria, 
hypertension, and swelling of glomerular endothelial cells.25 These 
symptoms also develop in patients with malignant tumours treated 
with VEGF-A-inhibitors, such as bevacizumab.18 Taken together, 
these studies underscore the notion that lack of VEGF-A—via 
inactivation of VEGF-A through high sFlt-1 concentrations—plays 
an important role in the development of endotheliosis in the 
glomerulus during preeclampsia.
VEGF-A inhibition leads to endotheliosis and proteinuria in 
preeclampsia, but the underlying mechanisms are not yet fully 
elucidated, and multiple factors seem to play a role. The glomerular 
endothelial injury during preeclampsia might not exclusively result 
from increased sFlt-1 concentrations. For example, hypertension 
and its accompanying high shear stress during preeclamptic 
pregnancy might result in injury of the glomerular endothelium as 
well. Perhaps, hypertension-induced injury makes the glomerular 
endothelium even more sensitive to the high concentrations of sFlt-
1, which will aggravate the endothelial injury. 
Injury to the endothelial cell might also affect the nearby 
podocytes via different mechanisms. Firstly, as mentioned before, 
the VEGF-A-signaling between podocytes and endothelial cells 
is thought to be crucial for the maintenance of the glomerular 
filtration barrier. When this ‘crosstalk’ between podocytes and 
endothelial cells is interrupted during preeclampsia through 
increased sFlt-1 concentrations, podocytes may become injured.23 
Secondly, neutralization of VEGF-A induces the release of 
endothelin-1 (ET-1) from endothelial cells. ET-1 triggers shedding 
of nephrin (an important podocyte-specific protein which is 
involved in the maintenance of the glomerular permeability) from 
podocytes.26 Considering these observations, it is highly likely 
that podocytes are injured in the setting of preeclampsia. Injured 
podocytes may detach from the glomerular basement membrane, 
and consequently be shed into the urine.27 Indeed, increased loss of 
podocytes in urine—from here on referred to as ‘podocyturia’—was 
found in women with preeclampsia.27 Podocyturia in the setting of 
preeclampsia is discussed in detail in the section ‘Urinary footprints: 
podocyturia’ on page 29 in this Introduction.
Because knowledge on the function of the placenta during 
preeclampsia is essential to understand the renal pathophysiology, 
an introduction on placental dysfunction during preeclampsia is 
given below. 




Part 2 Placental dysfunction in preeclampsia
IMPAIRED PLACENTAL IMPLANTATION IN PREECLAMPSIA
The pathophysiology of preeclampsia is usually divided into 
two stages.28 The preclinical stage is characterized by abnormal 
placental development, whereas the clinical stage is associated 
with dysregulation of angiogenic factors and systemic endothelial 
dysfunction. The abnormal placental development that characterizes 
the first stage of the pathophysiology of preeclampsia is associated 
with impaired remodeling of spiral arteries.5, 29 In normal pregnancy, 
the remodeling of the uterine spiral arteries occurs via different 
steps.30 Around implantation, vascular changes arise in the endo- 
and myometrium and, subsequently, trophoblast invasion of the 
uterine vessels starts. Initially, endovascular trophoblast cells 
migrate down the lumen of spiral arteries.  In the first period, these 
cells occlude these arteries. This early plugging by trophoblast 
cells protects the embryo against a high oxygen environment.31 
When embryogenesis is complete after 10-12 weeks, these plugs 
are gradually resolved by intravascular migration of trophoblast 
cells. Consequently, the intervillous circulation is fully established, 
and oxygen concentrations within the placenta increase. In 
preeclampsia, the process of endovascular trophoblast invasion 
is impaired, leading to placental flow defects. In the majority of 
patients who develop preeclampsia, placental flow defects can 
be detected as early as 12 weeks of gestation.32-34 Flow defects 
may result in placental oxidative stress, which may predispose a 
woman to preeclampsia.35 It has been suggested that an important 
underlying cause of the impaired placentation is an aberrant 
interaction between the maternal and fetal (trophoblast) immune 
system.36
ANGIOGENIC IMBALANCE AS A CONSEQUENCE?
The second stage of preeclampsia is characterized by dysregulation 
of angiogenic factors followed by the clinical manifestations of 
the syndrome. The aforementioned placental flow defects in the 
first stage are believed to result in placental dysfunction. The 
preeclamptic placenta releases excessive amounts of the anti-
angiogenic factors sFlt-1, and soluble endoglin (sEng).19, 24, 25, 37  
By neutralizing VEGF-A and placental growth factor (PlGF), sFlt-
1 prevents these factors from binding to its membrane-bound 
receptors. Endoglin is a co-receptor for transforming growth factor 
B (TGF-β). The soluble form, sEng, binds and neutralizes TGF-β. 
The factors VEGF-A, PlGF, and TGF-β are essential for normal 
endothelial function and maintenance. As a consequence, low 
concentrations of these factors in the setting of preeclampsia are 
thought to result in endothelial dysfunction.38 The important role 
of sFlt-1 and sEng in the pathophysiology of preeclampsia has 
been demonstrated in animal models, in which administration 
of these anti-angiogenic factors induces the manifestations of 
preeclampsia.25, 37











Figure 3: The placenta and syncytial knot formation. 
The placenta provides the fetus with oxygen and nutrients. The outermost layer of the 
placenta is called the syncytiotrophoblast. The syncytiotrophoblast forms multinucleated 
placental fragments called  ‘syncytial knots’. The knots—called syncytial aggregates upon 
their release from the placenta —are shed into the maternal circulation.    
SHEDDING OF PLACENTAL FRAGMENTS CONTRIBUTES TO 
ENDOTHELIAL DYSFUNCTION
Within the placenta, the anti-angiogenic factors are produced 
by the outermost layer of the placental villi.39 This outermost 
layer of the placenta is a multinucleated structure called the 
syncytiotrophoblast. During both normal pregnancy and 
preeclampsia, the syncytiotrophoblast forms so called ‘knots’, which 
are multinucleated placental fragments. These syncytial knots—
called syncytial aggregates upon their release from the placenta—
are shed into the maternal circulation. Importantly, a recent 
study showed that these syncytial knots contain high amounts 
of the anti-angiogenic protein sFlt-1, particularly in women with 
preeclampsia.40 Moreover, circulating syncytial aggregates remain 
transcriptionally active for at least 48 hours.40 The formation of 
these knots is markedly increased in the preeclamptic placenta.40 
In addition, in preeclampsia in particular, these syncytial knots are 
released into the maternal circulation.41, 42 This makes it is possible 
that these aggregates may serve as an autonomous source of sFlt-1 
protein within the maternal circulation, thereby contributing to the 
generalized endothelial dysfunction that characterizes preeclampsia. 
This idea has been further supported by in vitro experiments 
showing that syncytiotrophoblast fragments interfere with 
endothelial cell growth.43, 44
ENDOTHELIAL DYSFUNCTION
Altogether, the angiogenic imbalance that characterizes 
preeclampsia leads to generalized endothelial dysfunction. 
Numerous studies have shown that preeclampsia is characterized by 
endothelial injury. Women with preeclampsia are characterized by 
decreased flow-mediated vasodilatation.45, 46 Furthermore, in vitro 
experiments have shown that serum from women with preeclampsia 
is capable of altering endothelial function.47, 48 Importantly, the 
clinical findings of severe preeclampsia may be explained by 
endothelial dysfunction in the different target organs including the 




brain (eclampsia or seizures), the liver (the hemolysis, elevated liver 
function, and low platelet count (HELLP) syndrome), and the kidney 
(proteinuria). 
IS THERE MORE?
Preeclampsia is believed to result from an imbalance in pro- and 
antiangiogenic factors, and it is evident that reduced VEGF-A-
signaling plays an important role in the pathogenesis of the renal 
lesions in preeclampsia. However, not all women with preeclampsia 
have increased sFlt-1 serum concentrations,19 which suggests 
that other factors may be involved. Recently, increasing evidence 
points towards the involvement of complement activation in the 
pathogenesis of preeclampsia. 
COMPLEMENT SYSTEM
The complement system is part of the innate immune system. Where 
the adaptive immune system is acquired during life, the innate immune 
system acts in a non-specific manner and is present at birth. The 
innate immune system provides immediate defense against infections, 
therefore it is called the ‘first line of defense’. The complement system 
defends the host against infection, but it also provides a bridge 
between the adaptive and the innate immune system. In addition, 
it is involved in the clearance of necrotic and apoptotic cells.49 The 
complement system consists of more than 30 proteins in plasma and 
on cell surfaces, of which a schematic overview is shown in Figure 4. 
Activation of the system is highly regulated, as it needs to be ready 
for action at all times.50, 51 Specific triggers, like an invading pathogen, 
can initiate a cascade of amplifying enzymatic reactions and positive 
feedback loops which are also known as complement activation 
pathways. There are three different pathways that can activate the 
complement system, namely the classical, the lectin, and the alternative 
pathway. Activation of any of the three pathways is triggered by 
specific initiators, but they do share a final common pathway as all 
three pathways converge at the level of C3. 
The classical pathway becomes activated when its recognition 
molecule C1q binds to immune complexes, i.e., antibodies bound 
to an antigen, or to apoptotic cells. After an antibody response has 
developed, this pathway links innate immunity to B-cell mediated 
immune activity.  However, activation of the classical pathway 
can also lead to tissue injury and graft rejection via deposition of 
antibodies. Deposition of auto- and alloantibodies might occur in 
the setting of auto-immune diseases and organ transplantation, 
which illustrates that the complement system can act as friend or 
foe.52
The lectin pathway is initiated by binding of mannose-binding 
lectin or ficolin to mannose (carbohydrates) on the surfaces of 
pathogens.50, 51 After recognition of the pathogen, the lectin pathway 
follows the same steps as the classical pathway, via C4 and C2, 
leading to activation of the final common pathway. This overlap 
between the classical and lectin pathway makes it difficult to 
distinguish between these two routes. 
The last pathway, the alternative pathway, mainly amplifies the 
reactions initiated by the classical- and the lectin pathway, thereby 
providing a positive feedback loop. To achieve this function, the 
alternative pathway is constantly being activated by the hydrolysis 
of C3. Whenever C3 is activated by the classical or lectin pathway, 
Factor D and B immediately bind to it. This complex is stabilized by 
the presence of properdin, leading to the formation of an enzyme 
that leads to more C3 activation, resulting in a positive feedback 
loop. At the same time, this pathway is strictly regulated to prevent 
excessive activation. 
Activation of the complement system has various effects. Firstly, 
it leads to the release of anaphylatoxins, C3a and C5a, thereby 
attracting leukocytes. Secondly, opsonization of the target with 
specific membrane-bound fractions allows phagocytosis. Lastly, 
activation of the complement system leads to the generation of the 
lytic Membrane Attack Complex (MAC). 




This complex of enzymes creates pore-like structures on cell 
membranes, leading to cell lysis and, eventually, cell death. Given 
the multitude of effects that the complement system can exert, 
there are mechanisms in place to limit complement activation 
where and when it occurs.53 Probably for this reason, almost half 
of all complement components have regulatory functions.54 These 
complement regulatory proteins are either membrane-bound 
or soluble, and protect the host tissue by inhibiting activation, 
amplification, and the formation of the MAC. Membrane-bound 
complement regulatory proteins are abundantly present on tissues 
that are in direct contact with blood, which contains complement 
components. Illustratively, complement regulatory proteins are 
highly expressed on endothelial cells, and on placental- and 
renal tissues.55, 56 Soluble regulators, such as factor H, I, and C4-
binding protein, regulate the alternative pathway by preventing 
amplification of the cascade, which results in blockade of the 
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Figure 4: A schematic overview of the complement system.
THE ROLE OF COMPLEMENT IN PREECLAMPSIA
Increasing evidence suggests that complement dysregulation is 
involved in the development of preeclampsia. Firstly, within the 
placenta, preeclampsia is associated with excessive complement 
activation at the fetal-maternal interface.57-59 Secondly, elevated 
concentrations of complement degradation products in both serum 
and urine samples are found in women with preeclampsia.60, 61 
Finally, mutations in genes encoding for complement regulatory 
proteins have been found in women with preeclampsia,62 and in 
HELLP syndrome.63 In people with either inherited or acquired 
mutations in their genes encoding for complement regulatory 
proteins, one would perhaps expect systemic complement activation. 
Clinically, however, these mutations are primarily associated 
with atypical Hemolytic Uremic Syndrome (aHUS), which is often 
affecting the kidney. This finding suggests that particularly the 
kidney is vulnerable to excessive complement dysregulation.64
COMPLEMENT ACTIVATION AND THE KIDNEY
Within the kidney, the fenestrated endothelium that lines the 
glomerular basement membrane is  particularly vulnerable to 
complement activation as demonstrated in a variety of renal diseases.65 
The anatomic composition of the renal endothelium is thought to 
cause this susceptibility, as the fenestrated structure allows immune 
complexes to deposit more easily than in the normal inner layer 
of a vessel.66 High vascular stress and hypertension might result in 
additional injury of the glomerular endothelium. During preeclampsia—
characterized by hypertension—excessive sFlt-1 concentrations may 
provide the additional hit which aggravates endothelial injury. It 
has been shown that injury to the renal endothelium can lead to 
complement activation.67 So the observation that preeclampsia is 
characterized by complement dysregulation, combined with severe 
endothelial injury within the kidney during preeclampsia suggests 
that complement activation might play an important role in the renal 
complications of preeclampsia.




CONSEQUENCES OF RENAL INJURY: FOOTPRINTS IN URINE
Regardless of which mechanism is responsible for renal injury 
during preeclampsia, it is evident that extensive kidney injury 
is present, as shown by—sometimes severe—proteinuria.  During 
preeclampsia not only proteins are lost in urine, but also podocytes, 
and—most likely—other smaller molecules. The combination of 
these markers could result in a ‘urinary footprint’ specific for 
preeclampsia. Whether specific urinary biomarkers might help to 
distinguish preeclamptic patients from control subjects early in 
pregnancy is discussed below.
Part 3 Prediction of preeclampsia
PREDICTION IS CHALLENGING
Predicting who will develop preeclampsia remains challenging. 
The ability to predict preeclampsia is currently of limited benefit 
because in most patients neither the development of the disorder 
nor its progression from mild to severe disease can be prevented, 
and there is no cure except delivery. Nevertheless, the accurate 
identification of women at risk, early diagnosis, and appropriate 
management (such as antenatal corticosteroids for fetal lung 
maturation, treatment of severe hypertension, and early delivery) 
may improve maternal outcome, and possibly fetal outcomes as 
well. A good test for predicting who will develop preeclampsia 
should be rapid, simple, non-invasive, inexpensive, and easy-to-
perform.68 In particular, a test should adequately predict whether 
a condition, such as preeclampsia, will develop. For this purpose 
likelihood ratios are used, of which two versions exist: one for 
positive, and one for negative test results. The ‘likelihood ratio 
positive’ is defined as the probability of a person who has the 
disease testing positive (sensitivity) divided by the probability of a 
person who does not have the disease testing positive (1-specificity). 
The ‘likelihood ratio negative’ is defined as the probability of a 
person who has the disease testing negative (1-sensitivity) divided 
by the probability of a person who does not have the disease testing 
negative (specificity). A good test for preeclampsia should have 
a likelihood ratio positive >15, and a likelihood ratio negative 
<0.1.69 Ideally, early prediction of preeclampsia should provide an 
opportunity for preventive strategies and close surveillance. Many 
tests to predict preeclampsia have been assessed for their relation to 
vascular resistance, endothelial dysfunction, fetal-derived products, 
and hormones. However, in a systematic review only a few tests 
reached a specificity above 90%, and no single test met the clinical 
standards for a predictive test.70 Although no single marker seems 
to be able to reliably predict such a heterogeneous syndrome as 
preeclampsia, prediction models based on combined information 
on maternal factors, biophysical,- and biochemical markers during 
early pregnancy are continuously being improved and show 
promising high sensitivity and specificity.6 However, these models 
still need optimization, and the use of urinary biomarkers for the 
prediction of preeclampsia might be worthwhile. 
URINARY FOOTPRINTS: PODOCYTURIA
The role of podocyte injury in proteinuric kidney disease has been 
the subject of extensive research in diverse settings. Evidence was 
found that urinary excretion of viable podocytes is confined to a 
phase of active ongoing glomerular damage.71 Interestingly, previous 
studies have reported significantly higher levels of podocytes in 
urine of patients with atypical HUS,72 IgA-nephropathy,73 diabetes 
mellitus,74 lupus nefritis,75 and focal segmental glomerulosclerosis 
(FSGS),75 which were shown by either immunohistochemistry 
on cultured podocytes or increased podocyte mRNA levels using 
quantitative Polymerase Chain Reaction (qPCR). These results 
suggest that podocytes are shed from the glomerulus in disease 
states. Interestingly, podocytes appear to be lost—although to a 
much lesser extent—in urine of healthy subjects as well.75 Although 
it remains debatable what the underlying mechanism for this 




phenomenon is, it could be speculated that podocytes are shed 
because they are senescent, and that their loss is compensated for 
by other glomerular cells. In preeclampsia, Garovic et al27 showed 
for the first time that the presence of podocyturia, detected with 
podocyte specific immunohistochemical stainings on cultured 
podocytes, is a highly sensitive and specific method for the 
detection of this syndrome at disease onset. The method used in 
this study is labour-intensive, and time-consuming. Part of the 
work described in this thesis has therefore been focused on another 
method to detect podocytes in urine of women with preeclampsia.
URINARY FOOTPRINTS: METABOLOMICS
In addition to cells, small molecules are probably voided in the 
urine of women with preeclampsia as well. These small molecules 
are called metabolites. The set of metabolites that reflects the 
organism under a particular set of conditions is called the 
metabolome.76 The metabolome is the product of genetic and 
environmental conditions, and provides a new logical framework 
to elucidate disease etiology. Analyzing metabolites in body fluids, 
such as plasma and urine, provides information that cannot directly 
be obtained from the genotype or gene expression profiles. More 
importantly, the metabolome putatively contains crucial information 
on disease development.77
High-tech procedures allow analysis of the metabolome, in which 
many molecules are identified in one single experiment.77 One of 
the techniques to discriminate between different metabolites, is 
analyzing their magnetic properties. This technique is called nuclear 
magnetic resonance spectroscopy, and allows identification and 
quantification of many metabolites in one sample. To identify the 
origin of the metabolites, their magnetic characteristics are matched 
to a metabolite database. This analysis may provide a deeper 
understanding of interactions between different systems involved 
in the pathophysiology of a particular disease. It is therefore 
imaginable that a large-scale analysis of metabolites would 
provide—in addition to prediction of a disease—much more insight 
in disease etiology. 
In the setting of preeclampsia, metabolomics analysis has 
recently been performed in plasma. In the first trimester of 
pregnancy, plasma samples were collected from women who later 
during pregnancy developed preeclampsia.78-80 The metabolomic 
profiles of the women who later developed preeclampsia were 
distinct from those of pregnant control subjects in all studies. 
In contrast to plasma samples, the technique for obtaining urine 
samples has the benefit of being non-invasive, and relatively easy. 
In disease settings other than preeclampsia, predictive metabolomic 
profiles have been successfully defined in urine samples.81, 82 Given 
the fact that the kidney is one of the major target organs which 
is severely injured during preeclamptic pregnancy combined with 
the non-invasive character of the technique for obtaining urine 
samples, in the work described in this thesis we investigated 
whether urinary metabolomics analysis can be used for the 
prediction of preeclampsia.
Part 4 This thesis
In preeclampsia, not only the fetus and its growth are affected, 
but severe maternal morbidity can occur as well, even leading 
to maternal mortality. Further unraveling the pathophysiologic 
mechanisms underlying this systemic syndrome could contribute 
to the development of diagnostic tools and the identification 
of therapeutic targets. This thesis focuses on the prediction and 
the systemic—in particular the maternal renal—consequences of 
preeclampsia.




AIMS OF THE WORK DESCRIBED IN THIS THESIS
•	 To explore whether placenta-derived fragments are retained in the 
maternal lung, and whether they still retain the anti-angiogenic 
factor sFlt-1  
•	 To investigate the relation between complement dysregulation in the 
kidney and preeclampsia
•	 To determine whether the podocyte number within the glomeruli 
in preeclampsia is altered and whether this is compensated for by 
recruitment of other cells
•	 To investigate the relationship between urinary podocyte loss and 
preeclampsia
•	 To explore whether a distinctive urinary metabolomic profile in the 
first trimester is predictive for preeclampsia.
THESIS OUTLINE
In the studies described in chapters 2, 3, and 4 we investigated 
autopsy samples from women who died during pregnancy, 
either with or without preeclampsia. The placental expression of 
sFlt-1 is explored in the studies described in chapter 2, which 
furthermore focus on the systemic spread of placenta-derived 
fragments in preeclampsia, and their contribution to sFlt-1 
expression. Complement activation plays an important role in the 
pathophysiology of preeclampsia, as is shown by genetic mutations 
and increased concentrations of complement activation products 
in both serum and placentas from preeclamptic women. Given the 
fact that the complement system is involved in many renal diseases, 
combined with the observation that the kidney is one of the major 
target organs in preeclampsia, the studies described in chapter 
3 were designed to explore complement activation in kidneys of 
women with preeclampsia. In the studies described in chapter 4, we 
further investigated the renal injury in women with preeclampsia, 
with a special focus on changes in podocyte numbers, and possible 
compensating mechanisms for podocyte injury and loss. With so 
many systemic and renal changes occurring during preeclampsia, 
changes in urine may be found, providing ‘urinary biomarkers’ 
of preeclampsia. Therefore, the studies described in chapters 5 
and 6 were devoted to changes observed in urine of women with 
preeclampsia. A new technique to detect loss of podocytes in 
urine of women with preeclampsia was investigated in the studies 
described in chapter 5. To further explore the pathophysiology of 
preeclampsia, the studies described in chapter 6 were devoted to a 
urinary metabolomics analysis in the first trimester of pregnancy 
to predict preeclampsia. In chapter 7, the general discussion, the 
findings of the work described in this thesis are summarized and 
placed in a more general perspective. The general discussion is 
followed by a summary in Dutch. 
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Abstract
Preeclampsia is associated with increased levels of the circulating 
anti-angiogenic factor sFlt-1 and with an excessive shedding of 
placenta-derived multinucleated syncytial aggregates into the 
maternal circulation. However, it remains unclear whether these 
aggregates are transcriptionally active in the maternal organs 
and can therefore contribute to the systemic manifestations of 
preeclampsia.
In this study, we measured placental sFlt-1 mRNA levels in 
preeclamptic- and control placentas and performed RNA in situ 
hybridization to localize the main placental expression site of sFlt-1 
mRNA. Because the maternal lung is the first capillary bed that 
circulating syncytial aggregates traverse, we studied the presence 
and persistence of placental material in lungs of preeclamptic and 
control subjects. To confirm the placental origin of these aggregates 
in maternal lungs, immunohistochemistry for the placenta-
specific marker hCG and Y-chromosome in situ hybridization were 
performed.
Using human placental tissue, we found that syncytial knots 
are the principal site of expression of the anti-angiogenic factor 
sFlt-1. In addition, autopsy material obtained from women with 
preeclampsia (n=9), showed significantly more placenta-derived 
syncytial aggregates in the lungs than in control subjects (n=26). 
Importantly, these aggregates still contained the anti-angiogenic 
factor sFlt-1 following their entrapment in the maternal lungs.
The current study confirms the important role of syncytial 
knots in placental sFlt-1 mRNA production. Additionally, it 
shows a significant association between preeclampsia and larger 
quantities of sFlt-1 containing syncytial aggregates in maternal 
lungs, suggesting that the transfer of syncytial aggregates to the 
maternal compartment may contribute to the systemic endothelial 
dysfunction that characterizes preeclampsia. 
Introduction
Preeclampsia is a severe, pregnancy-specific syndrome that 
is characterized by endothelial dysfunction and presents with 
hypertension and proteinuria after the 20th week of gestation. 
Therapeutic options are limited beyond delivery of the fetus and 
placenta and therefore, preeclampsia remains one of the major 
causes of fetal and maternal morbidity and mortality worldwide, 
and particularly in developing countries.1
The widespread endothelial dysfunction that characterizes 
preeclampsia is believed to be due to an imbalance between pro- 
and anti-angiogenic factors.2, 3 The placenta is a major source 
of circulating anti-angiogenic factors during both normal and 
preeclamptic pregnancies.3-6 In preeclampsia in particular, the 
outermost layer of the placenta—the syncytiotrophoblast—forms 
“knots” that contain high amounts of the anti-angiogenic protein 
sFlt-1.7 These syncytial knots are released into the maternal 
circulation, thereby becoming syncytial aggregates that can become 
lodged in maternal organs.8-10 Importantly, a recent study showed 
that upon their release, circulating syncytial aggregates remain 
transcriptionally active and likely serve as an autonomous source of 
sFlt-1 protein within the maternal circulation.7
We hypothesized that in preeclampsia, syncytial knots are the 
primary placental site of sFlt-1 production and that increased 
numbers of sFlt-1-containing syncytial aggregates are retained 
in the maternal lungs. To test this hypothesis, we first studied the 
expression of sFlt-1 in both normal and preeclamptic placentas. 
Next, we used placenta- and fetus-specific markers to investigate 
the presence of sFlt-1-containing syncytial aggregates in the lungs 
of women with preeclampsia and control subjects. 
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Methods
PATIENT SELECTION AND TISSUE COLLECTION
Placentas were obtained from preeclamptic11 (n=32) and control 
(n=37) subjects who delivered at the Leiden University Medical 
Center (LUMC), the Netherlands from 2007 through 2010. All 
women gave written informed consent. Parallel to the collection of 
placenta material, autopsy samples from women who died during 
pregnancy were obtained via a nationwide search using the Dutch 
PALGA system, a histopathology and cytopathology network 
and archive that includes all pathology laboratories within the 
Netherlands.12 The paraffin-embedded lung samples obtained from 
nine preeclampsia patients and 26 pregnant control subjects were 
provided by collaborating laboratories. The control subjects were 
women who died due to a cause other than a hypertensive disorder 
of pregnancy. The cause of death in each case was confirmed using 
the records of the National Maternal Mortality Committee of the 
Dutch Society of Obstetrics and Gynecology. To investigate the 
effect of pregnancy on maternal aggregates, an additional control 
group (n=11) comprised of non-pregnant, non-hypertensive women 
was included. All tissues were coded and handled anonymously 
in accordance with the Dutch National Ethics Guidelines (Code 
for Proper Secondary Use of Human Tissue, Dutch Federation of 
Medical Scientific Societies). This study was approved by the ethics 
committee of the LUMC.  
PLACENTAL sFlt-1 mRNA EXPRESSION
SYBR Green quantitative PCR was performed to quantify 
the placental sFlt-1 mRNA levels. The expression of sFlt-
1 was normalized to the expression of hypoxanthine 
phosphoribosyltransferase (HPRT) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). All cDNA samples were measured in 
duplicate. In addition, in situ hybridization was performed to 
identify the cells in the placenta that synthesized sFlt-1 mRNA. 
Accordingly, an RNA probe was prepared to specifically recognize 
sFlt-1 but not Flt-1 mRNA. Four placentas per group were 
examined. 
IMMUNOHISTOCHEMISTRY
To test for the presence of placental material in the maternal 
lungs, lung tissues from preeclamptic women were stained 
immunohistochemically for the trophoblast-specific marker hCG. 
If hCG-positive syncytial aggregates were observed, sequential 
sections were stained for Flt-1 protein to determine whether these 
syncytial knots still contained this anti-angiogenic protein.7 The 
control group was also screened using hCG staining to determine 
the specificity of these syncytial aggregates to preeclampsia. 
Sections were incubated with an anti-human beta-hCG antibody 
(1:1600, DakoCytomation) or an anti-human Flt-1 antibody (1:100, 
R&D Systems). Binding of the primary antibody was visualized 
using the appropriate secondary antibodies with diaminobenzidine 
as the chromogen. Placental tissue served as a positive control.
Y CHROMOSOME IN SITU HYBRIDIZATION
A DIG-labeled DNA probe that specifically recognizes the Y 
chromosome13 was used to determine whether the putative 
syncytiotrophoblast aggregates in the maternal lungs were of fetal 
origin. Sections of lungs from women who had carried a male 
fetus were incubated with the DIG-labeled probe. To visualize the 
probe, the sections were incubated first with a mouse-anti-DIG 
monoclonal antibody (Sigma-Aldrich) followed by goat-anti-mouse 
IgG Alexa-647 (Invitrogen). 
QUANTIFICATION OF STAINING 
The number of sFlt-1 mRNA positive syncytial knots was counted 
by two independent observers who were blind with respect to the 
groups. Two observers also scored the lung sections for the absence 
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or presence of hCG. When hCG-positive multinucleate aggregates 
were present, the sequential sections were tested for the co-
localization of hCG with Flt-1 protein and the Y chromosome. 
Results
CLINICAL DATA
Placentas were investigated from women with preeclampsia (n=32) 
and pregnant controls (n=37). Gestational age in the women with 
preeclampsia (mean 30.6 weeks, SD 1.3 weeks) was significantly 
lower than the controls (mean 39.6 weeks, SD 1.7 weeks; p<0.05). 
Clinical data of the women whose lungs were investigated is 
provided in Table 1. Furthermore, in these women, the presence 
of pulmonary edema was investigated at the clinical, gross and 
microscopic levels. Neither the presence of clinical symptoms of 
pulmonary edema nor evidence of pulmonary edema on either 
gross or microscopic examination differed significantly between the 
groups.
INCREASED PLACENTAL sFlt-1 mRNA EXPRESSION IN 
PREECLAMPSIA
To compare the levels of sFlt-1 mRNA in the preeclamptic and 
control placentas, quantitative PCR was used to measure sFlt-1 
mRNA. On average, the placental sFlt-1 mRNA levels were six-
fold higher in the preeclamptic placentas than in the placentas 
obtained from control subjects (p<0·001, Mann-Whitney test). The 
preeclamptic placentas had more intense sFlt-1 staining (measured 
using in situ hybridization) than control placentas, particularly in 
the syncytial knots (Figure 1). In addition, the number of syncytial 
knots was significantly higher in the preeclamptic women than 
in the control subjects (p<0·05, Figure 1). As expected, the sense 
control probe was negative in all samples (Figure 1). 
THE PRESENCE OF HCG POSITIVE AGGREGATES IN MATERNAL 
LUNGS IS SIGNIFICANTLY ASSOCIATED WITH PREECLAMPSIA 
Because hCG was highly expressed within the syncytial knots, 
we considered hCG to be a suitable specific marker to study the 
presence of syncytiotrophoblast aggregates in maternal lungs. 
hCG-positive multinucleate aggregates were observed in the lungs 
of six of the nine preeclamptic women. Following the observation 
that syncytial aggregates were present in the lungs of women 
with preeclampsia, we also stained control lung sections for 
hCG. Syncytial aggregates were observed in the lung samples of 
six of the 26 pregnant control subjects. Importantly, the women 
with preeclampsia had a significantly higher number of syncytial 
aggregates per 100 mm2 lung tissue (p<0·05, Mann-Whitney test, 
Figure 2). Syncytial aggregates were found in the pregnant control 
subjects whose gestational age was 10-40 weeks and in preeclamptic 
women with a gestational age of 32-39 weeks. We performed a 
separate analysis to exclude any potential effect of gestational age. 
Because the shortest gestational age in the preeclampsia group 
was 30 weeks, we performed an analysis in which we excluded 
the control subjects with a gestational age shorter than 30 weeks. 
Importantly, even though the gestational age of the resulting 
subset of controls was now similar to the preeclamptic women, 
the number of syncytial aggregates remained significantly higher 
in the preeclampsia group (p < 0.05; see Figure S1 in the online 
supplement). Aggregates were observed in subjects who died up 
to 13 days after delivery. The lung samples obtained from the 
additional control group of non-pregnant, non-hypertensive women 
contained no syncytial aggregates. The number of aggregates was 
not associated with gestational age, maternal age or the severity of 
preeclampsia.
On renal pathophysiology in preeclampsia
46  
II. Preeclampsia is associated with the presence of transcriptionally active placental  
    fragments in the maternal lung
47
SYNCYTIOTROPHOBLAST AGGREGATES IN THE MATERNAL LUNG 
RETAIN THE sFlt-1 PROTEIN
To test our hypothesis that syncytial aggregates retain sFlt-
1 protein after transferring to the maternal compartment and 
becoming entrapped in the maternal lung, we stained the hCG-
positive aggregates in the maternal lung samples for Flt-1 protein. 
Staining sequential sections for Flt-1 and hCG revealed that these 
proteins were co-localized within the aggregates (Figure 2). In the 
preeclampsia group, 56% of all hCG-positive aggregates were also 
positive for Flt-1; in contrast, in the control group, 26% of the 
syncytial aggregates were positive for Flt-1 protein (p<0.05; see 
Figure 3).
Y CHROMOSOME IN SITU HYBRIDIZATION STRONGLY SUPPORTS 
THE IDEA THAT MULTINUCLEATE AGGREGATES ARE OF FETAL 
ORIGIN
To confirm our hypothesis that the multinucleated syncytial 
aggregates in the maternal lung were of placental—and therefore 
fetal—origin, we performed Y chromosome in situ hybridization in 
lung samples obtained from women who were carrying a male fetus. 
A sequential section was used to investigate co-localization with 
hCG and Flt-1. We observed Y chromosome positive aggregates in 
the maternal lung samples, and sequential sections showed co-
localization between the Y chromosome and both hCG and Flt-1 
(Figure 2).
Discussion
Here, we report that multinucleate aggregates in the maternal lungs 
originate from the syncytiotrophoblast, and that these aggregates 
retain the anti-angiogenic protein sFlt-1. Syncytial knots—which 
become syncytial aggregates upon release from the placenta—are 
rich in sFlt-1 mRNA and protein, suggesting that these structures 
are the primary placental site of sFlt-1 production. The systemic 
spread of these syncytial aggregates was confirmed by the presence 
of hCG-positive multinucleate aggregates in the lungs of pregnant 
women, and the number of syncytial aggregates in the maternal 
lungs was significantly higher in the women with preeclampsia. Co-
localization of hCG with both the Y chromosome and sFlt-1 levels 
strongly supports the idea that these aggregates are of fetal origin 
and shows that these aggregates contain sFlt-1 even after their 
release from the placenta.
Our finding that syncytial knots are the primary placental site 
of sFlt-1 mRNA synthesis is in agreement with the observations 
that syncytial knots have the highest placental levels of sFlt-1 
protein and that these knots are more numerous in the setting of 
preeclampsia.7, 14 Syncytial knots detach readily from the placenta, 
becoming syncytial aggregates that circulate in the maternal blood.7 
It has long been known that circulating placental material—most 
likely trophoblast cells—can reach maternal organs, particularly the 
lungs.10 Using co-localization of hCG with the Y chromosome, we 
show that the placental multinucleate aggregates in the maternal 
lung were derived from the syncytiotrophoblast. Interestingly, 
these placenta-derived aggregates in the maternal lung still 
contained sFlt-1 protein. This observation supports the idea of 
circulating syncytial aggregates as a mechanism of sFlt-1 release 
into the maternal circulation. Importantly, we also found that 
preeclampsia was associated with a significantly higher number 
of syncytial aggregates within the maternal lung tissue. During 
both preeclamptic and normal pregnancies, the placenta is the 
On renal pathophysiology in preeclampsia
48  
II. Preeclampsia is associated with the presence of transcriptionally active placental  
    fragments in the maternal lung
49
principal source of sFlt-1. However, previous research has shown 
that approximately 25% of all sFlt-1 is derived from shed syncytial 
aggregates.7 It has been estimated that near the end of pregnancy, 
approximately 3 grams of this placental material is shed into the 
maternal circulation (i.e. into the maternal lungs) daily.15 Therefore, 
the cumulative quantity of these circulating aggregates—and their 
relative contribution to total sFlt-1 production—should not be 
underestimated.
The lungs of the preeclamptic women contained a significantly 
higher percentage of sFlt-1-positive syncytial aggregates than 
the control samples. This observation further supports the idea 
that preeclampsia is associated both with an increased number 
of circulating syncytial aggregates and with increased sFlt-1 
expression within these aggregates. By releasing sFlt-1, these 
aggregates may contribute to the systemic endothelial dysfunction 
that is characteristic of preeclampsia. This finding is also consistent 
with the observation that preeclamptic placentas contain more 
syncytial aggregates that are heavily loaded with sFlt-1 than 
placentas obtained following uneventful pregnancies.
In addition, the presence of syncytial aggregates in maternal 
organs—particularly in the early stages of pregnancy—may play 
a key role in the development of immune tolerance. As early 
as gestational week 10, we observed syncytial aggregates in 
maternal lungs. Because preeclampsia rarely presents prior to 20 
weeks of gestation,11 we could not investigate the presence of 
syncytial aggregates in the lungs of preeclamptic women early 
in pregnancy. We did, however, observe syncytial aggregates in 
the lungs of preeclamptic women at gestational week 32 and 
later, and other groups have reported the presence of trophoblast 
fragments in maternal blood in earlier stages of preeclamptic 
pregnancy.15 Altogether, circulating syncytial aggregates are present 
early in pregnancy, and we and others16 have found a strong 
association between increased shedding of syncytial aggregates and 
preeclampsia. Thus, one may speculate that the release and transfer 
of syncytial aggregates to the maternal compartment is an early 
event in the pathogenesis of preeclampsia. However, the relative 
contribution of sFlt-1 expression in these aggregates in early 
pregnancy is unclear.
The presence and persistence of fetal cells in maternal organs 
may also have both short-term and long-term implications for 
postpartum maternal health. Syncytial aggregates that remain in 
the maternal lungs may undergo further disaggregation, forming 
smaller microparticles. These sFlt-1-loaded microparticles may—via 
their release into the systemic maternal circulation—contribute to 
endothelial dysfunction in maternal organs other than the lungs. 
We found that even 13 days after delivery, hCG-positive syncytial 
aggregates can be detected within the maternal lungs. This finding 
supports the idea that placenta-derived syncytial aggregates may be 
involved in the post-partum complications that are associated with 
preeclampsia. Preeclampsia usually resolves rapidly after delivery, 
and its resolution is reflected by a parallel decrease in sFlt-1 levels.17 
However, in a subset of women, the symptoms and complications of 
preeclampsia can persist or present several days following delivery. 
Syncytial aggregates remain transcriptionally active up to 48 
hours after delivery, and estimates suggest that during pregnancy, 
25% of all circulating sFlt-1 is derived from circulating syncytial 
aggregates.7 Therefore, we propose that these aggregates may play 
an important role in postpartum (pre)eclampsia.
It must be acknowledged that the placentas in our study were 
not obtained from the same women from whom we obtained the 
lung tissues. Therefore, the preeclampsia phenotype of the women 
whose lung tissues were investigated might have been more severe 
than the phenotype of the women who provided the placentas. As a 
consequence of this potential mismatch between phenotypes, we were 
unable to correlate placental sFlt-1 production to the portion of sFlt-
1-loaded syncytial aggregates in the maternal lungs. To overcome this 
complication, an animal model could be used to study the association 
between placental sFlt-1 production and lung pathology.
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Trophoblast cells are likely not the only fetal cell population that is 
present in the maternal lung. A previous study using mice suggested 
that fetal cells in the maternal lung are comprised of a mixture 
of cell types that includes trophoblasts, mesenchymal stem cells, 
and cells from the immune system.18 We have now confirmed the 
presence of trophoblast cells in the human maternal lung. In the 
long run, the release of vital cells from the placenta may result 
in chimerism, as fetal cells can be retained in the maternal blood 
and organs for decades after delivery.19, 20 Because retained fetal 
cells have stem cell-like properties,21 it can be speculated that these 
cells provide a mechanism through which maternal health can be 
affected for decades after pregnancy. 
PERSPECTIVES
In conclusion, we have demonstrated that multinucleate aggregates 
in the maternal lungs originate from the syncytiotrophoblast, 
that their presence is significantly associated with preeclampsia 
and that these aggregates retain the anti-angiogenic protein sFlt-
1. Further studies are needed to determine the relevance and 
relative contribution of trophoblast cells—and other cell types—to 
maternal health. Likewise, understanding what drives the formation, 
detachment and transfer of syncytial knots to the maternal 
compartment—and why these knots produce sFlt-1—are important 
questions to be investigated. Nevertheless, this report highlights 
the importance of investigating further the role that syncytial 
aggregates play in preeclampsia and its complications.  
NOVELTY AND SIGNIFICANCE
What is new?
•	 Within the placenta, syncytial knots are the principal site of 
expression of the anti-angiogenic factor sFlt-1.
•	 Placenta-derived syncytial aggregates that become lodged in the 
maternal lungs retain the anti-angiogenic factor sFlt-1. 
•	 Preeclampsia is associated with significantly higher quantities of 
sFlt-1 loaded syncytial aggregates within the maternal lung.
What is relevant?
•	 Although the precise etiology of preeclampsia and its complications 
remains unknown, the condition is associated with excessive 
shedding of placental material into the maternal circulation. 
•	 Placenta-derived syncytial aggregates within the maternal lungs 
contain sFlt-1 and may contribute to the systemic endothelial 
dysfunction that characterizes preeclampsia.
•	 Furthermore, retained fetal cells within the mother may have stem 
cell-like properties, thereby providing a mechanism through which 
maternal health can be affected for decades after pregnancy
Summary
The current study confirms the important role of syncytial 
knots in placental sFlt-1 mRNA production. In addition, it 
demonstrates a significant association between preeclampsia and 
the presence of increased quantities of sFlt-1 containing syncytial 
aggregates in maternal lungs. These observations suggest that the 
transfer of syncytial aggregates into the maternal compartment 
likely contributes to the systemic endothelial dysfunction that 
characterizes preeclampsia.
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Characteristics PE (n=9) Controls (n=26)
Maternal age at death (years)
Death postpartum (%) †
   GA at birth (w) *
   Death Postpartum (h)
Death during pregnancy (%) †
   GA at death (w)
Death-Autopsy time (h)
Gender offspring
   Male (%)






















Table 1: Data are given as mean ± SD. * p<0.05 † p<0.01, PE= preeclampsia
Panel A shows the relative sFlt-1 mRNA levels in the placentas of women with preeclampsia 
and control subjects with mean+SEM (*p<0·001). 
 
Panel B (full colour version inside cover) shows typical examples of sFlt-1 mRNA in situ 
hybridization in the placenta of a woman with preeclampsia (a and b) and a control subject 
(c and d). The term “syncytial knots” describes multinucleated structures that are loosely 
attached to the tips of placental villi in situ. Each column represents an individual placenta, 
and the various RNA probes are shown horizontally. The antisense probe (a and c) revealed 
that the syncytial knots (arrowheads) were the primary placental site of sFlt-1 mRNA 
production in both placentas. The sense probe (b and d) was used as a negative control. 
Panel C shows the density of sFlt-1 mRNA-positive syncytial knots in the placentas of 
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Panel B shows additional examples of multinucleate aggregates in maternal lungs, with 
co-localization of hCG (subpanels a-d) and Flt-1 (subpanels e-h). Each row shows matched 
sequential sections.  
 
 
Panel C summarizes the number of hCG-positive syncytial aggregates within the maternal 






placenta maternal lung maternal lung
Panel A (full colour version inside cover) shows sections of placenta and sequential sections 
of maternal lungs that were stained for hCG or Flt-1 (using immunohistochemistry) or the 
Y chromosome (using in situ hybridization). To simplify the terminology, we use “syncytial 
knots” to describe multinucleated structures that are loosely attached to the tips of placental 
villi in situ and “syncytial aggregates” to describe detached multinuclear structures within 
the maternal lungs. The left column shows a placenta obtained from a preeclamptic patient, 
and the middle and right columns represent the lungs obtained from two women who were 
pregnant with a boy and died due to preeclampsia. The various stains are shown horizontally. 
Subpanels a-c show that within the preeclamptic placenta, the hCG (a) and Flt-1 (b) 
proteins are most abundantly present within the syncytial knots (arrowheads). In addition, Y 
chromosome in situ hybridization (c) shows the presence of the Y chromosome in the nucleus 
(visible as red puncta). Subpanels d and g show the presence of hCG-positive aggregates 
(arrowheads) in the lungs of two women who died due to preeclampsia. Subpanels e and 
h show the Flt-1 staining patterns in sections that were sequential to the sections shown 
in panels d and g, respectively. These images demonstrate that within the maternal lungs, 
hCG-positive aggregates also contain Flt-1 protein. The next sequential sections were used 
to perform Y chromosome in situ hybridization (subpanels f and i). These images show that 
the multinucleate aggregates contain Y chromosomes (arrowheads), indicating that it is very 
unlikely that these aggregates are not of fetal origin. Altogether, the figure demonstrates 
co-localization of hCG, Flt-1 and the Y chromosome in the multinucleate aggregates 
(arrowheads). 
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Panel A (full colour version inside cover) shows the presence of a hCG-positive aggregate in 
the lung of a control subject.  
 
Panel B (full colour version inside cover) shows negative Flt-1 staining in a section that was 
sequential to the section shown in Panel A. These images demonstrate that within the lungs 
of control subjects, the minority of the hCG-positive aggregates also contain Flt-1 protein.  
 
Panel C shows that within the preeclampsia group, 56% of all hCG-positive aggregates were 
also Flt-1 positive, whereas in the control group 26% of the syncytial aggregates showed 
positivity for Flt-1 protein. *p<0·05.    
hCG Flt-1
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Abstract
A growing body of evidence suggests that complement 
dysregulation plays a role in the pathogenesis of preeclampsia. 
The kidney is one of the major organs affected in preeclampsia. 
Because the kidney is highly susceptible to complement deposits, we 
hypothesized that preeclampsia is associated with renal complement 
activation. We performed a nationwide search for renal autopsy 
material in the Netherlands using a computerized database (PALGA). 
Renal tissue was obtained from 11 women with preeclampsia, 25 
pregnant controls, and 14 non-pregnant controls with hypertension. 
The samples were immunostained for C4d, C1q, MBL, properdin, 
C3d, C5b-9, IgA, IgG and IgM. Our findings in human samples were 
validated using a soluble fms-like tyrosine kinase 1 (sFlt-1) mouse 
model of preeclampsia. Preeclampsia was significantly associated 
with renal C4d —a stable marker of complement activation— and the 
classical pathway marker C1q. In addition, the prevalence of IgM 
was significantly higher in the kidneys of the preeclamptic women. 
No other complement markers studied differed between the groups. 
In the preeclampsia mouse model, the kidneys in the sFlt-1‒injected 
mice had significantly more C4 deposits than the control mice. The 
strong association between preeclampsia and renal C4d, C1q, and 
IgM levels suggests that the classical complement pathway plays a 
role in the pathogenesis of renal injury in preeclampsia. Moreover, 
our finding that sFlt-1‒injected mice develop excess C4 deposits 
indicates that angiogenic dysregulation may play an important 
role in complement activation within the kidney. We suggest that 
inhibiting complement activation may be beneficial for preventing 
the renal manifestations of preeclampsia. 
Introduction
Preeclampsia is a severe multisystem pregnancy-related 
complication; worldwide, preeclampsia causes high maternal and 
perinatal morbidity and mortality rates.1 Preeclampsia complicates 
2-8% of pregnancies and is characterized by endothelial damage, 
resulting in maternal hypertension and proteinuria after gestational 
week 20.2 The endothelial damage in preeclampsia is believed to 
arise from a dysregulation of proangiogenic and antiangiogenic 
factors, particularly the antiangiogenic factor soluble fms-like 
tyrosine kinase 1 (sFlt-1).3 
Although the precise pathogenesis of preeclampsia is unknown, a 
growing body of evidence suggests that complement dysregulation 
plays a role in the development of preeclampsia.4 In support of this 
notion, women with preeclampsia have complement dysregulation 
in the placenta, as well as elevated circulating levels of complement 
degradation products.5, 6 In addition, individuals with mutations in 
genes that encode complement regulatory proteins are predisposed 
to developing preeclampsia.7 Furthermore, treating preeclamptic 
mice with complement inhibitors can reverse proteinuria and 
histopathologic lesions.8 Finally, Eculizumab, a terminal complement 
inhibitor, has been used successfully to reduce preeclampsia-
associated conditions, thereby prolonging pregnancy in a patient 
with preeclampsia.9 
In preeclampsia, the kidney is a major target organ that develops 
severe damage, as demonstrated by renal symptoms that include 
proteinuria and by abnormal renal histology.10 These symptoms 
are believed to reflect endothelial damage due to increased sFlt-1 
levels, which prevent vascular endothelial growth factor (VEGF) 
from maintaining the renal endothelium.11 It has been shown that 
damage to the fenestrated glomerular endothelium can activate 
the complement system.12-14 Interestingly, a case report showed 
glomerular complement deposits in a patient with preeclampsia, 
suggesting that the complement system may indeed play a key role 
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in the pathogenesis of renal damage in preeclampsia.15 Furthermore, 
a recent study reported that patients with severe preeclampsia 
have a higher prevalence of urinary excretion of the terminal 
complement complex compared to control subjects.16
 Because preeclampsia is characterized by complement 
dysregulation, the kidney plays an important role in preeclampsia, 
and the kidney is highly susceptible to complement deposits, we 
hypothesized that complement activation is involved in the renal 
manifestations of preeclampsia. If correct, this hypothesis would 
support the notion that inhibiting complement activation might be a 
viable option for treating the renal manifestations of preeclampsia. 
To test this hypothesis, we measured the presence of complement 
components in a unique cohort of renal autopsy tissue samples 
collected from preeclamptic patients and control patients; in 
addition, we studied complement components in a sFlt-1‒induced 
mouse model of preeclampsia. 
Methods
PATIENT SELECTION AND NATIONWIDE PALGA SEARCH FOR 
RENAL AUTOPSY TISSUE 
To study the role of the complement system in the renal pathology 
of preeclampsia, we performed a nationwide search for renal 
autopsy tissues in the Netherlands using the Dutch Pathology 
Registry (PALGA), a histopathology and cytopathology network 
and registry that includes all pathology laboratories within the 
Netherlands.17 The search parameters were as follows: “autopsy”, 
“women”, “age between 18 and 45 years”, and “since 1990”. 
We included all patients who were pregnant and who had a 
confirmed case of preeclampsia. In addition, two control groups 
were included in the study. The first control group consisted of 
pregnant women without a hypertensive disorder either prior to 
or during their pregnancy; this group was included to investigate 
the effect of pregnancy alone. The second control group consisted 
of non-pregnant young women with a medical history of chronic 
hypertension; this group was included to investigate the effect of 
hypertension alone. The search yielded paraffin-embedded kidney 
samples from 11 patients with preeclampsia,18 25 pregnant controls, 
and 14 non-pregnant chronic hypertensive controls. If available, 
clinical characteristics were obtained from autopsy-reports. The 
records of the National Maternal Mortality Committee of the Dutch 
Society of Obstetrics and Gynecology were used to confirm the 
cause of death of each pregnant case.19 All tissue samples were 
coded and treated anonymously in accordance with Dutch national 
ethics guidelines (Code for Proper Secondary Use of Human Tissue, 
Dutch Federation of Medical Scientific Societies). This study was 
approved by the Medical Ethics Committee of the Leiden University 
Medical Center (P12.107). 
sFlt-1 MOUSE MODEL OF PREECLAMPSIA
All animal experiments were performed at the Beth Israel Deaconess 
Medical Center in accordance with International Animal Care and Use 
Committee guidelines. We used the sFlt-1‒induced mouse model of 
preeclampsia,20 which overexpresses the sFlt-1 protein and develops 
high blood pressure, proteinuria, and endotheliosis. In brief, pregnant 
female CD1 mice (Charles River, Wilmington, MA) received a tail 
vein injection of 2 x 109 pfu of either an adenovirus encoding sFlt-1 
(Ad-sFlt-1) or an equivalent dose of adenovirus empty vector CMV 
null (Vector Laboratories, Philadelphia) at gestational day 9.5. This 
model has been well characterized by a number of groups in both 
rats and mice and leads to hypertension, proteinuria and glomerular 
endothelial damage 7-10 days after adenoviral injection of sFlt-1.3, 20-22 
For our studies, mice were euthanized on gestational day 17.5 and one 
kidney from each mouse was frozen for immunofluorescence, and the 
other kidney was formalin-fixed and embedded in paraffin.  Paraffin-
embedded kidney sections were stained with Periodic Acid Schiff (PAS) 
or silver using standard protocols.
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HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND 
IMMUNOFLUORESCENCE
Sections of human kidney samples were stained with Periodic 
Acid Schiff (PAS) and silver using a standard protocol. To measure 
human renal complement activation, various complement system 
components were stained using immunohistochemistry. We used 
primary antibodies against the following proteins: C4d (Biomedica 
Gruppe, 1:50), a split product of C4 that binds covalently to the 
target tissue and can arise from the classical and mannose-binding 
lectin (MBL) pathways; C1q (DakoCytomation, 1:800), which reflects 
activation of the classical complement pathway; MBL (Sigma-
Aldrich Biotechnology, 1:500), which reflects activation of the 
lectin pathway; properdin (kindly provided by the Department of 
Nephrology, Leiden University Medical Center, 1:200), which reflects 
activation of the alternative complement pathway; and C3d (Abcam, 
1:800) and SC5b-9 (Quidel, 1:150), both of which are formed by 
activation of any of the three aforementioned pathways. To identify 
apoptotic cells, the samples were immunostained for caspase-3 
(Cell Signaling Technology Inc., 1:300). Immunohistochemistry 
was performed after the sections were deparaffinized and treated 
for antigen retrieval. Staining was visualized using the appropriate 
HRP-labelled secondary antibodies with diaminobenzidine as 
the chromogen. Finally, the sections were counterstained with 
hematoxylin. 
To examine the presence of immunoglobulin deposits in the 
human glomeruli, immunofluorescence was performed for IgA, IgG, 
and IgM separately. First, the sections were treated with protease 
XXIV (SigmaAldrich) at 37°C for one hour. The sections were then 
incubated for one hour with FITC-labeled rabbit anti-human IgA 
(DakoCytomation; 1:20), FITC-labeled goat anti-human IgG (Protos 
Immuno Research; 1:25), or FITC-labeled rabbit anti-human IgM 
(DakoCytomation; 1:20). To study classical complement activation 
in the mouse kidneys, frozen sections were stained for C4d using 
a rat monoclonal anti-C4 antibody (Cedarlane Laboratories, 
1:200), which binds to murine C4, C4b, and C4d. To identify 
endothelial cells, adjacent sections were stained for CD31 using 
a rat monoclonal anti-CD31 antibody (BD Pharmingen, 1:100). A 
FITC-labelled secondary antibody was used to visualize the primary 
antibodies.
QUANTIFICATION OF IMMUNOHISTOCHEMISTRY AND 
IMMUNOFLUORESCENCE
The human kidney sections were scored histologically by an 
experienced renal pathologist who was blinded with respect to 
the subjects’ clinical data. Each stained sample was evaluated and 
scored by two independent observers. Because the renal pathological 
manifestations of preeclampsia are present in the glomerulus, we 
scored the staining of the various markers in the glomerulus only, 
scoring ≥50 glomeruli per section. The immunostained complement 
components were scored semi-quantitatively as follows: 0 represents 
an absence of—or traces of—glomerular staining; 1 represents 
segmental glomerular staining; and 2 represents global staining 
of the glomeruli. If positive (i.e., a score of 1 or 2), the kidney 
sections were further classified as having either focal (10-50% of the 
glomeruli) or diffuse (>50% of the glomeruli) deposits. Caspase-3 
staining was analyzed by counting the number of caspase-3‒
positive cells in 50 glomeruli and comparing the number of positive 
cells between the study groups. For immunofluorescence, the 
slides were analyzed for either the absence or presence of immune 
deposits in the glomeruli using both a fluorescence microscope 
(DM5500B, Leica Instruments) and a confocal laser-scanning 
microscope (LSM 700, Zeiss).
STATISTICAL ANALYSIS
Categorical variables were analyzed using the Chi-square test. 
Differences in quantitative parameters between groups were 
analyzed using a one-way ANOVA (for normally distributed data) 
or the non-parametric Kruskal-Wallis test (for non-normally 
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distributed data). Correlations between ordinal data and numerical 
data were calculated using a Spearman’s or Pearson’s coefficient, 
respectively. All analyses were performed using the SPSS statistical 
software package (version 20.0; IBM Corp.). Differences with p<0.05 
were considered to be statistically significant.
Results
CLINICAL DATA 
The clinical characteristics of the human subjects included in the 
study were previously described, and are shown in chapter 4, page 
100.23 The hypertensive control group was significantly older than 
the other study groups (p<0.05); no other significant differences 
were observed with respect to the remaining clinical characteristics. 
HISTOLOGY
The majority (82%) of the women with preeclampsia had prominent 
glomerular lesions, including various degrees of endotheliosis, 
podocyte swelling, and double contours of the glomerular basement 
membrane (also known as tram tracking). As previously published, 
in this cohort, endotheliosis was present in 55% of the samples 
from the women with preeclampsia; in contrast, endotheliosis was 
less prevalent in the pregnant controls and hypertensive controls 
(12% and 15%, respectively; p<0.05 versus the patients with 
preeclampsia).23 Tram tracking and podocyte swelling were present 
exclusively in the women with preeclampsia (in 36% and 18% of 
patients, respectively; p<0.05 versus the control groups). 
IMMUNOHISTOCHEMISTRY 
To study complement activation, we stained the kidney sections for 
several complement components. Figure 1 shows typical examples 
of immunostained adjacent kidney sections from a patient with 
preeclampsia (“PE”), a pregnant control (“PC”), and a hypertensive 
control (“HC”). The glomeruli in all 11 preeclamptic patients 
were positive for C4d; in contrast, only 15/25 (60%) pregnant 
controls and 3/14 (21%) non-pregnant hypertensive controls were 
positive for C4d. The C4d staining in the glomeruli was either 
segmental or global. Positive C4d staining was strongly associated 
with preeclampsia (p<0.0001). The presence of C4d correlated 
significantly (p<0.05) with endotheliosis and tram tracking. C1q was 
detected in 9/11 (82%) of the kidney sections obtained from women 
with preeclampsia; in contrast, C1q was detected in only 6/25 
(24%) of the pregnant controls and 2/14 (14%) of the non-pregnant 
hypertensive controls. Positive C1q staining was significantly 
associated with preeclampsia (p<0.01), and C1q staining and C4d 
staining were positively correlated (p<0.0001). Detailed information 
regarding the staining patterns of C4d and C1q in the patient and 
control groups is given in Figure 1. 
MBL was present in one preeclamptic patient and one pregnant 
control; in both samples, the staining pattern was segmental; no 
significant differences were found between cases and controls with 
respect to MBL staining. Properdin was not detected in any of 
kidney samples. 
With respect to C3d, the staining pattern was usually segmental. 
In preeclamptic patients, 5/11 (45%) of the kidney sections were 
positive for C3d; in contrast, only 2/25 (8%) of the pregnant 
controls and 2/14 (14%) of the non-pregnant hypertensive controls 
were positive for C3d subjects. No significant difference was found 
between the patient and control groups, and no correlation was 
found between C4d and C3d staining (data not shown). The most 
abundant C5b-9 staining was detected in sclerotic glomeruli; C5b-
9 was present only rarely in functioning glomeruli. However, a 
significant correlation (p<0.05) was found between C5b-9 and C3d 
staining (Figure S1 shows typical staining patterns of C3d and C5b-
9 in the patient and control samples). In all of the aforementioned 
immunostained sections, all of the positive kidney sections had 
diffuse deposits of complement components. Finally, no significant 
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difference was found between the patient and control groups 
with respect to caspase-3 staining. Specifically, the samples from 
preeclamptic women had an average of 0.05 caspase-3‒positive 
cells/glomerulus, and the samples from the pregnant controls and 
hypertensive controls averaged 0.02 and 0.12 caspase-3‒positive 
cells/glomerulus, respectively. 
IMMUNOFLUORESCENCE
IgA was not detected in any of the samples. In contrast, IgG deposits 
were detected at weak levels in a mesangial pattern. No significant 
difference was found between the three groups with respect to IgG 
positivity, with 27%, 8%, and 21% of the preeclamptic patients, 
pregnant controls, and non-pregnant hypertensive controls, 
respectively, testing positive for IgG. IgM (Figure 2) was detected 
in 36%, 4%, and 21% of the preeclamptic patients, pregnant 
controls, and non-pregnant hypertensive controls, respectively 
(p<0.05 between the groups) (Figure 2C). Typical examples of IgM-
positive and IgM-negative sections are shown in Figure 2A and 
2B, respectively. We also measured the prevalence of IgM staining 
based on whether the sections were C4d-positive or negative 
(Figure 2D). We found that 14% of the 21 C4d-negative kidney 
sections contained IgM deposits; 7% of the 14 kidney sections with 
segmental C4d staining contained IgM, and 27% of the 15 kidney 
sections with global C4d staining contained IgM. Although IgM 
deposits were more prevalent in the kidney sections with global 
C4d, this correlation was not significant. In contrast, the presence of 
IgM was correlated significantly with tram tracking (p<0.001). 
RELATIONSHIP BETWEEN CLINICAL CHARACTERISTICS AND C4D
Among the 36 samples obtained from the preeclamptic patients 
and pregnant controls, 10 samples were negative for C4d, 11 
samples were C4d-positive with segmental staining, and 15 samples 
were C4d-positive with global staining. Global C4d deposits were 
significantly correlated with increased gestational age (p<0.05), 
whereas C4d-negative staining was not correlated significantly 
with gestational age. Neither the level of proteinuria nor peak blood 
pressure was correlated with the pattern of C4d staining. 
sFlt-1 MOUSE MODEL OF PREECLAMPSIA
Next, we used a sFlt-1 mouse model of preeclampsia3, 20-22 to study 
whether sFlt-1‒induced endothelial damage is associated with 
complement activation. As reported previously, injecting sFlt-
1 into the tail vein caused a preeclampsia-like phenotype, with 
significantly elevated blood pressure, urinary albumin secretion, and 
endotheliosis (a characteristic renal lesion in preeclampsia), which 
was measured using open capillary volume.3, 20 The percentage of 
C4-positive kidneys in the sFlt-1‒injected mice was significantly 
higher than in the control mice (Figure 3). The sFlt-1‒injected mice 
had significantly more C4-positive glomeruli (p<0.05; Figure 3C). 
Confocal immunofluorescence microscopy revealed that the C4 
deposits were present on the endothelial cells. This finding was 
confirmed by studying adjacent sections, in which C4 and CD31 co-
localized, indicating complement activation in endothelial cells. 
Discussion
The mechanisms that underlie the renal pathology in preeclampsia 
are poorly understood. Here, we report that the kidney sections from 
all of the preeclamptic women in our study were positive for C4d 
deposits. In contrast, C4d deposits were significantly less prevalent 
in two control groups comprised of non-hypertensive pregnant 
women and non-pregnant women with chronic hypertension. 
Importantly, the significant correlation between C4d deposits and 
the classical complement pathway component C1q in glomeruli 
strongly suggests that the classical complement pathway was 
activated. The lack of significant correlation between C4d and MBL, 
and the absence of properdin staining, makes it extremely unlikely 
that complement activation is attributed to either the lectin or 
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alternative complement pathway. The hypothesis that angiogenic 
dysregulation plays an important role in triggering complement 
activation in the kidney is supported by our finding of excessive 
numbers of C4 deposits in the glomeruli of sFlt-1-injected mice, an 
established model of preeclampsia. Taken together, these findings 
suggest that preeclampsia is associated with activation of the 
classical complement pathway in the kidney.  
We previously described a relationship between preeclampsia 
and classical complement pathway activation in the placenta.5 Thus, 
both the current study and our previous study raise the question 
of what drives activation of the classical complement pathway 
in the setting of preeclampsia. In general, complement imbalance 
can arise from excessive activation and/or inadequate regulation 
of the complement system. Excessive complement activation can 
arise from angiogenic dysregulation, which is believed to cause 
the initial preeclampsia-related renal injury due to increased sFlt-1 
levels preventing vascular endothelial growth factor (VEGF) from 
maintaining the renal endothelium.3, 11 We hypothesized that the 
resulting endothelial damage in the kidney might drive excessive 
complement activation. In our study, the presence of the IgM 
isotype was significantly associated with preeclampsia. Although 
glomerular IgM deposits have been observed in a wide range of 
renal diseases, the role of these deposits has remained elusive, 
suggesting that these IgM deposits might not always be involved 
in the pathogenesis of these particular renal diseases. However, 
the presence of IgM deposits might have other explanations. 
First, they could reflect the binding of IgM antibodies to damaged 
endothelium. Natural IgM-antibodies play a major role in the 
clearance of damaged cells24, 25, and they can bind to both hypoxic26 
and apoptotic cells27, 28 through intracellular antigens that become 
externalized under these conditions. The binding of IgM antibodies 
to either hypoxic or apoptotic cells triggers the activation of the 
complement system.26-28 Taken together, these studies strongly 
suggest that the initial endothelial damage —mediated via high 
sFlt-1 levels in the kidneys of preeclamptic women—could trigger 
the binding of IgM antibodies, thereby activating the complement 
system. Our finding of classical complement pathway components 
in the glomeruli of women with preeclampsia, combined with excess 
deposits of C4 on glomerular endothelial cells in our sFlt-1‒injected 
mice, highly support this hypothesis.
Secondly, the presence of IgM antibodies and the activation of 
the classical complement pathway in the kidneys of preeclamptic 
women could have resulted from auto-antibodies such as 
angiotensin II type 1 receptor agonistic antibodies (AT1-AA),
29, 
30 anti-phospholipid auto-antibodies,31 and/or anti-laminin auto-
antibodies.32 In the context of preeclampsia, complement activation 
could result from these auto-antibodies binding to glomerular 
structures or by the deposition of circulating antibody‒antigen 
immune complexes and their subsequent entrapment in renal tissue. 
In our study, although we observed glomerular immunoglobulins 
both in preeclamptic patients and in some controls, IgM was the 
only immunoglobulin isotype that was significantly more prevalent 
in the patients with preeclampsia. If immunoglobulin deposits had 
resulted from auto-antibodies, we would have expected to find 
increased IgG deposits in the kidneys of these women. Therefore, 
our observations suggest that it is unlikely that the glomerular 
complement deposits in the kidneys of the preeclamptic women 
were caused by auto-antibodies. 
Inadequate regulation of the complement system may also have 
caused glomerular complement activation. In the kidney, several 
complement regulatory proteins are expressed at high levels,33-35 
suggesting the importance of renal complement regulation. In our 
study, we found no correlation between late complement cascade 
components and preeclampsia, suggesting that the complement 
cascade does not become activated—at least to an excessive degree—
beyond the level of C3. Complement regulatory mechanisms may be 
responsible for this phenomenon. However, the association between 
preeclampsia and mutations in genes that encode complement 
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regulatory proteins suggests that inadequate complement regulation 
plays a role in preeclampsia.7 Indeed, a putative mechanism for 
inadequate regulation is related to complement regulator factor 
H, which regulates both the alternative and classical complement 
pathways,36 and mutations in factor H have been observed in 
relation to preeclampsia. Importantly, reduced levels of factor H 
have been related to angiogenic imbalance within the kidney.37  
Regardless of which mechanism is responsible for renal 
complement activation in women with preeclampsia, 
understanding how complement activation contributes to the 
clinical manifestations of preeclampsia is essential. Given that 
complement activation is strongly associated with preeclampsia 
(and its characteristic angiogenic imbalance), inhibiting complement 
activation may be a promising therapeutic approach for targeting 
both the placental and renal manifestations of preeclampsia. 
Importantly, both proteinuria and the typical renal histological 
changes have been reversed in mouse models of preeclampsia that 
were treated using complement inhibitors.8 In one patient with 
severe preeclampsia, the terminal complement inhibitor Eculizumab 
has been used successfully to reduce preeclamptic manifestations 
and to prolong pregnancy.9 
PERSPECTIVES
Our study is the first to demonstrate extensive activation of the 
classical complement pathway in the kidneys of women with 
preeclampsia. The presence of excessive C4 deposits in our sFlt-
1‒induced preeclampsia mouse model strongly supports the 
notion that preeclampsia-related renal complement activation is 
initiated by endothelial damage. In summary, our results suggest 
that complement activation might contribute to renal injury 
in preeclampsia. Moreover, our findings provide evidence that 
inhibiting the complement system might significantly reduce both 
the renal and placental manifestations of preeclampsia. 
NOVELTY AND SIGNIFICANCE
What is new?
•	 The kidney sections from all of the preeclamptic women in our 
study were positive for C4d deposits indicating that preeclampsia is 
associated with activation of the classical complement pathway in 
glomeruli.
•	 The hypothesis that angiogenic dysregulation plays an important 
role in triggering complement activation in the kidney is supported 
by our finding of excessive numbers of C4 deposits in the glomeruli 
of sFlt- 1‒ injected mice, an established model of preeclampsia. 
What is relevant?
•	 Our study suggests that initial endothelial damage —mediated via 
high sFlt-1 levels in the kidneys of preeclamptic women—could 
trigger the binding of IgM antibodies, thereby activating the 
complement system.
•	 Complement activation might contribute to renal injury in 
preeclampsia. 
•	 Our findings provide evidence that inhibiting the complement 
system might significantly reduce the renal manifestations of 
preeclampsia. 
Summary
The strong association between preeclampsia and renal C4d, C1q, 
and IgM levels suggests that the classical complement pathway 
plays a role in the pathogenesis of renal injury in preeclampsia. 
Moreover, our finding that sFlt-1‒injected mice develop excess 
C4 deposits indicates that angiogenic dysregulation may play an 
important role in complement activation within the kidney. We 
suggest that inhibiting complement activation may be beneficial for 
preventing the renal manifestations of preeclampsia. 
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Immunohistochemistry of human kidney sections (full colour version inside cover)
Adjacent sections of glomeruli were immunostained for C4d (A‒C), C1q (D‒F), mannose-
binding lectin (G‒I), or properdin (J‒L). Each column contains adjacent sections and shows a 
single glomerulus. The left column shows a glomerulus from a patient with preeclampsia (PE), 
with global C4d staining. The middle column shows a glomerulus from a pregnant control 
(PC), with segmental C4d staining. The right column shows a C4d-negative glomerulus from 
a hypertensive control (HC). C1q staining was present in C4d-positive glomeruli (D) but also 
in C4d-negative glomeruli. In C4d-positive glomeruli, co-localization of C1q and C4d was 
observed (A and D). MBL was rarely observed (G-I) and properdin was never observed (J-L). 
Summary of the prevalence of each C4d (M) and C1q (N) staining pattern in the three groups. 
Kidneys sections from all preeclamptic patients were positive for C4d, with global staining in 
the majority of the kidney sections. In contrast, the majority of the pregnant and hypertensive 
controls showed a segmental or negative C4d staining pattern. Overall comparison revealed 
that C4d was significantly increased in preeclampsia (p<0.0001). 
 
Panel N shows the staining patterns for C1q. Overall comparison revealed that C1q was 
significantly increased in preeclampsia (p<0.01) (N). **p<0.01, ***p<0.0001.  
Immunofluorescence staining of IgM (full colour version inside cover)
Representative images of an IgM-positive glomerulus (A) and an IgM-negative glomerulus 
(B). IgM deposits were significantly more prevalent in the kidney sections from the women 
with preeclampsia compared to the two control groups.  
 
Distribution of the percentage of IgM-positive sections based on C4d staining pattern 
(p>0.05) (C). *p<0.05. Distribution of IgM deposits according to C4d staining pattern 










III. Complement activation in the kidney during preeclampsiaOn renal pathophysiology in preeclampsia
78  79
 
Representative images of C4 deposits in a glomerulus from a sFlt-1‒injected (A) and control-
injected (B) mouse.   
 
 
Summary of the average (±SD) percentage of C4-positive glomeruli (C) in the kidneys of sFlt-
1‒injected mice (N=6 mice) and control mice (N=5 mice). *p<0.05.  
         
 
 
Immunohistochemical staining pattern of C3d and C5b-9 in human kidneys
Adjacent sections were immunostained for C3d (A‒C) or C5b-9 (D‒F). Each column 
represents an individual glomerulus. The left column shows a glomerulus from a patient with 
preeclampsia (PE), showing global staining. The middle column shows a glomerulus from 
a pregnant control (PC), with a segmental staining pattern (arrowhead). The right column 
shows a glomerulus from a hypertensive control (HC). C3d (A-C) deposits were observed in 
glomeruli from all study groups whereas C5b-9 (D-F) deposits were infrequently observed. 
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Preeclampsia is a pregnancy-related complication that causes 
significant perinatal and maternal morbidity and mortality 
worldwide. Preeclampsia is characterized by hypertension and 
proteinuria, and increased shedding of podocytes into the urine 
is a common finding. This finding raises the question of whether 
preeclamptic nephropathy involves podocyte damage. We therefore 
studied podocyte-related changes in a unique sample of renal 
tissues obtained from women who died of preeclampsia.  
DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS
Using a nationwide database of the Dutch Pathology Registry (PALGA), 
we identified a cohort of 11 women who died from preeclampsia. Three 
control groups were also identified and consisted of normotensive 
women who died during pregnancy (n=25), and non-pregnant controls 
either with (n=14) or without (n=13) chronic hypertension. Clinical 
data regarding the pregnant patients were obtained from the National 
Maternal Mortality Committee of the Dutch Society of Obstetrics 
and Gynaecology. Renal tissues were obtained. Glomerular lesions, 
including podocyte numbers, podocyte proliferation, and parietal cell 
activation were measured and compared between the four groups. 
RESULTS
The preeclamptic patients had prominent characteristic glomerular 
lesions, including endothelial cell swelling, podocyte swelling, 
and double contours of the glomerular basement membrane. 
Importantly, we found that the number of podocytes per glomerulus 
did not differ significantly between the preeclamptic and control 
groups. However, preeclampsia was associated with a significant 
increase in intraglomerular cell proliferation (p=0.004) and activated 
parietal epithelial cells on a podocyte location (p=0.01). 
CONCLUSIONS
Our findings suggest that the recently described mechanisms of 
podocyte replacement play a role in preeclampsia. Our results also 
suggest that the podocyte plays an important role in preeclamptic 
nephropathy and subsequent progressive renal damage, including 
focal and segmental glomerulosclerosis. These findings provide key 
new insights into the pathogenesis of preeclamptic nephropathy, 
and they open new possibilities for developing therapeutic 
modalities.
Introduction
Preeclampsia is a serious pregnancy-related complication that affects 
up to 8% of all pregnancies, thereby causing significant perinatal 
and maternal morbidity and mortality worldwide.(1) Preeclampsia 
is believed to arise–at least in part–from an imbalance between 
the pro- and antiangiogenic factors in the maternal circulation; 
the maternal kidney is particularly sensitive to this imbalance, as 
reflected by the occasional finding of severe proteinuria.(1, 2) 
As far back as 1918, the glomerulus was recognized as the 
principal site of renal damage in preeclampsia.(3) Later, the 
glomerular podocyte became the focus of attention in relation to 
proteinuria. Because renal biopsies are rarely performed in pregnant 
preeclamptic patients, how the podocyte is affected by preeclampsia 
has remained largely unknown, although endotheliosis is generally 
considered a characteristic histopathological glomerular lesion 
in preeclampsia. Recently, Vikse(4) suggested that a previously 
undetected renal disease might become “overt” in the preeclamptic 
setting. Preeclampsia is a major risk factor for developing 
chronic kidney disease - in particular, focal and segmental 
glomerulosclerosis (FSGS), which is considered primarily a disease 
of podocytes - later in life. However, how preeclampsia increases 
the risk of renal disease is poorly understood. 
Recently, our group and others reported significantly higher 
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numbers of podocytes in the urine (i.e. podocyturia) of women 
with preeclampsia compared to pregnant control subjects.(5, 6) 
This podocyturia remained in the preeclamptic patients up to 
one month after delivery, although their proteinuria resolved.(7) 
Structural changes in the podocyte, including abnormal expression 
of podocyte-related proteins, were recently reported in a limited 
number of patients with preeclampsia.(8, 9) These findings suggest 
that the podocyte plays a key role in preeclampsia. In particular, 
the increased shedding of podocytes into the urine of preeclamptic 
patients raises the question of whether the origin of preeclamptic 
renal disease involves podocyte damage. Moreover, this hypothesis 
is reminiscent of the podocytopathy that may underlie the 
subsequent renal deterioration that is seen in FSGS. To investigate 
the association between preeclampsia and glomerular lesions in 
general, and podocyte-related injury in particular, we collected a 
unique sample of renal autopsy tissues obtained from preeclamptic 
patients and control subjects.
Methods
PATIENT SELECTION AND NATIONWIDE PALGA SEARCH FOR 
RENAL TISSUE 
Autopsy samples were obtained following a nationwide search 
of the Dutch Pathology Registry (PALGA), a histopathology and 
cytopathology network and registry that includes all pathology 
laboratories within the Netherlands.(10) We included pregnant 
patients who died from preeclampsia as defined by international 
guidelines established by the International Society for the Study 
of Hypertension in Pregnancy (ISSHP).(11) Three control groups 
were also obtained. One control group consisted of pregnant 
women without a hypertensive disorder either prior to, or during 
the pregnancy. The two other control groups consisted of non-
pregnant young women either with, or without a medical history 
of chronic hypertension. We obtained paraffin-embedded kidney 
samples taken from 11 preeclampsia patients, 25 normotensive 
pregnant controls, 14 chronic hypertensive non-pregnant controls, 
and 13 normotensive non-pregnant controls. The patients’ clinical 
characteristics were obtained from their autopsy-reports. The cause 
of death in each pregnant case was confirmed by reviewing the 
records of the National Maternal Mortality Committee of the Dutch 
Society of Obstetrics and Gynecology.(12) A thorough review of 
the autopsy reports— including kidney weight—confirmed that the 
control subjects had no evidence of underlying renal disease.  All 
tissues were coded and handled anonymously in accordance with 
the Dutch National Ethics Guidelines (Code for Proper Secondary 
Use of Human Tissue, Dutch Federation of Medical Scientific 
Societies). This study was approved by the ethics committee of the 
Leiden University Medical Center (P12.107).  
HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND 
IMMUNOFLUORESCENCE
Sections of renal tissue samples were stained with haematoxylin and 
eosin, periodic acid-Schiff (PAS), silver, and phosphotungstic acid-
hematoxylin (PTAH) using standard methods. Immunohistochemistry 
was used to identify and count podocytes based on staining for WT-1, 
a podocyte-specific transcription factor.(13) To confirm the origin of 
swollen endothelial cells, we performed CD31 staining experiments. 
Because cell proliferation can affect the number of podocytes, 
we also performed immunohistochemical staining for Ki-67, a 
marker of cell proliferation.(14) The sections were deparaffinized, 
and after antigen retrieval, immunohistochemistry was performed. 
The sections were stained with antibodies against WT-1 (rabbit 
anti-human polyclonal antibody sc-192 lotnumber D2104, Santa 
Cruz Biotechnology, 1:250), or CD31 (Dako, 1:400) or Ki-67 
(Thermo Fisher Scientific, 1:200), and staining was visualized 
using the appropriate secondary antibodies and diaminobenzidine 
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as the chromagen. Finally, the sections were counterstained with 
hematoxylin. 
Double immunofluorescence stainings were performed.  For 
the first double staining, we used an antibody against CD44 (a 
glycoprotein involved in cell adhesion, cell matrix interactions, and 
cell migration (Abcam, 1:200)), which is expressed by activated 
parietal epithelial cells12 and an antibody against CD45 (a leukocyte 
common antigen, Ancell 1:800). Staining was visualized using 
goat anti-mouse Alexa 488 IgG2a and Alexa 546 Ig1. For a 
second double-staining experiment, we used antibodies against 
CD44 (Abcam, 1:200) and Ki-67 (Thermo Fisher Scientific, 1:200). 
Staining was visualized using the goat anti-mouse Alexa 488 IgG2 
(1:200) and Alexa 546 Ig1 (1:200) secondary antibodies. We also 
performed a third double-staining experiment using antibodies 
against WT-1 (Santa Cruz Biotechnology, 1:250) and CD44 (Abcam, 
1:200). WT-1 was visualized using the appropriate secondary 
antibody and diaminobenzidine as the chromagen, and CD44 was 
visualized using the FITC-labelled goat anti-mouse IgG antibody 
(1:200).
QUANTIFICATION OF HISTOLOGY
Sections were examined and scored by an experienced renal 
pathologist who was blinded with respect to the patients’ clinical 
data. At least 50 glomeruli per section were examined, and the 
following parameters were scored: presence of endotheliosis, 
double contours of the glomerular basement membrane (tram 
tracking), swelling of podocytes, mesangial changes, glomerulitis, 
and focal and segmental glomerulosclerosis (FSGS). As described 
by previously Strevens et al(15), endotheliosis was scored semi-
quantitatively as follows: 0 (no endotheliosis), 1 (<20% of the 
lumen was obliterated), 2 (20-80% of the lumen was obliterated), 
or 3 (>80% of the lumen was obliterated). Global sclerosis was 
recorded as a percentage of the total number of glomeruli scored. 
PTAH-confirmed microthrombi, interstitial fibrosis and tubular 
atrophy (IFTA), and acute tubular necrosis (ATN) were scored as 
either absent or present. To quantify vessel changes, the presence of 
hyalinosis and intimal fibrosis of arteries was scored. Finally, signs 
of ischemia, congestion, and edema were also evaluated.
MORPHOMETRY AND QUANTIFICATION OF  
IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE
Because differences between the groups with respect to glomerular 
surface areas can affect the absolute number of podocytes, PAS-stained 
slides were used to measure the surface areas of the glomerular tuft 
and Bowman’s capsule of 30 randomly selected glomeruli (using 
ImageJ 1.47d software; National Institutes of Health, downloaded 
from http://rsb.info.nih.gov/ij). For the immunohistochemical and 
immunofluorescence stained sections, at least 30 glomeruli per section 
were analyzed by two observers who were blinded with respect to 
the patients’ clinical data. The number of WT-1 positive nuclei per 
glomerular cross-section was counted using ImageJ 1.47d. Randomly 
selected regions of the outer renal cortex were analyzed. Because 
estimates of podocyte number vary widely between studies(16), we 
measured podocytes in a control group containing non-pregnant, 
non-hypertensive women as a measure of the number of podocytes 
per glomerular cross section in healthy adult women. Ki-67 staining 
was quantified by counting the number of Ki-67-positive cells within 
the glomeruli  (both intraglomerular and lining Bowman’s capsule). 
Finally, the presence of CD44-positive cells in the glomeruli was 
scored along the inner lining of Bowman’s capsule—in an anatomic 
parietal epithelial cell location—and covering the glomerular basement 
membrane on a podocyte location (i.e., not counting endothelial cells) 
as previously described by Fatima et al (17). The podocyte location was 
confirmed by co-localization between CD44 and WT-1. In addition, 
the number of cellular bridges (i.e., bridges between Bowman’s capsule 
and the glomerular tuft) was scored in both CD44-stained and silver-
stained samples. CD44-positive leukocytes, which were confirmed by 
co-staining with CD45, were excluded from the scoring analysis.
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STATISTICAL ANALYSIS
Categorical variables were compared using the Chi-square test. 
Differences in quantitative parameters between groups were 
assessed using either the one-way ANOVA (for normally distributed 
data) or the non-parametric Kruskal-Wallis test (for non-normally 
distributed data). Correlations were calculated using either a 
Spearman’s (for ordinal data) or Pearson’s (for numerical data) 
coefficient. All analyses were performed using the SPSS statistical 
software package (version 20.0; Armonk, NY: IBM Corp). Differences 




The clinical characteristics of the four groups are summarized 
in Table 1. The hypertensive non-pregnant control group was 
significantly (p=0.03) older than the other study groups. No other 
significant differences were observed with respect to the other 
clinical characteristics.
CHARACTERISTIC RENAL HISTOLOGY FINDINGS IN 
PREECLAMPSIA
The majority (81%) of the women with preeclampsia had prominent 
glomerular lesions, including various degrees of endotheliosis, 
swelling of podocytes, and tram tracking. Endotheliosis was present 
in 55% of the women with preeclampsia. Although endotheliosis 
is generally considered to be the principal feature of preeclamptic 
glomerular changes, it was also observed - albeit to a significantly 
lesser extent (p=0.003) - in both the pregnant control group (12%) 
and the hypertensive non-pregnant control group (15%). Both tram 
tracking (p<0.001) and podocyte swelling (p=0.02) were present 
in the preeclampsia group only. With the exception of one patient 
with preeclampsia, endotheliosis and tram tracking were not present 
simultaneously. The presence of podocyte changes was correlated 
significantly with the presence of endotheliosis (p=0.001). The 
presence of endotheliosis was not correlated with blood pressure, 
proteinuria, gestational age, or maternal age. No correlation was 
found between renal histopathological lesions and gestational age. 
The hypertensive non-pregnant control subjects had significantly 
more severe ischemic glomerular lesions than the preeclamptic 
patients; these and other lesions are summarized in Table 2. 
Supplemental Figures S1 and S2 show typical examples of renal 
histology from all four study groups.
MORPHOMETRIC ANALYSES 
Glomerular surface areas did not differ significantly between the 
preeclampsia and control groups. However, the chronic hypertensive 
non-pregnant control subjects had significantly larger surface areas 
in the glomerular tuft and Bowman’s capsule than the normotensive 
non-pregnant control subjects (Figure 1A and B). Similar results 
were obtained when we calculated glomerular volume using the 
Weibel-Gomez method.(18) 
THE PREECLAMPSIA PATIENTS AND CONTROL GROUPS HAVE 
SIMILAR NUMBERS OF PODOCYTES 
No significant difference in the number of podocytes was found 
between the preeclamptic group and the control groups (Figure 
1C). Supplemental Figure S3A shows a typical example of WT-1 
staining. WT-1 staining was not correlated with either the renal 
histopathological lesions or patient characteristics. 
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PREECLAMPSIA IS ASSOCIATED WITH INCREASED CELLULAR 
PROLIFERATION 
The women with preeclampsia had significantly more 
intraglomerular Ki-67-positive cells compared to the hypertensive 
and normotensive non-pregnant control groups (p=0.004; Figure 
2A). Furthermore, the women with preeclampsia had significantly 
more Ki-67-positive parietal epithelial cells than the pregnant 
controls and the hypertensive non-pregnant control subjects 
(p=0.02; Figure 2B). Supplemental Figure S3B shows a typical 
example of Ki-67 staining. Ki-67 and CD44 staining was co-
localized (an example is shown in Supplemental Figure S4). Ki-67 
staining was not correlated with either the renal histopathological 
lesions or patient characteristics. 
PREECLAMPSIA IS ASSOCIATED WITH AN INCREASED NUMBER 
OF CD44 POSITIVE PARIETAL CELLS ON A PODOCYTE LOCATION 
We scored the presence and location of CD44-positive/ CD45-
negative cells within the glomeruli for the four study groups (Figure 
3A-C). The podocyte location was confirmed by co-localization 
of CD44 and WT-1 staining (an example is shown in Figure S5A 
and B). The number of CD44-positive cells on a podocyte location 
was significantly higher in the women with preeclampsia than 
in all three control groups (Figure 3D). Moreover, the presence of 
CD44-positive cells was significantly associated with the presence 
of Ki-67-positive intraglomerular cells (p=0.03). Although a 
trend was observed between preeclampsia and CD44-positive 
cells on a parietal epithelial cell location, this association did not 
reach statistical significance (p=0.07; Figure 3E). The number of 
cellular bridges did not differ significantly between the study 
groups; however, the presence of cellular bridges was significantly 
associated with the presence of FSGS (p=0.02). An example of a 
cellular bridge is shown in Supplemental Figure S6.
Discussion
In our cohort of preeclamptic women, podocyte changes and tram 
tracking of the glomerular basement membrane were the most 
typical preeclampsia-associated lesions, occurring in 18% and 
36% of patients, respectively; in contrast, none of the patients 
in our control groups had either of these lesions. Endotheliosis, 
a lesion that has been previously described as a characteristic of 
preeclampsia, was present in 55% of the preeclampsia patients, 
but it was also present – albeit at much lower percentages - in the 
pregnant controls and the hypertensive non-pregnant controls. 
We also provide the first report that although the number of 
glomerular podocytes is unaffected in preeclampsia (as determined 
by histological evaluation), preeclampsia is characterized by a 
higher number of activated parietal epithelial cells. A mechanism 
to explain our findings might come from elegant experiments by 
Appel et al., who used a rat model for lineage tracing and gene 
tagging and found that parietal epithelial cells migrate into the 
glomerular tuft.(19) Moreover, our findings strongly suggest that 
lost podocytes are replaced by progenitor cells of the parietal 
epithelium in the context of preeclampsia.  Importantly, none of the 
patients had any indication of underlying renal disease, suggesting 
that these findings are likely attributable to preeclampsia.  
Preeclampsia is characterized by an increase in the shedding of 
podocytes into the urine,(5-7) and this can occur before the onset of 
clinical manifestations.(20) Furthermore, the expression of podocyte-
specific proteins such as nephrin and GLEPP-1 is significantly 
lower in kidney biopsies from patients with preeclampsia than from 
control subjects.(8, 9) Given the increased shedding of podocytes, our 
current findings that the number of glomerular podocytes remains 
stable suggests an increased turnover of podocytes in preeclampsia. 
Podocytes have traditionally been regarded as highly differentiated, 
non-dividing cells, which would imply that these cells cannot 
regenerate following podocyte injury and/ or loss. However, a 
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recent study reported that the parietal epithelial cells that line 
Bowman’s capsule can replace injured and lost podocytes.(19) On the 
other hand, a recent mouse study reported that proteinuria inhibits 
the differentiation of parietal epithelial cells into podocytes by 
sequestering retinoic acid.(21) 
Recently, it has been shown that parietal epithelial cells – but not 
podocytes – upregulate their de novo expression of CD44 (marker 
of cell migration) following podocyte injury and/ or loss.(22, 23) CD44 
can also be expressed by endothelial cells.(24) However, in our study 
CD44 co-localized with WT-1, and CD44 positivity on a podocyte 
location was significantly higher in the preeclampsia patients than 
in the three control groups. Based on the aforementioned study 
describing parietal epithelial cell migration in a rat model (19), 
our findings suggest that during preeclampsia, activated parietal 
epithelial cells can migrate and replace lost podocytes. Additional 
data to support this mechanism included the increased cell 
proliferation and the co-localization of Ki-67 and CD44 staining 
that was observed in the glomeruli of the women with preeclampsia. 
Together with the observed co-localization between WT-1 and 
CD44, these findings confirm that the Ki-67-positive cells present 
on a podocyte location are indeed podocytes.
The replacement of lost podocytes by activated parietal 
epithelial cells is a compensatory mechanism that - if successful 
- is accompanied by remodeling the glomerular architecture.(25) 
However, under certain conditions, this replacement mechanism 
cannot compensate fully, thereby leading to renal damage 
that is histologically characterized by focal and segmental 
glomerulosclerosis. For example, in a mouse model of focal 
and segmental glomerulosclerosis,(23) an excessive proliferative 
response of parietal epithelial cells was involved in the progression 
of sclerotic lesions.(22, 23, 26) There is also evidence that in renal 
transplants, increased CD44 staining – an indicator of activated 
parietal epithelial cell - distinguishes early recurrent FSGS (which 
manifests with podocyte foot process effacement only) from 
minimal change disease.(17) These authors speculated that CD44 
expression in nephrotic patients without sclerosis has positive value 
in predicting progressive podocyte damage, including FSGS.(17) In 
our study, the patients with preeclampsia did not have significantly 
more FSGS in their kidneys; nevertheless, the significant correlation 
between FSGS and CD44-positive cellular bridges (connecting 
Bowman’s capsule and the glomerular tuft) supports the previous 
notion that CD44 positive cells are involved in the formation of 
sclerotic lesions.(17, 23) The results reported by Fatima et al.(17) provide 
insight into the implications of our current findings, as women 
with preeclampsia have a higher risk of developing FSGS later in 
life(27);  moreover, we found that the preeclamptic women in our 
study had higher CD44 positivity on a podocyte location compared 
to the control groups. We therefore speculate that this increased 
CD44 positivity in preeclamptic kidneys is a sign of progressive 
podocytopathy and may have predictive value for FSGS in the long 
run. Our findings within the preeclamptic kidney during pregnancy 
might also explain the reported increased risk for women with 
preeclampsia to develop end-stage renal disease later in life.(4, 28) 
However, it bears mentioning that because we investigated autopsy 
material, we were unable to analyze any possible correlation 
between CD44 positivity during pregnancy and the development 
of sclerotic lesions later in life. The sequence of events and the 
aforementioned putative mechanisms that underlie podocyte 
replacement and subsequent podocytopathy during preeclampsia are 
illustrated in Figure 4.
An important lingering question is what early mechanism 
causes podocyte injury and loss during preeclampsia. In our study, 
preeclampsia was characterized by damage to all three layers 
of the glomerular filtration barrier. Consistent with a previous 
report, although endotheliosis was observed – albeit relatively 
rarely - in the pregnant controls and hypertensive non-pregnant 
controls, endotheliosis was most prevalent among the women with 
preeclampsia.(15) A dysregulation of—and the resulting imbalance 
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between—proangiogenic and antiangiogenic factors is believed 
to cause endotheliosis; in particular, increased levels of the 
antiangiogenic factor sFlt-1 (soluble Fms-like tyrosine kinase) can 
prevent vascular endothelial growth factor (VEGF) from maintaining 
the renal endothelium.(29) Because VEGF is essential for the 
interaction between endothelial cells and podocytes,(30) dysregulation 
of VEGF also affects the podocyte. The notion that dysregulation of 
these factors plays a role in the renal manifestations of preeclampsia 
is supported by studies showing that endotheliosis is a key feature 
of glomerular injury in a podocyte-specific VEGF-knockout mouse.
(29) The same study also reported that similar lesions were observed 
in patients who were treated with the VEGF inhibitor bevacizumab.
(29) Based on these observations, it is highly likely that angiogenic 
imbalance plays a causative role in the renal manifestations of 
preeclampsia. However, preeclampsia may arise from a variety of 
causative factors other than angiogenic imbalance alone.(31)
In conclusion, building on our previous report that preeclampsia 
is characterized by increased shedding of podocytes into the 
urine,(6) we now present the first report that the absolute number of 
glomerular podocytes is actually unchanged during preeclampsia. 
This finding might be explained by increased cell proliferation and/
or significantly increased numbers of activated parietal epithelial 
cells, suggesting that these activated cells can migrate to a podocyte 
location. Our results indicate that podocytopathy plays a central 
role in preeclamptic nephropathy, thereby contributing – at least 
in part - to the increased risk of developing FSGS later in life. This 
notion is consistent with previous reports that podocytopathy plays 
a role in other forms of FSGS, and it lends credence to speculation 
that targeting the podocyte may have therapeutic value.(32, 33) 
Indeed, several studies showed that modulatig podocyte turnover by 
regulating activation of parietal epithelial cells(34) can be achieved 
by certain therapies such as ACE inhibitors,(35) and inhibitors of 
the Notch signalling pathway.(36) Whether the activation of parietal 
epithelial cells is a mechanism to compensate for ongoing podocyte 
injury and loss, or whether these cells contribute to glomerular 
injury - or both - remains to be investigated. Nevertheless, 
unraveling the mechanisms of podocyte damage and parietal 
epithelial cell recruitment in the setting of preeclampsia may lead to 
novel approaches for treating renal injury. 
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Table 1 (previous page): Patient characteristics
Data are given as the median (IQR) unless otherwise specified. PE: preeclampsia, PC: 
normotensive pregnant controls, HC: hypertensive non-pregnant controls, NPC: normotensive 
non-pregnant controls. NA: Not applicable. SD: standard deviation. * p =0.03, ** p=0.001, *** 
p=0.006. # data on hypertensive therapy of the hypertensive controls was available from 4 
patients.  
Histological parameters PE (n=11) PC (n=25) HC (n=14) NPC (n=13) p-value
ATN (%) 0 (0) 4 (16) 3 (21) 3 (23) 0.41
Congestion (%) 0 (0) 0 (0) 0 (0) 3 (23) 0.007
Endotheliosis (%) 6 (55) 3 (12) 2 (14) 0 (0) 0.003
   <20% of the lumen (%)
   20-80% of the lumen (%) 













FSGS (%) 1 (9) 2 (8) 5 (36) 0 (0) 0.03
Global sclerosis >1% (%) 1 (9) 0 (0) 5 (36) 1 (8) 0.04
Glomerulitis (%) 0 (0) 6 (24) 1 (7) 2 (15) 0.23
Hyalinosis (%) 1 (9) 4 (16) 7 (50) 10 (77) <0.001
IFTA (%) 0 (0) 0 (0) 2 (14) 0 (0) 0.06
Intima fibrosis (%) 2 (18) 7 (28) 11 (79) 5 (39) 0.006
Ischemia (%) 0 (0) 1 (4) 3 (21) 1 (8) 0.17
Mesangium changes (%) 1 (9) 0 (0) 4 (29) 1 (8) 0.04
Microthrombi (%) 1 (9) 0 (0) 1 (7) 0 (0) 0.20
Edema (%) 1 (9) 0 (0) 0 (0) 1 (8) 0.34
Podocyte changes (%) 2 (18) 0 (0) 0 (0) 0 (0) 0.02
Tram tracking (%) 4 (36) 0 (0) 0 (0) 0 (0) <0.001
Table 2: Renal histological parameters in the patients and control groups
Values are expressed as number of patients (%). ATN: acute tubular necrosis, FSGS: focal and 
segmental glomerulosclerosis. All FSGS cases were classified as the “Not otherwise specified” 
(NOS) variant. IFTA: interstitial fibrosis tubular atrophy. PE: preeclampsia, PC: normotensive 
pregnant controls, HC: hypertensive non-pregnant controls, NPC: normotensive non-pregnant 
controls.
Characteristics PE (n=11) PC (n=25) HC (n=14) NPC (n=13)
Age (years) 32.5 (29.5-35.8) 31.0 (28.3-36.6) 41.8 (34.4-43.5) * 33.5 (24.6-40.0)
Gestational age (weeks) 35.7 (34.1-39.0) 33.4 (16.7-40.0) NA NA
Parity (mean (SD)) 0.6 (1.0) 0.8 (1.0) NA NA
Proteinuria (g/ 24 hours)
Blood pressure (mmHg)
          Systolic
          Diastolic
Antihypertensive therapy (n (%))
Comorbidities (n (%))
          Sickelcell anemia
          WPW syndrome
          Asthma
          Hyperhomocysteinemia
          Hypertension
          Epilepsia
          Mammacarcinoma
          Renal insufficiency
          Depression
          Obesity
Cause of death (n (%))
          Preeclampsia related
          EUG
          Thromboembolism
          Amniotic fluid embolism
          Arrhythmias 
          Cardiac arrest
          Eci
          Malignancy
          Aortadissection
          Infection
          Cardiomyopathy
          Pheochromocytoma 
          Cerebral bleeding
          Suicide
          High energy trauma
          Drowning
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Figure 1: Morphometric analysis and podocyte number 
Glomerular surface areas were calculated for the glomerular tuft (A, * p=0.003) and 
Bowman’s capsule (B, * p=0.002) in the preeclampsia patients and control groups. Panel 
C summarizes the number of WT-1 positive podocytes per glomerulus in the women with 
preeclampsia, and the control groups.  
 
Figure 2: Ki-67 analysis
Panel A summarizes the percentage of glomeruli with Ki-67-positive cells (* p=0.004), and 
panel B summarizes the percentage of glomeruli with Ki-67-positive parietal epithelial cells 
(* p=0.02). In A and B, each symbol represents an individual patient or control. 
Double staining of CD44 and CD 45 (full colour version inside cover)
Sections were co-stained for CD44 (green) and CD45 (red), and the number of CD44-positive/ 
CD45-negative cells was scored within the glomeruli. Panel A shows double staining of 
CD44 positive/ CD45 negative cells on a podocyte location (arrowheads). The nuclei were 
counterstained with DAPI (blue). Note that the CD44-positive cells (B) are CD45-negative (C).  
Panel D summarizes the number of CD44-positive cells on a podocyte (visceral epithelial cell, 
VEC) location (** p =0.01, *** p =0.001). Panel E summarizes the number of CD44-positive cells 
on a parietal epithelial cell location (p=0.07). In D and E, each symbol represents an individual 








Typical examples of renal histology in preeclampsia and control subjects  
(full colour version inside cover)
PAS stain showing examples of the various glomerular lesions seen in patients and controls. 
In preeclamptic patients significantly more endotheliosis (arrow) was observed (a), while the 
majority of pregnant controls showed no glomerular pathology (b). In hypertensive controls 
a greater surface area of the glomerular tuft and Bowman’s capsule was prominent (c), but 
non-pregnant controls showed generally normal glomeruli (d).
Schematic overview of the putative mechanism underlying podocyte replacement in 
preeclampsia
Hypertension, dysregulation of VEGF, and other factors cause damage and loss of podocytes 
during preeclampsia, resulting in increased shedding of podocytes into the urine.  In 
preeclampsia, an increase in turnover of podocytes results from increased proliferation 
of parietal epithelial cells and higher numbers of activated parietal epithelial cells on a 
podocyte location. As a result of this increased turnover, the absolute number of glomerular 
podocytes is stable during preeclampsia. The replacement of lost podocytes by activated 
parietal epithelial cells is a compensatory mechanism, that – if sufficient – leads to the 
resolution of clinical symptoms, including proteinuria. However, if compensation is not 
sufficient, this mechanism can trigger persistent podocytopathy, with progressive proteinuria 
and renal function loss later in life, histologically characterized by focal and segmental 
glomerulosclerosis (FSGS).
Figure S1 Figure 4 
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CD44 and Ki-67 staining  (full colour version inside cover)
Sections were co-stained for CD44 (green) and Ki-67 (red). Panel A shows double staining 
of a CD44 positive/ Ki-67 positive cell on a podocyte location (arrow). The nuclei were 
counterstained with DAPI (blue). Note that the CD44-positive cells shown a membrane 
staining pattern (B) with Ki-67-positive nuclear staining pattern (C).  
CD-44 positive cells on a podocyte location  (full colour version inside cover)
Sections were co-stained for WT-1 (dark grey) and CD44 (green). Note the WT-1-positive 
cells indicating podocytes (A, an example is indicated by an arrow). In Panel B, a CD44-
positive cell (arrow), is also WT-1 positive (A, arrow).
Cellular bridge  (full colour version inside cover)
This figure shows an example of a cellular bridge (arrow) in a silver stain. 
 
 
Renal histology in preeclampsia  (full colour version inside cover)
This figure shows typical examples of histologic lesions in patients with preeclampsia. In 
preeclamptic patients significantly more endotheliosis (a, arrow). Note that endotheliosis 
(a, arrow) consists of endothelial cells, as shown by the positivity for the endothelial marker 
CD31 (b, arrow). In patient with preeclampsia significantly more tram tracking (c, arrow) was 
observed than in controls, and podocytes (arrow) were prominently present (d). 
 
 
WT-1 and Ki-67 staining (full colour version inside cover)
Panel A shows a typical section with intraglomerular WT-1 positive cells (arrowhead) 
indicating podocytes. Panel B shows a typical section with Ki-67 positivity, a marker of cell 
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Abstract
Preeclampsia is a significant cause of maternal and fetal morbidity 
and mortality worldwide. A clinically useful screening test that can 
predict development of preeclampsia at an early stage is urgently 
needed. The detection of podocyturia by immunohistochemistry 
after cell culture has been noted as a reliable marker for 
preeclampsia. However, this method is laborious and carries the 
risk of cell-culture contamination. The aim of this study was to 
investigate the diagnostic value of qPCR as a rapid method to detect 
preeclampsia.
Clean-catch urine samples were collected from 
preeclamptic(n=35), healthy pregnant(n=34), and healthy non-
pregnant(n=12) women. Furthermore, a control group of women 
with gestational hypertension(n=5) was included. qPCR analysis was 
performed for podocyte-specific markers. ROC-curve analyses were 
performed.
Significantly elevated mRNA levels of nephrin, podocin 
and VEGF were detected in preeclamptic women compared to 
healthy pregnant and healthy non-pregnant controls. In addition, 
significantly elevated levels of nephrin mRNA were detected in 
urine of preeclamptic women compared to women with gestational 
hypertension. A positive correlation (ρ=0.82, p<0.0001) was 
observed between nephrin and VEGF mRNA levels in preeclamptic 
women. ROC-curve analyses demonstrated a strong ability of this 
method to discriminate between the different study groups.
qPCR analysis of podocyte-specific molecules in urine samples 
is a rapid and reliable method to quantify podocyturia. We 
demonstrate that this method distinguishes preeclamptic patients 
from healthy controls and women with gestational hypertension. 
This method may be a tool for the detection of preeclampsia at an 
earlier stage, thereby preventing maternal and fetal morbidity and 
mortality.
Introduction
Preeclampsia affects 2-8% of all pregnancies and is an important 
cause of maternal and fetal morbidity and mortality worldwide. 
Preeclampsia is a pregnancy-specific, multisystemic disorder, with 
the kidney as one of the major target organs. Proteinuria and new-
onset hypertension after 20 weeks of gestation are the defining 
diagnostic criteria for preeclampsia.1 
Proteinuria arises when there is damage to the glomerular 
filtration barrier (GFB). The GFB consists of a basement membrane 
between a layer of fenestrated endothelium and a layer of 
glomerular visceral epithelial cells, known as podocytes. The 
histological hallmark of preeclampsia in the kidney is glomerular 
endotheliosis. Endotheliosis is characterized by the swelling of 
endothelial cells, enlarged glomerular volume with hypertrophy, and 
loss of glomerular endothelial fenestrae. Podocyte damage and foot 
process effacement are visible with electron microscopy.2 
Although the exact pathophysiologic mechanisms leading to 
preeclampsia-related proteinuria remain unknown, it is evident that 
preeclampsia is associated with elevated serum levels of soluble 
Fms-like tyrosine kinase 1 (sFlt-1) and Endoglin (sEng) and reduced 
serum levels of Vascular Endothelial Growth Factor-A (VEGF-A).3-5 
VEGF-A regulates angiogenesis in all endothelial beds and is 
required in the early stages of vascular development. In the kidney, 
VEGF-A is expressed in tubular epithelial cells and in differentiated 
podocytes in the glomerulus. It appears that a paracrine/juxtacrine 
VEGF-signaling pathway is responsible for the cross-talk between 
endothelial cells and podocytes. It is thought that this signaling 
is crucial for the formation and maintenance of the glomerular 
filtration barrier.6 
There is increasing evidence that podocytes play an important 
role in the renal manifestations of preeclampsia. It was 
demonstrated that a podocyte-specific conditional knock-out of 
VEGF-A in mice results in a loss of podocytes, the induction of 
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proteinuria, and glomerular abnormalities, such as thrombotic 
microangiopathy (TMA).7 This mechanism also appears to be 
relevant in humans, as was clearly demonstrated by a study in 
which patients with malignancies were treated with anti-VEGF 
therapy and developed glomerular endotheliosis, proteinuria and 
TMA, similar to what is observed in women with preeclampsia.7
Based on experimental models, it was suggested that the 
appearance of podocytes in urine could be a specific marker for 
glomerular disease. In different in vivo models of podocyte damage 
with transient or continuing injury, evidence was found that 
urinary excretion of viable podocytes is confined to the phase 
of active, ongoing glomerular damage, whereas the detection 
of proteinuria cannot distinguish between ongoing damage and 
persistent glomerular defects in the barrier’s function.8 Garovic 
et al. showed for the first time that podocyturia as detected by 
immunohistochemistry on cultured podocytes is a highly sensitive 
and specific method for the detection of preeclampsia at disease 
onset.9 Subsequently, Aita et al. showed that podocyturia was still 
present in patients with preeclampsia one month following delivery, 
while proteinuria disappeared.10 
Although prospective studies are still awaited, the publication by 
Garovic et al. holds the promise of a novel, possibly even predictive 
biomarker for preeclampsia. The method described by Garovic et al. 
has important drawbacks. Cell culture and immunohistochemistry 
are laborious protocols and carry the risk of cell-culture 
contamination. We therefore investigated the potential of 
quantitative polymerase chain reaction (qPCR) to detect the mRNA 
level of podocyte-specific molecules in urine-samples of women 
with preeclampsia. This method has been shown to be rapid and 
accurate in other clinical settings.11,12 We therefore hypothesized that 
this technique may be an alternative way to diagnose preeclampsia. 
Methods
PATIENTS 
A case-control study was conducted to investigate the potential of 
qPCR-based analysis of podocyturia as a biomarker for preeclampsia. 
Preeclamptic(n=35), healthy pregnant(n=34) and healthy non-
pregnant(n=12) women were included. Furthermore, a control group of 
women with gestational hypertension(n=5) was included.
According to the ACOG-guideline13 the definition of preeclampsia 
is a new-onset hypertension (defined as an arterial systolic blood 
pressure of >140mm Hg or arterial diastolic blood pressure >90 mmHg) 
and proteinuria (>300 mg in a 24-hour urine sample) after at least 20 
weeks of gestation. Gestational hypertension was defined as new-onset 
hypertension, but without concurrent proteinuria. Hypertension and/
or proteinuria had to be resolved within 12 weeks following delivery. 
Patients with known hypertension, renal disease or proteinuria before 
pregnancy were excluded. At the time of urine collection, all patients 
with preeclampsia were admitted to the Department of Obstetrics of the 
LUMC. To prevent contamination of the maternal urine with amniotic 
fluid or fetal urine, urine was collected from patients whose membranes 
were intact.
Healthy pregnant women were matched with the patients for parity, 
gestational age (±2 weeks) and age (±5 years). These women had no 
medical history of preeclampsia, other hypertensive disorders or renal 
disease. Healthy pregnant women were monitored at the obstetrical 
outpatient clinic of the LUMC. 
Healthy non-pregnant women were residents of the Department of 
Obstetrics and Gynecology of the LUMC. These women were matched 
with the healthy pregnant women for parity.
Urine samples were collected following the guidelines of the medical 
ethical review commission of the LUMC and in accordance with the 
recent guideline of the Dutch Federation of Scientific Societies. All 
samples were coded and processed anonymously. 
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URINE COLLECTION AND CELL ISOLATION
Clean-catch urine samples were obtained and processed within two 
hours of collection. Urine-samples were transferred to tubes and 
centrifuged at 1500 rpm for 5 minutes. Centrifuged urine samples 
were stored at -20oC. Albumin and creatinine levels were measured 
from these urine samples. Pellets of centrifuged urine samples were 
washed with phosphate buffered saline (PBS) and centrifuged again 
at 1500 rpm for 5 minutes. The pellets were suspended in RNA-later 
and stored at -20oC until RNA isolation. 
The RNA was isolated using the Trizol method. Briefly, the 
cell suspension in RNA-later was centrifuged at 13000 rpm for 
2 minutes. Pellets were then dissolved with Trizol and RNA was 
isolated as previously described.14 
QPCR
cDNA was generated with AMV reverse transcriptase (20 U/µl) 
(Roche), according to manufacturer’s instructions. For the qPCR 
reaction iQ™ SYBR® Green supermix was used. Expression of the 
different podocyte-specific markers was measured using gene-
specific primers. The primer sequences used are shown in Table S1. 
We measured expression of genes that code for proteins that localize 
to the slit diaphragm of podocyte foot processes (nephrin and 
podocin). These markers are known to be podocyte-specific. GAPDH 
was used as a positive control. The levels of VEGF mRNA were also 
measured. In the kidney, VEGF is expressed in podocytes and in 
the proximal tubular epithelium. To exclude the possible presence 
of proximal tubular epithelial cells, mRNA levels of megalin were 
also measured. mRNA levels detected by qPCR were corrected for 
creatinine concentration and calculated per ml urine. To investigate 
whether the podocyte-specific mRNA levels correlated with the 
number of viable podocytes, mRNA was isolated from six serially 
diluted samples of immortalized podocytes (kindly provided by M. 
Saleem).15
CELL CULTURE
From a subgroup of patients 5 ml of each urine sample was used 
to culture the cells on 8-chamber culture slides as described 
previously.9,16 The following day the medium was removed, and the 
slides were fixed with methanol. All eight chambers were incubated 
with an anti-podocin antibody (kindly provided by Dr. C. Antignac 
of Hopital Necker, Paris, France) at a dilution of 1:500.17  The slides 
were scored blindly for the presence of podocytes. Nucleated, 
positive-stained cells were considered to be podocytes. Podocyturia 
is expressed as the ratio of the number of podocytes to the 
creatinine content.
STATISTICAL METHODS
Descriptive statistics are reported as the means ± SD. Patient 
characteristics were compared using an unpaired T-test. The mRNA 
levels of VEGF and GAPDH in the different groups were compared 
using nonparametric tests (Kruskal-Wallis and Mann-Whitney 
U-test). All measurements were carried out in duplicate. The mean 
measurement was used for the statistical analysis. Because there 
were non-detects for nephrin and podocin (Table S2) censored 
boxplots were drawn and p-values were calculated using R-package 
NADA (Nondetects And Data Analysis for environmental data) 
software, as described previously.18 Correlations between the 
expression of the different markers, cultured podocytes and clinical 
characteristics were calculated using a Spearman’s coefficient. Using 
the receiver operating characteristic (ROC) curve, the area under 
the curve (AUC), sensitivity and specificity of three markers (VEGF, 
nephrin and podocin) treated separately and in combination were 
calculated. All significance tests were two-tailed and conducted at 
the 0.05 significance level using Graphpad Prism version 5.




Patient characteristics of the different patient groups are shown in 
Table 1. As expected, women with preeclampsia had a significantly 
higher body mass index, elevated systolic and diastolic blood 
pressures, elevated levels of proteinuria, earlier deliveries and 
infants with lower birth weights compared to healthy pregnant 
controls. Women with gestational hypertension had significantly 
elevated systolic and diastolic blood pressures compared to healthy 
pregnant controls. 
mRNA LEVELS
qPCR was performed for nephrin, VEGF, podocin, GAPDH and 
megalin. mRNA levels for these proteins were examined in urine-
samples of preeclamptic, non-preeclamptic pregnant and non-
pregnant control women. In all samples, expression of GAPDH was 
detectable and there were no differences in the mRNA levels of this 
gene between the groups. 
Significantly elevated levels of podocin (p<0.001), nephrin 
(p=0.01) and VEGF (p<0.001) were detected in the urine samples 
of preeclamptic women compared to healthy pregnant controls 
(see Figure 1). The mRNA levels of podocin (p<0.00001), nephrin 
(p<0.001) and VEGF (p=0.01) were also found to be significantly 
elevated in samples from preeclamptic women compared to healthy 
non-pregnant controls. Furthermore, the mRNA levels of podocin 
(p<0.01) and VEGF (p=0.03) were significantly higher in the group 
of healthy pregnant women than in the healthy non-pregnant 
controls. For nephrin, the difference between these two groups 
was not significant. Non-detects (i.e. mRNA levels were under the 
detection limit of the qPCR) were observed for podocin and nephrin 
(Table S2). No megalin mRNA was detectable in any of the analyzed 
urine samples (data not shown). Furthermore, an additional control 
group containing women with gestational hypertension was 
analyzed using qPCR. Significantly higher levels of nephrin mRNA 
were detected in the urine from the preeclamptic women than from 
the women with gestational hypertension (p<0.05). In addition, the 
levels of VEGF and podocin mRNA were increased 9.5-fold and 4.0-
fold respectively, in the urine from preeclamptic patients, although 
these differences did not reach significance (data not shown).
To investigate whether the mRNA levels of podocyte-specific 
markers correlated with the number of viable podocytes, mRNA was 
isolated from a serial dilution of a known quantity of immortalized 
podocytes (kindly provided by M. Saleem). The Spearman’s 
correlation coefficient revealed that the number of podocytes was 
significantly correlated with nephrin mRNA levels (R=0.98, p<0.01) 
as shown in Figure 2. 
To determine whether relative expression levels were different 
between the various podocyte markers, mRNA levels were correlated 
with one another. Using Spearman’s correlation coefficient, a 
correlation of 0.82 (p<0.0001) between nephrin and VEGF was 
observed in the preeclamptic women and in the pregnant controls 
(see Figure 3).  Likewise, a Spearman’s correlation coefficient was 
measured to test whether the severity of proteinuria correlated 
with the mRNA levels of podocyte-specific markers. The albumin/
creatinine ratio did not correlate with the mRNA levels of either the 
combined or separate podocyte-specific markers in the patients with 
preeclampsia or in the controls.
CELL CULTURE
To determine whether the mRNA levels of podocyte-specific markers 
were correlated with the number of viable podocytes in patient 
samples, cells were cultured from urine collected from a subgroup 
of patients, and each patient’s nephrin mRNA level was plotted 
against the patient’s corresponding podocyte count. A Spearman’s 
correlation coefficient revealed that the number of podocytes correlated 
significantly (R=0.72, p<0.05) with the levels of nephrin mRNA. 
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TEST CHARACTERISTICS: ROC CURVE ANALYSIS
A Receiver Operating Characteristic (ROC) curve analysis was 
performed. The area under the curve (AUC), sensitivity and 
specificity for the three markers (VEGF, nephrin and podocin) 
separately (see Table 2) and combined (see Table 2 and Figure 4) 
were calculated to discriminate between the different groups. The 
three markers combined had a higher overall value for the different 
calculated characteristics than when the markers were treated 
separately. For the group of preeclamptic women compared to 
healthy pregnant controls, the AUC for the three markers combined 
was 0.82, with sensitivity and specificity values of 68.6 and 88.2, 
respectively. The test characteristics for the group of women with 
preeclampsia compared to healthy non-pregnant women, again 
combining the three markers, were as follows: the AUC was 0.99, 
the sensitivity 94.3 and the specificity 91.7. All of these results are 
summarized in Table 2.
Discussion
To our knowledge, this is the first study to describe the use of qPCR 
to quantify podocyturia in the context of preeclampsia. In the 
present study, significantly elevated levels of nephrin, podocin and 
VEGF mRNA were detected in the urine of preeclamptic women as 
compared to levels in healthy pregnant controls and healthy non-
pregnant controls. Significantly higher levels of nephrin mRNA 
were detected in urine from preeclamptic women than in urine from 
women with gestational hypertension.
In addition, we observed significantly elevated mRNA levels of 
VEGF and podocin in the urine of healthy pregnant controls as 
compared to healthy non-pregnant controls. Furthermore, the AUC, 
sensitivity and specificity for the three markers (nephrin, podocin 
and VEGF) treated separately and in combination indicate that 
this method is capable of discriminating between preeclamptic and 
non-preeclamptic women. Taken together, qPCR-based analysis 
of podocyturia is a highly promising, non-invasive method for 
detecting preeclampsia.
Despite decades of research into preeclampsia, predicting 
which women are at increased risk of developing this condition 
remains problematic. Many studies have attempted to identify a 
predictive biomarker. Numerous molecules in serum of patients 
with preeclampsia, such as sFlt-1, VEGF, sEng, Placental Growth 
Factor, P-Selectin, and Placental Protein 13, have been proposed as 
candidates for early detection of preeclampsia. However, no single 
molecule has proven to be reliable as a predictive tool.19 
Our observation that mRNA levels of podocin, nephrin and 
VEGF are significantly elevated in the urine of preeclamptic women 
compared to those in non-preeclamptic patients is in agreement 
with the results of Garovic et al.9 In this case-control study, the 
authors report an impressive correlation between podocyturia 
detected by immunologic staining of podocyte-specific markers and 
the presence of preeclampsia. Podocyturia was a highly sensitive 
and specific (both 100%) predictor and the correlation with the 
condition was stronger than for any of the known angiogenic 
factors. Although our sensitivity and specificity values are not 
100%, our confirmation of the correlation between podocyturia 
and preeclampsia as described by Garovic et al. is an important 
step for the use of podocyturia as a potential early biomarker for 
preeclampsia. 
There are also several interesting differences between our 
data and the results of Garovic et al. that bear mentioning. In 
normotensive women, and in women with either hypertension or 
proteinuria but without preeclampsia Garovic et al. did not observe 
podocyturia as measured using a urinary podocin-staining protocol. 
In contrast with these results, our qPCR-based analysis revealed 
the expression of podocyte-specific molecules in the urine of both 
pregnant and non-pregnant healthy women. This finding indicates 
that in normal pregnancy - and even in non-pregnant states - there 
is loss of podocytes in the urine that can be detected using qPCR. 
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Interestingly, these results are in agreement with the most recent 
study by Garovic et al., which illustrated that podocyturia, shown 
by the identification of a podocyte-specific peptide using mass 
spectrometry, was measurable in women with a normal pregnancy 
and was further increased in preeclampsia.16
Furthermore, we found that the mRNA levels of the podocyte-
specific markers were lower in women with gestational hypertension 
than in preeclamptic patients, with nephrin being the most 
prominently reduced (p<0.05). These results suggest that measuring 
the expression of podocyte-specific markers can distinguish between 
gestational hypertension and preeclampsia. 
The ultimate goal of qPCR analysis of podocyturia is the 
detection of pre-clinical stages of preeclampsia prior to the 
occurrence of proteinuria, thereby identifying women at risk of 
developing the disease. In this stage, it is likely that the number of 
podocytes in the urine is relatively low. Therefore, a sensitive test is 
needed to detect small differences in the quantity of podocytes. In 
this context, qPCR analysis is a promising method.
One of the challenges in the current study was to ensure both 
the quality and quantity of the RNA isolated from urinary cells. 
To minimize the possibility that differences in mRNA levels were 
caused by variations in the processing methods, every urine sample 
was handled by following to a strict protocol. Because the RIN 
(RNA Integrity number) showed that the RNA in most samples 
was partially degraded, we used random primers to synthesize the 
cDNA. In addition, specific PCR primers were chosen to generate 
small amplification fragments. Although some samples were 
negative (non-detects) for nephrin and/or podocin (Table S2), the 
housekeeping gene GAPDH was detected in every sample, and its 
expression levels were similar among all study groups. This result 
suggests that the quality of RNA isolated from urinary cells was 
sufficient for amplification. Therefore, the possibility of non-detects 
being attributable to RNA degradation seems negligible.
The method used by Garovic et al. has several disadvantages 
compared to the method described in the present study. Cell 
culturing followed by immunostaining of urinary podocytes carries 
the risk of contamination during cell culture. Moreover, this method 
is relatively time-consuming (a test result can be produced in two 
days at the earliest), whereas the detection of podocyturia using 
qPCR can be performed within four hours. 
An important issue is the choice of the markers used in the 
experiments. Podocin and nephrin are proteins that are expressed in 
the slit-diaphragm of the podocyte foot process, and can therefore 
be used as podocyte-specific markers.20,21 VEGF was chosen as an 
additional marker because its expression is known to be high in 
podocytes.22 As VEGF is also expressed in the proximal tubular 
epithelium, we examined the expression of megalin, which is 
expressed on tubular epithelial cells only. Because we could not 
detect megalin mRNA in our samples, the observed VEGF mRNA 
was likely derived from podocytes. 
We found a significant correlation (p<0.0001) between the mRNA 
levels of VEGF and nephrin, indicating that the mRNA levels are 
a representative marker for the number of podocytes in the urine. 
Although preeclampsia has been associated with reduced VEGF 
signaling, the increased VEGF mRNA levels measured in our study 
seem to reflect the high abundance of podocytes in the urine of 
women with preeclampsia. Previous work performed by Baelde et 
al. demonstrated a strong correlation between the mRNA levels of 
nephrin and podocin and the number of podocytes as measured by 
WT-1 staining (a podocyte-specific stain) in kidney biopsies.23 
Importantly, it is difficult to discriminate between viable and 
apoptotic podocytes using qPCR analysis of urinary sediments. 
However, our finding that the number of cultured, viable podocytes 
correlates strongly with the expression levels of podocyte-specific 
markers suggests that measuring the expression of these markers 
provides a reliable estimate of the number of viable podocytes. 
However, based on this experiment, although we cannot exclude the 
possibility that qPCR may also detect mRNA from apoptotic cells, 
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our results nevertheless show that mRNA levels increase with an 
increase in the number of viable podocytes.
An interesting observation in the present study was the 
significant difference in the mRNA levels of VEGF and podocin 
in healthy pregnant controls compared to levels in healthy non-
pregnant women. This finding suggests a physiologic shedding of 
podocytes during normal pregnancy. Previous studies show that 
preeclampsia is associated with a maternal systemic inflammatory 
response (MSIR).24,25 Interestingly, a milder MSIR is also seen during 
normal pregnancy. It is proposed that this MSIR only leads to the 
clinical symptoms of preeclampsia when one or more maternal 
systems decompensate. According to this model, the increased 
podocyturia seen in healthy pregnant controls may be the result 
of endothelial dysfunction due to the physiologic MSIR, whereas 
the further increase of podocyturia seen in preeclamptic women 
resembles the dysregulation and decompensation of one or more 
maternal systems.   
The present study has two primary limitations. First, we 
measured mRNA levels in the urine of women with preeclampsia, 
gestational hypertension and healthy pregnant controls. Previous 
studies have reported significant higher levels of podocyte-specific 
mRNA detected using qPCR in patients with Diarrhea+ Hemolytic 
Uremic Syndrome (D+ HUS)11, IgA nephropathy26 and diabetic 
nephropathy26,27 relative to healthy controls. Therefore, it is difficult 
to rely solely on podocyturia to differentiate between preeclampsia 
and other underlying renal diseases. 
Secondly, because we used a case-control study design, it is 
impossible to calculate the predictive value of our qPCR analyses. A 
previous study suggested that podocyturia might be more sensitive 
than proteinuria as a marker of glomerular disease severity.8 
Interestingly, in the present study, the albumin/creatinine ratio was 
not correlated with the mRNA levels of podocyte-specific markers in 
patients with preeclampsia. Aita et al. reported that podocyturia can 
be present in patients with preeclampsia even after delivery, whereas 
proteinuria has disappeared by this stage.10 In addition, several 
other studies have suggested the potential use of podocyturia for 
detecting ongoing glomerular damage.28,29 
In conclusion, a prospective study is needed to assess whether 
podocyturia at an early stage is a more reliable marker for 
preeclampsia than conventional biomarkers, such as proteinuria. 
PERSPECTIVES
We have shown for the first time that qPCR-based analysis of 
podocyte-specific molecules in urine samples is a rapid and 
sensitive method for quantifying podocyturia in patients with 
preeclampsia. Our current results are promising and qPCR-detected 
podocyturia may be a useful diagnostic tool to detect preeclampsia 
during the early stages of pregnancy. A prospective study should 
assess whether this test can predict which women are predisposed 
to preeclampsia. If so, this would be an important, much-needed 
step toward improving the diagnosis of preeclampsia and possibly 
toward therapies for the prevention of maternal and fetal morbidity 
and mortality worldwide.
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NOVELTY AND SIGNIFICANCE 
 
What is New?
qPCR-based analysis of podocyte-specific molecules in urine 
samples for quantifying podocyturia in patients with preeclampsia. 
What is Relevant?
•	 Preeclampsia is a common pregnancy-specific hypertensive disorder 
with serious maternal and fetal morbidity and mortality.
•	 A clinically useful screening test that can predict the development 
of preeclampsia at an early stage is urgently needed to prevent fetal 
and maternal morbidity and mortality worldwide.
Summary
We have shown that qPCR-based analysis of podocyte-specific 
molecules in urine samples is a rapid and sensitive method for 
quantifying podocyturia in patients with preeclampsia.
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31.22 ± 3.73 
39.8 ± 1.34
3530.8 ± 518.0
30.00 ± 2.34 
0.40 ± 0.55
26.47 ± 2.78 
142.00 ± 9.75 * 















Table 1: Patient characteristics
Data are given as the mean ± SD. * Denotes a statistically significant difference (p<0,01) 
compared to the healthy controls. PE: preeclampsia, PC: pregnant control, GH: gestational 
hypertension, NPC: non-pregnant control.
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Markers AUC Sensitivity Specificity
1. PE vs. PC
    Podocin
    VEGF
    Nephrin
    Combined
2. PE vs. NPC
    Podocin
    VEGF
    Nephrin
    Combined
3. PC vs. NPC
    Podocin
    VEGF
    Nephrin






































In this table, the Area Under the Curve (AUC), sensitivity and specificity for the three markers 
(VEGF, nephrin and podocin) treated separately and in combination are shown. The test 
characteristics are calculated for the different groups. PE: preeclampsia, PC: pregnant control, 
NPC: non-pregnant control.
 
Boxplots for VEGF, nephrin and podocin
This figure shows the boxplots for podocin (A), VEGF (B) and nephrin (C) mRNA levels. For 
podocin and nephrin, censored boxplots are shown. A regular boxplot was drawn for VEGF. 
The detection limits for podocin and nephrin were 4.95 * 10-8 and 3.83 * 10-7, respectively. 
For podocin and VEGF, the calculated differences between the different groups were found to 
be statistically significant. Differences in nephrin mRNA levels were found to be statistically 
significant between the examined groups, except for levels between the healthy pregnant 
controls and the healthy non-pregnant controls. A logarithmic scale was used for all panels. 
PE: preeclamptic patients, PC: pregnant controls, NPC: non-pregnant controls.
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Correlation between number of immortalized podocytes and nephrin mRNA level
In this figure, the statistically significant correlation between the number of immortalized 
podocytes in six samples and nephrin mRNA level is shown. An R-value of 0.98 (p<0.01) was 
calculated using a Spearman’s coefficient.
Correlation between nephrin and VEGF mRNA expression levels
In this figure, the statistically significant correlation between nephrin and VEGF mRNA levels 
is shown. An R-value of 0.82 (p<0.0001) was calculated using a Spearman’s coefficient. 
Logarithmic scales are used for both axes. PE: preeclamptic patients, PC: pregnant controls, 
NPC: non-pregnant controls.  
Figure 4: ROC curves 
In this figure, the ROC curves for the three combined markers (VEGF, nephrin and podocin) 
are shown. In panel A, the ROC curve is shown for the preeclamptic group compared to the 
healthy pregnant controls. The calculated AUC was 0.82. Panel B shows the ROC curve for the 
preeclamptic group compared to the healthy non-pregnant women. Here, the AUC was 0.99. 
Panel C shows the ROC curve for the healthy pregnant women compared to the healthy non-
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Figure 3
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Preeclampsia is a severe pregnancy complication with high maternal 
and fetal morbidity and mortality rates. The pathophysiology of 
preeclampsia is poorly understood, and no viable screening test 
exists. We therefore evaluated whether urinary metabolomics can be 
used to identify predictive biomarkers of preeclampsia in the first 
trimester.
METHODS
Urine samples were obtained from pregnant women between 11 
weeks 0 days and 13 weeks 6 days of gestation. We performed 
a nested case-control study that included 73 women who later 
developed preeclampsia and 138 control subjects who were 
matched for Body Mass Index and gestational period at the time 
of sample collection. Urine samples were analyzed using Proton 
Nuclear Magnetic Resonance (1H-NMR), and the concentrations of 
36 metabolites were compared between the two groups. Because 
ethnicity appeared to be a strong confounding factor, a stratified 
analysis was performed for the two largest ethnic subgroups, 
Caucasians and Blacks.
RESULTS
In the first trimester, the Caucasian patients who later developed 
preeclampsia had significantly different concentrations of 18 
metabolites compared to the control Caucasian subjects. In 
contrast, the Black patients who later developed preeclampsia had 
significantly different concentrations of three metabolites compared 
to the control Black subjects. 
DISCUSSION
This is the first study to use urinary metabolomics in an attempt 
to identify markers for predicting preeclampsia early in pregnancy. 
Our finding of differential metabolite concentrations in urine 
samples obtained before the onset of preeclampsia may facilitate 
early disease prediction and provide insight into the pathogenesis of 
preeclampsia.
Introduction
Preeclampsia is a severe pregnancy-related condition characterized 
by hypertension and proteinuria after gestational week 20.1 
Preeclampsia is associated with high maternal morbidity and 
mortality rates,2, 3  and fetal outcome is often compromised by 
a combination of intra-uterine growth restriction and preterm 
delivery.1 Although the pathophysiology of preeclampsia is 
poorly understood, evidence suggests that the disease results 
from a complex interaction between poor placental perfusion —as 
a consequence of ineffective remodeling of the spiral arteries in 
early pregnancy—and a maternal response to placenta-derived 
components causing systemic endothelial dysfunction.1, 4
Currently available models for predicting preeclampsia depend 
upon a combination of maternal factors (including demographics, 
medical history, and obstetric history) and clinical tests (including 
booking blood pressure and uterine artery Doppler velocimetry).5, 
6 However, the development of high-end analytical technologies 
in the past two decades has opened new possibilities for using 
exploratory, hypothesis-free approaches to screen for new markers 
of preeclampsia. Metabolomics—and in particular metabolomics of 
bodily fluids—is one such promising approach.7 Metabolomics is a 
discipline that arose from the explosive development of analytical 
sciences and a re-discovery of the holistic nature of biology.7 The 
most promising aspect with respect to the medical sciences is the 
ability to provide a methodological framework for exploratory 
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studies, thereby generating new ideas and facilitating the discovery 
of novel associations between disease pathogenesis and the 
metabolic composition of bio-fluids.7 
In the setting of preeclampsia, metabolomics analysis has 
been performed using plasma samples.8-11 Recently, a pilot study 
measured urinary metabolomics in patients with preeclampsia 
at gestational week 36.12 Changes in the plasma metabolome are 
reflected in the urine; importantly, urine samples are relatively easy 
to obtain and are usually free of proteins and lipids.13 Moreover, 
urinary metabolomics has been used successfully to study other 
diseases.14, 15 Here, we present the first study that uses urinary 
metabolomics to identify first-trimester biomarkers for predicting 
preeclampsia. 
Methods
PATIENTS AND URINE COLLECTION
This nested case-control study is part of a larger prospective study 
currently being conducted by the Fetal Medicine Foundation in, 
London, UK to predict important fetal and obstetric disorders in the 
first trimester. The long-term objective of the project is to develop 
and evaluate existing and newly identified biomarkers that can 
be used to predict preeclampsia. The details of the larger study 
have been described previously.8, 9 Pregnant women residing in the 
London area were prospectively screened from March 2006 through 
September 2009. Each participant provided written informed 
consent, and the study was approved by the King’s College Hospital 
Research Ethics Committee. In brief, pregnant women at 11 weeks 
0 days through 13 weeks 6 days gestation were recruited. Maternal 
characteristics and medical history were documented, and first-
trimester ultrasound was performed, including crown-rump length 
(CRL) and uterine artery Doppler pulsatility index, was performed. 
Maternal urine samples were obtained and stored at -80°C for 
subsequent laboratory analysis. The study cohort consisted of 80 
single-fetus pregnancies that subsequently developed preeclampsia 
and a matched group of 160 control subjects who did not develop 
preeclampsia. Each preeclamptic patient was matched for both Body 
Mass Index (BMI) and maternal age with two control subjects who 
delivered a healthy, full-term neonate with appropriate birth weight; 
in addition, the control subjects did not develop a hypertensive 
disorder of pregnancy, and they each provided a urine sample 
within three days of assessment of their matched preeclampsia case. 
Preeclampsia was defined based on the International Society for 
the Study of Hypertension in Pregnancy.16 No HELLP syndrome or 
gestational hypertension cases were included.
NUCLEAR MAGNETIC RESONANCE (NMR) SAMPLE 
PREPARATION 
Samples were thawed, centrifuged at 3,000´g for 5 min at 4°C to 
remove any precipitates, then transferred into deep 96-well plates. 
For sample preparation, 540 ml urine was mixed with 60 ml of 
pH 7.4 buffer (1.5 M K2HPO4 in D2O) containing 4 mM sodium 
3-trimethylsilyl-tetra-deuteriopropionate (TSP) and 2 mM NaN3. The 
samples were mixed and transferred to NMR tubes using two Gilson 
215 liquid handlers controlled by a Bruker Sample Track LIMS 
system (Bruker BioSpin, Karlsruhe, Germany).
NMR SPECTROSCOPY 
1H NMR data were collected at 27°C using a Bruker 600 MHz 
AVANCE II spectrometer equipped with a 5 mm TCI cryogenic probe 
head and a z-gradient system. After automatic tuning and matching 
of the probe head, 90° pulses were automatically calibrated for each 
individual sample using a homonuclear-gated nutation experiment17 
on the locked and shimmed samples. One-dimensional (1D) 1H-NMR 
spectra were recorded using the first increment of a NOESY pulse 
sequence with presaturation (γB1 = 50 Hz) during a relaxation delay 
of 4 seconds, with a mixing time of 10 msec to ensure efficient 
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water suppression.18 Sixteen scans of 65,536 points covering 12,335 
Hz were recorded and zero-filled to 65,536 complex points. Prior 
to Fourier Transformation (FT), an exponential window function 
was applied with a line-broadening factor of 1.0 Hz. The spectra 
were automatically phased, baseline corrected, and referenced to the 
internal standard (TSP ; δ 0.0). 2D J resolved (JRES)19 spectra with 
presaturation (γB1 = 50 Hz) were acquired with 12,288 data points 
over a spectral width of 10,000 Hz (F2 dimension), performing two 
scans for each of the 40 increments. Pre-FT data were weighted in 
both dimensions using a sine-bell function, and the spectra were 
tilted by 45° to provide orthogonal chemical shift (F2) and coupling 
constant (F1) axes; the spectra were subsequently symmetrized 
about the F1 axis. The chemical shift scale was referenced to an 
internal standard (TSP; δ 0.0). 2D-NMR spectra (1H-1H COSY, 1H-1H 
TOCSY and 1H-13C HSQC-DEPT135) were also recorded for selected 
samples and were used for spectra annotation.
DATA ANALYSIS
The metabolites were annotated using reference spectra from 
the Bruker Bioref database and an in-house reference data set. 
The identities of the metabolites were confirmed using Statistical 
Total Correlation SpectroscopY (STOCSY) method.20 The identified 
metabolites were quantified using deconvolution and subsequent 
integration of their resonance via in-house automation routine. 
Absolute concentrations were calculated using TSP as an internal 
reference. Metabolite concentrations were normalized to creatinine 
and log-transformed. Principal component analysis (PCA) and 
partial least squares discriminant analysis (PLS-DA) were performed 
to identify trends in the data using SIMCA software. The Mann-
Whitney U test was used to compare the metabolite concentrations 




The clinical characteristics of the preeclamptic patients and control 
subjects are summarized in Table 1. After excluding some samples 
because of insufficient sample volume or analytical failure, 1H-NMR 
spectra of the urine samples from 73 patients with preeclampsia 
and 138 control subjects were included in the final analysis. The 
two study groups differed significantly with respect to ethnicity and 
birth weight. 
MULTIVARIATE ANALYSIS 
To investigate the primary sources of variance within our data, 
we subjected the entire data set to principal component analysis 
(PCA). The score plot of the PCA model (29 components explaining 
66% of the variability; see Figure 1A) shows that the differences 
between the preeclampsia patients and control subjects are not 
reflected by the first two principal components (which account 
for approximately 18% of the total variance). Moreover, an 
attempt to build a regression model with diagnosis as class 
identity—preeclampsia versus non-preeclampsia—resulted in a 
poor, unstable model (data not shown). One possible explanation 
for this observation is that a strong confounding factor may 
have influenced the data. Because ethnic background differed 
significantly between the two groups, ethnicity may be one such 
confounding factor. To test this possibility, we re-plotted the data 
in Figure 1A according to each subject’s ethnic background (Figure 
1B). The two largest ethnic subgroups in our cohort—Caucasians 
(i.e., people of European descent) and Blacks (i.e., people of African 
descent)—influenced the data significantly. Because the remaining 
ethnic subgroups—South Asian, East Asian, and Mixed ethnicity—
comprised only 10% of the entire cohort, we performed the 
subsequent analyses using the Caucasian (n=119) and Black (n=69) 
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subgroups only. A PCA model based on this subset of the data (25 
components accounting for 66% of the variance) shows that the 
differences between these two major ethnic groups are represented 
in the first two principal components (Figure 2A). Thereafter, using 
a supervised analysis, we built a two class PLS-DA regression model 
using ethnicity as class identity (Figure 2B). This approach yielded a 
robust model with a cumulative explained variance (RY2) of 0.828 
and predictive fraction (Q2Y) of 0.498.
Given the abovementioned results, ethnicity is likely the 
confounding factor that obscured the differences in urinary 
metabolic profiles between our preeclampsia patients and control 
subjects. Therefore, we examined the differences between the 
Caucasian preeclampsia patients and Caucasian control subjects, 
and between the Black preeclampsia patients and Black control 
subjects. However, multivariate modeling of these data did not yield 
a statistically sound model (data not shown).
Next, we explored whether ethnicity was an equally strong 
confounder among the control subjects and/or among the patients 
with preeclampsia. In the control group, a two class PLS-DA 
regression model with ethnicity as a class identity yielded a strong, 
statistically valid model. However, we did not obtain a valid model 
when we applied the same approach to the preeclampsia group 
(Supplemental Figure S1). 
UNIVARIATE ANALYSIS 
Because our supervised multivariate modeling was inconclusive, 
we next performed a targeted analysis. We selected a set of 36 
physiologically relevant metabolites with consistent resonances 
in each preeclampsia patient and control subject. The identified 
metabolites were then quantified using spectral deconvolution 
and analyzed using the nonparametric Mann-Whitney U test with 
one-tailed exact p-value. Because ethnicity appeared to be a strong 
confounder, we compared the metabolite concentrations between 
the patients and control subjects within the Caucasian and Black 
subgroups. Table 2 compares the concentrations of 36 individual 
metabolite concentrations between the Caucasian preeclamptic 
patients and control subjects, and between the Black preeclamptic 
patients and control subjects. Remarkably, within the Caucasian 
subgroup, 18 of the 36 metabolites differed significantly between 
the preeclamptic patients and the control subjects. Within the 
Black subgroup, three metabolites differed significantly between 
the preeclamptic patients and control subjects. Two of these 
metabolites—2-hydroxyisobutyric acid and trigonelline—differed 
significantly in the Caucasian subgroup as well; the third significant 
metabolite—formate—did not differ significantly between the 
Caucasian preeclamptic patients and controls. 
Discussion
Preeclampsia is a multifactorial syndrome, and understanding 
its pathophysiology requires a broad, bias-free view provided by 
modern “omics” technologies such as metabolomics. Here, we 
performed an exploratory metabolomics analysis in an attempt to 
identify a first-trimester urinary metabolomics signature among 
women who develop preeclampsia later in their pregnancy. We 
found that ethnic background was a confounding factor, prompting 
us to analyze the two primary ethnic groups separately. Within the 
Caucasian subgroup, 18 of the 36 metabolites differed significantly 
between the women who later developed preeclampsia and the 
control subjects. Within the Black subgroup, three metabolites 
differed significantly between the women who later developed 
preeclampsia and the control subjects. 
Measuring the urinary metabolomics profile can be useful for 
assessing specific conditions; however, the eventual predictive 
signatures of those profiles are closely correlated with various 
factors, including the patient’s lifestyle, diet, and ethnicity.21, 22 
Indeed, in our cohort, ethnicity appeared to be a strong confounder, 
as shown by the two-class PLS-DA model in which ethnic origin 
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was used as a class identity (Figure 2B). A straightforward 
multivariate case-control based model provided poor results, and 
it is unknown why we were unable to identify strong metabolic 
correlates when we used a case-control modeling strategy on each 
ethnic subgroup separately; however other confounding factors 
should certainly be considered. Moreover, given the complex 
physiological and metabolic changes that occur during pregnancy, 
in combination with the abovementioned confounding factors, a 
prospective follow-up study throughout pregnancy may yield more 
insight into pregnancy-related physiology.
Here, using a more targeted analysis and simple nonparametric 
univariate tests, we found that the metabolites that are associated 
with preeclampsia differed between the two major ethnic subgroups. 
Because this is the first study to investigate preeclampsia-related 
urinary metabolomics in the first trimester of pregnancy, we 
can only compare our results with studies that investigated 
metabolomics differences in plasma and with a recent pilot study 
of the urinary metabolome at gestational week 36.12 Because the 
studies that measured plasma included either ethnically diverse 
groups8, 9, 11 or one ethnic subgroup10 of patients with preeclampsia 
and controls subjects, it is certainly conceivable that ethnicity might 
have influenced the outcome of these studies. 
In our study, we observed a striking number of metabolites that 
differed significantly between the ethnic subgroups. However, these 
results should be interpreted with caution, as the disproportionate 
number of preeclamptic patients and control subjects in the Caucasian 
subgroup may have influenced the results. In contrast, the number of 
patients and control subjects in the Black subgroup was more balanced, 
and only a relatively small number of metabolites differed significantly 
between the preeclampsia patients and control subjects. Two of the 
metabolites that differed in the Black subgroup—2-hydroxyisobutyric 
acid and trigonelline—overlapped with the Caucasian subgroup. Thus, 
the pathophysiology of preeclampsia might differ—at least partially—
among different ethnic groups. 
A thorough discussion of the functional significance of the 
metabolites that differed significantly in our cohort is beyond 
the scope of this article. However, in both ethnic subgroups, the 
concentrations of two metabolites—2-hydroxyisobutyric acid 
and trigonelline—were significantly lower in the patients with 
preeclampsia than in their respective control subjects. The first 
metabolite, 2-hydroxyisobutyric acid, is a relatively well-studied 
compound, and increasing concentrations of this metabolite 
are associated with conditions that involve energy metabolism 
deficiency.23 Remarkably, in our study we observed significantly 
lower concentrations of 2-hydroxyisobutyric acid in the patients 
with preeclampsia. In a recent pilot study, Austdal et al. reported 
that samples collected at gestational week 35-36 contained similar 
concentrations of 2-hydroxyisobutyric acid between preeclamptic 
patients and control subjects.12 The second metabolite, trigonelline, 
also differed significantly between preeclamptic patients and control 
subjects in both ethnic subgroups. Although trigonelline excreted 
through the urine is usually dietary in origin,24 trigonelline can 
be produced endogenously via methylation of nicotinic acid and 
involving S-adenosyl-methionine. To the best of our knowledge, 
experimental evidence for endogenous trigonelline synthesis exists 
for rodents only, and the endogenous synthesis of this metabolite is 
largely unexplored in humans.25 
Low concentrations of trigonelline are associated with impaired 
lung function,26 helminth infection,27 and diabetes mellitus.28 In 
particular, studies regarding diabetes mellitus lend credence to the 
notion that trigonelline is functionally significant in hypertension.29 
Administering trigonelline to rats with type 2 diabetes normalized 
several hypertension-related enzymes, including angiotensin 
converting enzyme (ACE).29 Austdal et al. also reported that 
trigonelline levels are lower in patients with preeclampsia at 35-36 
weeks of gestation.12 This finding is consistent with our observation 
that trigonelline levels were significantly lower in the women who 
later developed preeclampsia than in the control subjects, regardless 
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of their ethnicity. Whether low levels of trigonelline are associated 
with the development of hypertension, or whether preeclampsia 
(and its associated hypertension) induces low levels of trigonelline—
or both—remains to be investigated.
In conclusion, this study is the first urinary metabolomics screen 
in pregnant women who later developed preeclampsia. Our finding 
that the levels of specific metabolites differ in first-trimester urine 
samples between patients who develop preeclampsia and control 
subjects may provide a viable method for predicting preeclampsia 
early, even before symptoms develop, and may provide key insight 
into the disease’s pathogenesis. Future studies using a larger cohort 
of patients are needed to expand these findings—particularly 
with respect to the role of ethnicity. Ideally, these studies should 
combine 1H-NMR with other metabolomics techniques such as mass 
spectrometry. A comprehensive metabolomics analysis will likely 
increase our understanding of the pathophysiology of preeclampsia, 
which in turn will facilitate the development of preventive and 
therapeutic strategies.
Characteristics PE (n=73) Controls (n=138)
Maternal age, years (SD) 32.3 (5.9) 32.5 (5.7)
Nulliparity, n (%) 40 (54.8) 61 (44.2)
Smoking, n (%) 2 (2.7) 7 (5.1)
Ethnicity, n (%) *
  Caucasian 24 (32.9) 95 (68.8)
  Black 35 (47.9) 34 (24.6)
  South Asian 7 (9.6) 2 (1.4)
  East Asian 1 (1.4) 1 (0.7)
  Mixed 6 (8.2) 6 (4.3)
BMI (SD) 28.6 (5.2) 28.0 (5.1)
PE early, n (%) 15 (20.5) NA
Live birth, n (%) 71 (97.3) 138 (100)
Birth weight, g (%) 2575.8 (945.9) 3541.9 (363.5)*
Patient characteristics
BMI: Body Mass Index; PE: preeclampsia. PE early: preeclampsia requiring delivery before 
gestational week 34. *p<0.001. 
Table 1
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Table 2 (previous page): Concentrations of metabolites in the urine of the indicated groups 
measured using nuclear magnetic resonance
Values represent the concentrations of metabolites in micromolar. Data are shown as median 
(standard deviation). PE: preeclampsia.
Figure 1A                    Figure 1B
Principal components analysis plot
Figure 1A shows a principal components analysis plot of the patients with preeclampsia (in 
open triangles) and control subjects (in solid squares). The x-axis represents the first principal 
component (the most significant vector), and the y-axis represents the second principal 
component (the second most significant vector). No separation was observed between the 
patients with preeclampsia and the control subjects based on 29 components that explained 
approximately 70% of the variance. Figure 1B shows the same principal components analysis 
plot, with the subjects coded according to their ethnic background. The open circles represent 
Caucasians, the solid hexagons represent Blacks, the open diamonds represent Asians (both 
South and East Asian), and the grey triangles represent mixed ethnicity.
Metabolite Caucasian subjects (n=119) Black subjects (n=69)
PE, n=24 Control, n=95 p-value PE, n=35 Controls, n=34 p-value
1-Methylnicotinamide 9.6 (13.4) 17.8 (13.8) 0.160 18.0 (36.9) 17.4 (13.9) 0.877
2-Hydroxyisobutyric acid 23.1 (37.9) 53.7 (23.8) 0.002 41.3 (35.4) 51.2 (39.3) 0.037
Acetate 169.5 (118.5) 198.4 (131.4) 0.022 217.9 (140.8) 238.1 (130.9) 0.366
Acetoacetate 36.7 (93.8) 70.3 (96.2) 0.071 60.0 (128.3) 57.3 (83.7) 0.658
Acetone 6.6 (5.9) 11.5 (7.7) 0.017 12.0 (12.1) 11.6 (67.5) 0.995
Alanine 190.1 (375.3) 381.9 (311.4) 0.025 403.9 (435.0) 467.5 (275.4) 0.204
Carnitine 617.6 (1593.7) 1047.8 (1250.5) 0.119 651.7 (1094.6) 901.0 (886.4) 0.333
Citrate 1778.5 (2134.5) 3832.4 (2742.0) 0.003 3520.3 (3803.8) 3846.2 (2334.0) 0.734
Creatine 572.6 (827.8) 567.1 (836.1) 0.496 309.1 (865.3) 676.1 (632.1) 0.173
Creatinine 4714.0 (5518.2) 8165.4 (5360.8) 0.019 8364.9 (7433.7) 8237.3 (5662.4) 0.503
Dimethylamine 128.1 (162.7) 212.6 (126.3) 0.032 211.3 (380.2) 268.4 (180.3) 0.241
Dimethylglycine 41.0 (42.2) 63.6 (53.6) 0.014 60.1 (53.1) 59.21 (51.56) 0.269
Formate 132.4 (136.7) 171.1 (123.7) 0.174 139.1 (135.6) 212.8 (99.6) 0.030
Fumarate 0.8 (1.1) 4.1 (4.5) 0.001 4.2 (6.9) 3.4 (6.0) 0.807
Glucose 86.75 (207.4) 239.7 (192.2) 0.015 261.4 (228.5) 215.3 (208.5) 0.368
Glycine 1604.8 (2034.8) 2269.9 (1562.0) 0.105 2266.1 (3147.1) 2370.1 (1987.8) 0.571
Guanidinoacetate 515.7 (683.6) 856.5 (466.9) 0.141 770.6 (733.2) 823.7 (575.7) 0.734
Hippurate 690.4 (867.4) 1102.6 (829.9) 0.094 1133.6 (801.2) 1300.9 (950.5) 0.139
3-Hydroxybutyrate 28.5 (37.4) 31.1 (53.0) 0.952 33.5 (40.0) 22.6 (37.8) 0.584
3-Hydroxyisovaleriate 135.7 (214.6) 210.3 (174.1) 0.100 189.6 (197.7) 239.0 (229.8) 0.102
Isobutyrate 14.6 (22.7) 35.9 (31.4) 0.002 38.0 (35.9) 44.4 (43.6) 0.338
Lactate 262.7 (465.2) 602.6 (456.8) 0.006 578.8 (409.9) 533.8 (314.4) 0.620
Methylguanidine 213.2 (205.9) 321.0 (186.7) 0.031 324.9 (286.4) 329.8 (283.0) 0.676
Phenylacetylglycine 266.7 (391.3) 511.6 (330.4) 0.034 412.7 (446.4) 555.1 (519.1) 0.159
Propylene glycol 31.9 (50.2) 43.0 (48.4) 0.194 41.3 (38.7) 28.1 (36.3) 0.813
Pyruvate 29.9 (48.4) 51.9 (44.3) 0.135 37.8 (47.8) 47.1 (47.4) 0.146
Scyllo-inositol 36.4 (54.4) 80.7 (52.0) <0.001 85.2 (60.8) 75.1 (59.3) 0.461
Succinate 47.5 (54.1) 102.5 (59.1) <0.001 77.2 (106.6) 91.8 (77.8) 0.536
Sucrose 17.5 (31.9) 24.0 (37.4) 0.153 8.7 (32.8) 10.3 (35.9) 0.898
Trigonelline 7.8 (18.8) 26.7 (41.6) <0.001 30.1 (46.4) 80.5 (71.4) 0.009
TMAO 253.9 (382.3) 391.5 (280.6) 0.130 316.5 (353.5) 402.6 (255.3) 0.610
Tyrosine 63.6 (69.6) 64.6 (50.7) 0.595 71.7 (62.6) 77.9 (67.6) 0.516
Valine 18.3 (18.9) 28.2 (15.5) 0.037 27.0 (20.9) 31.6 (29.1) 0.284
Pseudouridine 158.8 (190.1) 256.7 (155.6) 0.062 282.8 (262.0) 285.6 (210.3) 0.541
Glyoxylate 1.5 (1.1) 1.2 (1.3) 0.723 0.9 (2.5) 1.4 (2.5) 0.842
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Figure 2A                 Figure 2B
Principal component analysis plot based on ethnicity
Principal component analysis plot based on the two largest ethnic groups in the cohort, 
Caucasians (shown in open circles) and Blacks (shown in solid hexagons). 25 components 
explain approximately 66% of the variance (Figure 2A). Figure 2B shows a partial least 
squares discriminant analysis (PLS-DA) model (cross-validated score plot). R2X = 0.202, R2Y 
= 0.828, Q2 = 0.498; p=4.59058e-24.
Figure S1: Influence of ethnic background 
Principal Component Analysis (PCA; panels A and C) and PLS-DA (panels B and D) models 
with ethnic origin as class identity. The dark grey symbols represent Blacks, and the light grey 
symbols represent Caucasians. For the patients with preeclampsia, the PCA (A) resulted in 
a non-significant PLS-DA model (B; R2X = 0.102, R2Y = 807, Q2 = 0.009, p=0.683). For the 
control subjects, the PCA (C) resulted in a significant PLS-DA model (D; R2X = 0.202, R2Y = 
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Summary
Preeclampsia is a complication of pregnancy which can suddenly 
change from a relatively mild phenotype into a life-threatening 
situation. One of the organs that is always involved during 
preeclampsia is the kidney. The placenta plays an important 
role in the renal pathophysiology of preeclampsia. The placenta 
produces excessive amounts of anti-angiogenic factors which 
are associated with systemic endothelial dysfunction. Although 
the underlying mechanisms of renal injury during preeclampsia 
remain unclear, women with preeclampsia have an increased risk of 
developing renal disease later in life. This observation suggests that 
preeclampsia ‘marks’ the mother—putatively in combination with 
pre-existent conditions—which might contribute to serious sequel 
throughout her life.  
The widespread endothelial dysfunction in preeclampsia is 
believed to be due to increased serum levels of anti-angiogenic 
factors—in particular sFlt-1—produced by the placenta.1 The studies 
described in CHAPTER 2 were focused on the mechanisms of 
sFlt-1 production within the placenta, and the systemic spreading 
of this anti-angiogenic factor. During both preeclampsia and 
uncomplicated pregnancy, the placenta is the principal source of 
sFlt-1. The outermost layer of the placenta, the syncytiotrophoblast, 
forms ‘knots’ that contain the anti-angiogenic protein sFlt-1, 
particularly during preeclampsia. Previous research has shown that 
these knots—called syncytial aggregates after detachment from the 
placenta—account for approximately 25% of all sFlt-1 protein in the 
maternal circulation.2 In this thesis, the spread of these syncytial 
aggregates was further investigated. We showed that—within the 
placenta—syncytial knots are indeed the primary production site 
of sFlt-1, which is significantly higher in placentas from patients 
with preeclampsia.  These knots detach from the placenta, and the 
systemic spread of the syncytial aggregates was confirmed by the 
presence of hCG-positive multinucleate aggregates in the lungs of 
pregnant women. We showed that preeclampsia is associated with 
higher numbers of syncytial aggregates in the maternal lung. In 
lung samples obtained from women who were carrying a male fetus 
co-localization of hCG and the Y-chromosome was observed, which 
strongly supports the idea that these aggregates are of fetal origin. 
Importantly, we observed that women with preeclampsia show 
increased sFlt-1 expression within these aggregates, as compared 
to the non-preeclamptic pregnant control subjects. It may be 
speculated that these aggregates influence the development of local 
immune tolerance in maternal organs early in pregnancy. Later 
in pregnancy, the sFlt-1 produced by these aggregates may cause 
endothelial injury. The presence and persistence of fetal cells in the 
maternal circulation and organs may also have both short- and 
long-term consequences for postpartum maternal health. On short-
term, the sFlt-1-loaded syncytial aggregates may undergo further 
disaggregation, forming smaller particles. Via the release of these 
smaller particles into the maternal circulation, it is not unlikely 
that these sFlt-1-loaded smaller particles contribute to endothelial 
dysfunction in maternal organs other than the lungs. On long-term, 
the fetal cells may result in chimerism, as they can be retained in 
the maternal blood and organs for decades after delivery.3 These 
cells—having stem cell-like properties—might affect maternal health 
for years after pregnancy, but it is currently unknown whether they 
cause disease or might have beneficial effects, or both.4, 5
Within the kidney, endothelial dysfunction can be caused by an 
imbalance between anti- and pro-angiogenic factors. In particular, 
vascular endothelial growth factor-A (VEGF-A)-signaling—necessary 
for the maintenance of the glomerular filtration barrier—seems to be 
affected during preeclampsia. Putative mechanisms playing a role 
in renal injury during preeclampsia were investigated in the studies 
described in CHAPTERS 3 and 4. Previous studies have shown 
that injury to the fenestrated endothelium within the glomerulus 
can lead to complement activation.6  Combining this observation 
VII. Summary and general discussionOn renal pathophysiology in preeclampsia
160 161
with the notion that preeclampsia is characterized by complement 
dysregulation—shown in placentas7-9 and serum10—we explored 
complement activation in the preeclamptic kidney in the studies 
described in chapter 3.  
In the studies described in chapter 3 we investigated renal autopsy 
tissues from women who died due to preeclampsia, as well as 
control subjects, for the presence of complement components.  
Preeclampsia was significantly associated with the presence of 
C4d—a stable marker of complement activation—and markers of 
classical pathway activation. To explore whether complement 
activation during preeclampsia in the kidney is caused by 
antibody-mediated injury, we performed immunofluorescence 
stainings on the renal autopsy tissues mentioned, for the presence 
of immunoglobulins. Immune deposits of the IgM-subtype were 
significantly more frequently observed in kidneys of women with 
preeclampsia, whereas IgG deposits were sporadically observed in 
all study groups, and IgA was never observed.  It is not possible 
to investigate the causative role of sFlt-1 in the activation of the 
complement system in the kidney in vivo in humans. Therefore, 
a sFlt-1-induced-mouse model of preeclampsia was used. Mice 
injected with sFlt-1 show increased deposition of C4 in the 
kidneys as compared to control mice. These findings suggest that 
angiogenic imbalance may play an important role in activation 
of the complement system in the kidney during preeclampsia. The 
observations described in this chapter raise the question: what 
causes the presence of the IgM-subtype in glomeruli of patients with 
preeclampsia? Although glomerular IgM deposition is observed in a 
variety of renal diseases and its role remains elusive, the presence of 
this subtype might have several explanations. Firstly, the presence 
of the IgM-subtype could reflect the binding of IgM antibodies to 
endothelium injured by sFlt-1. Natural IgM-antibodies play a major 
role in the clearance of damaged cells,11, 12 and they can bind to 
both hypoxic13 and apoptotic cells14, 15 through intracellular antigens 
that become externalized under these conditions. Secondly, IgM is 
a large molecule, and due to its polymeric nature, it easily binds 
non-specifically to endothelium.16 Finally, although we did not 
observe other immunoglobulin subtypes, it may be hypothesized 
that the presence of IgM might be caused by auto-antibodies.17 
Altogether, the studies in this chapter show that preeclampsia is 
strongly associated with activation of the classical pathway of 
the complement system in the kidney. These findings suggest that 
complement activation might amplify local inflammation, and could 
contribute to the renal injury in preeclampsia. Our findings further 
support the concept of complement inhibition as a therapeutic 
tool, targeting both the renal and placental manifestations of 
preeclampsia. 
The extent of renal injury during preeclampsia was investigated 
in the studies described in chapter 4. Preeclampsia is characterized 
by loss of podocytes into the urine. Therefore, this chapter was 
devoted to quantification of the numbers of podocytes within the 
glomeruli of patients with preeclampsia and of control subjects, 
using the same renal autopsy tissues as in chapter 3. The numbers 
of glomerular podocytes did not differ significantly between the 
preeclamptic and control groups. Podocyte injury and loss are 
often associated with increased parietal epithelial cell activation. 
Therefore, we evaluated parietal epithelial cell activation in 
the setting of preeclampsia. Women with preeclampsia showed 
significantly higher numbers of activated parietal epithelial cells 
on a podocyte location. It remains to be investigated whether 
activation and proliferation of parietal epithelial cells compensate 
for ongoing podocyte injury and loss, or whether these cells 
contribute to glomerular injury, or both. The findings described in 
this chapter may provide new insights into the renal complications 
of women with preeclampsia later in life. Parietal epithelial cell 
activation is associated with focal and segmental glomerulosclerosis 
(FSGS),18 and women with preeclampsia have a higher risk of 
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developing FSGS later in life.19 As further discussed below, we 
hypothesize that the higher numbers of activated parietal epithelial 
cells in the preeclamptic kidney as described in this chapter, may 
play an important role in the pathogenesis of the development of 
FSGS later in life.  
It is evident from the studies described in chapters 3 and 4, that 
the kidney—and in particular, the glomerulus—is targeted during 
preeclampsia. An important cause of this, as mentioned earlier, is 
believed to be the angiogenic imbalance, in which an excess of 
particularly sFlt-1 prevents VEGF-A from adequately maintaining 
the renal endothelium. As a VEGF-A-signaling pathway is 
responsible for cross-talk between endothelial cells and podocytes, 
it is believed that both endothelial cells and podocytes are injured in 
situations of angiogenic imbalance. Injured podocytes may detach 
from the glomerular basement membrane. After detachment from 
the glomerular basement membrane, podocytes are shed into the 
urine. Podocyturia during preeclampsia was further investigated in 
the studies described in CHAPTER 5. In this chapter, we explored the 
potential of using quantitative polymerase chain reaction (qPCR) as 
a means to detect the mRNA levels of podocyte-specific molecules 
in urine samples of women with preeclampsia and of control 
subjects. Women with preeclampsia showed significantly elevated 
urinary mRNA levels of nephrin, podocin, and VEGF as compared 
to normotensive pregnant control subjects, and non-pregnant 
control subjects. In addition, significantly elevated levels of nephrin 
mRNA were detected in urine of women with preeclampsia as 
compared to that of women with gestational hypertension. We 
found mRNA encoding for podocyte-specific molecules in urine of 
non-pregnant women, normotensive pregnant women, and women 
with gestational hypertension, which indicates that during all these 
conditions, there is a (physiological) loss of podocytes in urine. It 
may be speculated that normal pregnancy, gestational hypertension, 
and preeclampsia are a continuous spectrum of (mild) endothelial 
dysfunction, contributing to podocyturia.  The results from the 
studies described in this chapter demonstrate that qPCR is a highly 
promising, non-invasive method for quantifying podocyturia in 
patients with preeclampsia, but it still needs to be assessed whether 
measuring podocyturia is a more reliable marker than conventional 
biomarkers are. Importantly, a very recent study showed that 
podocyturia precedes proteinuria and the clinical features of 
preeclampsia,20 which is discussed in detail on page 168 of this 
chapter.  
To identify possible first-trimester biomarkers in preeclampsia, 
the work described in CHAPTER 6 focused on the presence of 
metabolites in early-pregnancy urine samples, and their potential 
role in predicting preeclampsia. The set of metabolites that reflects 
the organism under a particular set of conditions, is called the 
metabolome.21 The metabolome is the product of environmental 
and genetic conditions, and provides a new logical framework to 
elucidate disease etiology. In the studies described in chapter 6, 
first trimester urine samples were analyzed using nuclear magnetic 
resonance spectroscopy. The concentrations of 36 metabolites 
were compared in a nested case-control study of 73 women who 
developed preeclampsia later during pregnancy and 138 pregnant 
control subjects derived from a prospective cohort study consisting 
of 33.602 singleton pregnancies.22 Although ethnicity appeared 
to be a strong confounding factor, we identified a first trimester 
urinary metabolomics signature within the two largest ethnical 
subgroups—Caucasians and Blacks—for patients developing 
preeclampsia later in pregnancy. The significantly different urinary 
metabolomics signature in the first trimester of pregnancy in 
women destined to develop preeclampsia, potentially holds the 
promise of a screening test, and offers insight into the pathogenesis 
of preeclampsia.
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General Discussion
ON RENAL PATHOPHYSIOLOGY IN PREECLAMPSIA
Because the kidney is always involved in preeclampsia, the causes 
and consequences of kidney injury, both on the short- and long 
term, will be discussed below. 
CAUSES AND CONSEQUENCES OF ENDOTHELIAL INJURY
As mentioned earlier, endothelial injury is considered to play an 
essential role in the pathogenesis of preeclampsia. A significant part 
of this injury is thought to arise by the excessive amounts of the 
anti-angiogenic factor sFlt-1, which is produced by the placenta 
during pregnancy. However, not all pregnant women with high sFlt-
1 serum concentrations develop preeclampsia. The overlap of sFlt-1 
concentrations between women with preeclampsia and women 
with uncomplicated pregnancies illustrates this phenomenon.1 
Therefore, the rise in sFlt-1 can not solely be held accountable 
for the endothelial injury observed during preeclampsia. It 
remains debatable why some patients are so sensitive to high 
concentrations of sFlt-1, whereas other patients abide the high 
concentrations of sFlt-1 very well. sFlt-1 binds to VEGF-A, which 
leads to low concentrations of bio-active VEGF-A.23, 24 Thereby, 
the physiological functions of VEGF-A are impaired, including 
proliferation, angiogenesis, lymphogenesis, inducing endothelial cell 
permeability, and vasodilation.23, 24 Perhaps, pre-existent endothelial 
injury increase the vulnerability for a rise in sFlt-1. It is known 
that conditions associated with endothelial injury predispose to 
preeclampsia, such as diabetes mellitus, obesity, and hypertension.25 
It may be that women with such pre-existent endothelial injury 
are more vulnerable to the stress imposed on the endothelium 
during pregnancy.26-28 Thus, the rise in sFlt-1 which occurs during 
preeclamptic pregnancy might aggravate pre-existent endothelial 
injury. Furthermore, other anti-angiogenic factors, such as soluble 
Endoglin,29 have been described to play an important role in the 
endothelial injury during preeclampsia. These observations support 
the hypothesis that endothelial injury during preeclampsia is a 
multifactorial condition. Taken together, there is an overlap between 
the concentrations of anti-angiogenic factors in healthy pregnant 
women and women with preeclampsia. This phenomenon could be 
explained by the assumption that healthy pregnant women are not 
as sensitive to high concentrations of anti-angiogenic factors, or 
might not have pre-existent endothelial injury, or both. Rising levels 
of anti-angiogenic factors alone may not be sufficient to cause 
systemic endothelial injury. 
Preeclampsia is associated with certain genetic variants.30 These 
genetic variants concern genes associated with the coagulation, 
fibrinolysis, immunological, and renin-angiotensin-aldosterone 
systems. In addition, these genetic variants also seem to concern 
genes involved in cardiovascular disease and its risk factors, such 
as diabetes mellitus, obesity, and hypertension.30 Illustratively, 
women with preeclampsia have an 8-fold higher risk of death 
from cardiovascular causes later in life than women who have 
had an uncomplicated pregnancy.31 However, not all women with 
preeclampsia do develop cardiovascular disease later in life.32, 33 
The question that remains is, whether preeclampsia is the cause of 
remaining endothelial injury, causing cardiovascular disease later 
in life, or that the genetic make-up and other risk factors of these 
women result in pre-existent endothelial injury and predispose to 
both preeclampsia and cardiovascular disease.  
The different genetic predispositions associated with preeclampsia 
could also be the reason for distinct metabolic profiles in women 
with preeclampsia, compared to pregnant control subjects. In a 
recent study, a metabolomics signature in serum was described to 
be specific for preeclampsia.34 In the results described in chapter 6, 
we observed that the levels of specific metabolites differ in first-
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trimester urine samples between patients who develop preeclampsia 
and control subjects, and we found that ethnic background was a 
confounding factor. These findings may provide a viable method 
for predicting preeclampsia early, even before symptoms develop, 
and may provide key insight into the disease’s pathogenesis. It may 
be, that the factors playing a role in early pregnancy could also 
contribute to the pre-existent endothelial injury, and subsequent 
vulnerability for sFlt-1 in preeclampsia.  
Within the murine preeclamptic kidney, endothelial injury through high 
sFlt-1 levels manifests as endotheliosis (swelling of endothelial cells).35 
However, there is increasing evidence that complement activation 
also contributes to the kidney injury in preeclampsia. The results 
described in chapter 3 are the first observations to suggest a putative 
role that injured endothelium itself might play in initiating activation 
of the complement system during preeclampsia. In particular, the 
presence of complement deposits in a sFlt-1-induced-mouse model 
of preeclampsia, strongly supports the hypothesis that sFlt-1 induced 
endothelial injury is—at least in part—responsible for activation of the 
complement system. Activation of the complement system can be the 
result of binding of auto-antibodies.36, 37 In the kidney specifically, 
complement activation could result from binding of auto-antibodies 
to glomerular structures, or by glomerular deposition of circulating 
immune complexes.6 In preeclampsia, immune complex deposition 
and subsequent complement activation could, for instance, result 
from binding of angiotensin II type 1 receptor agonistic antibodies 
(AT1-AA). These antibodies are frequently observed in women 
with preeclampsia,17 and in a murine model the presence of these 
antibodies resulted in glomerular complement activation.38 However, 
not all women with preeclampsia have circulating antibodies against 
the angiotensin II type I receptor. In the work described in chapter 
3 of this thesis, glomerular complement activation was observed 
in all studied women with preeclampsia. Although the number of 
patients studied was relatively small, this finding suggests that 
other mechanisms than binding of auto-antibodies might also be 
responsible for activation of the complement system. Indeed, another 
putative cause for complement activation is the interplay between the 
complement system and dysregulation of pro- and anti-angiogenic 
factors resulting in angiogenic imbalance. Within the kidney there is 
evidence that complement activation is a consequence of angiogenic 
imbalance. The high concentrations of circulating sFlt-1 bind to 
VEGF-A, which leads to low concentrations of bio-active VEGF-A.23, 
24 In vivo cell experiments showed that on the podocytes’ surface, 
low concentrations of VEGF-A lead to reduced concentrations of the 
important complement regulator, factor H.39 Dysfunction of factor H 
is also associated with atypical Hemolytic Uremic Syndrome (aHUS).40 
Since aHUS and preeclampsia show overlapping histopathologic renal 
lesions—such as double contours of the glomerular basement membrane 
and signs of thrombotic microangiopathy—the underlying pathogenic 
mechanisms of these conditions may share the same pathways. In 
aHUS, the presence of mutations in factor H is associated with the 
deposition of complement products on the surface of platelets, resulting 
in a prothrombotic state.41 The other way around, complement may be 
activated on the membrane of activated platelets.42 Thus, these findings 
may suggest that complement dysregulation during preeclampsia, in 
particular regarding factor H, is linked to conditions associated with 
high incidence of thrombosis, which indeed seems to be the case.43 This 
multifaceted vicious cycle may aggravate the kidney injury during 
preeclampsia. In following, there are several questions that need to 
be answered. Is activation of the complement system a cause or a 
consequence of endothelial injury? Is activation of the complement 
system within glomeruli of patients with preeclampsia a result of sFlt-1 
induced endothelial injury? Or is the complement system activated 
through autoantibodies directed against the angiotensin II type I 
receptor, thereby causing endothelial injury? And does this endothelial 
injury then cause activation of the complement system, and thereby 
activation of the coagulation system?
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PODOCYTURIA: PREDICTION AND A GLIMPSE INTO THE FUTURE
Endothelial injury is thought to give rise to the clinical 
manifestations of preeclampsia, including hypertension and 
kidney injury.35 Clinically, this kidney injury results in worsening 
of kidney function and loss of proteins in the urine: proteinuria. 
Within the relatively short period of preeclamptic pregnancy, the 
glomerular filtration barrier is severely injured, which leads to 
leakage of proteins. Interestingly, Yu et al.44 demonstrated that 
in rat models of puromycin aminonucleoside-induced nephrosis, 
mesangioproliferative nephropathy, and hypertensive nephropathy, 
proteinuria is present during both active and chronic phases of 
glomerular injury, whereas podocyturia is confined to active, 
ongoing glomerular damage only. Based on these findings, 
podocyturia seems to be a good marker of ongoing glomerular 
damage. 
In the work described in chapter 5 of this thesis, increased podocyte 
specific mRNA levels were observed in urine of women with 
preeclampsia, as compared to pregnant control subjects. This  rapid 
and sensitive method seems useful in quantifying podocyturia. The 
question that remains is: is podocyturia a diagnostic tool to detect 
preeclampsia during the early stages of pregnancy, i.e. before the 
onset of clinical symptoms? Recently, a very promising paper was 
published, in which the authors describe that podocyturia precedes 
both proteinuria and the clinical features of preeclampsia.20 In 
all preeclamptic patients, podocyturia was detected in the second 
trimester, whereas podocyturia was never observed in normotensive 
controls, nor in patients who developed gestational hypertension. 
Podocyturia in the second trimester had a significantly greater 
sensitivity and specificity (both 100%, providing perfect likelihood 
ratios) for the subsequent diagnosis of preeclampsia than any single 
angiogenic factor, such as sFlt-1 or s-Eng, or a combination of 
these factors. These findings implicate promising possibilities of 
using podocyturia for accurate identification of pregnant women 
at risk for preeclampsia. Importantly, these findings also add to 
our understanding of the pathophysiologic mechanisms leading to 
preeclampsia-related proteinuria. Podocyturia was observed in the 
second trimester before the onset of proteinuria.20 This may indicate 
that glomerular loss of podocytes may lead to a disruption of the 
glomerular filtration barrier and, thereby, to proteinuria. However, 
it has also been described that proteinuria impairs podocyte 
regeneration,45 and it may be speculated that proteinuria therefore 
leads to podocyturia. Another possibility is that proteinuria and 
podocyturia are both caused by one upstream mechanism. It could 
also be the case that proteinuria and podocyturia happen at the 
same time, but are the result of different underlying mechanisms. 
Despite the significant loss of podocytes in the urine, the work 
described in this thesis showed that the number of glomerular 
podocytes is unaffected in preeclampsia. The higher number of 
activated glomerular parietal epithelial cells present in kidneys 
from women with preeclampsia may suggest that lost podocytes are 
replaced by progenitor cells of the parietal epithelium.  
 
The replacement of lost podocytes by activated parietal epithelial 
cells could be a favourable phenomenon. In a Munich Wistar 
Frömter (MWF) rat model of spontaneous glomerular injury, this 
compensatory mechanism has been described to contribute to 
remodeling of the glomerular architecture, if successful.46 Perhaps 
this mechanism could be responsible for the fact that the glomerular 
lesions in preeclampsia usually disappear within a few weeks after 
delivery.47, 48 However, instead of a repair response by parietal 
epithelial cells, murine studies have illustrated the important role 
of parietal epithelial cells in the development of FSGS, by showing 
that an excessive proliferative response of parietal epithelial cells is 
involved in the progression of FSGS.49 In human renal transplants, 
activated parietal epithelial cells are present in significantly higher 
numbers in early recurrent FSGS than in minimal change disease.18 
Women with preeclampsia have a higher risk of developing 
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FSGS later in life19, but the pathogenesis of this phenomenon is 
poorly understood. Based on the aforementioned studies, one may 
hypothesize that an excessive proliferative response of parietal 
epithelial cells may lead to kidney injury, in particular FSGS.  
 
We found higher numbers of activated parietal epithelial cells in 
kidneys from women with preeclampsia than in the control groups. 
Taking the abovementioned studies into consideration, it could be 
hypothesized that the higher numbers of parietal epithelial cells 
in the preeclamptic kidney could be a sign of repair, or a sign of 
progressive podocytopathy. In case the higher numbers of parietal 
epithelial cells are a sign of progressive podocytopathy,  this 
podocytopathy may be associated with the risk of developing FSGS 
on the long run. In addition, the replacement of lost podocytes by 
activated parietal epithelial cells might also be responsible for the 
increased risk (relative risk of approximately 4) for women with 
preeclampsia to develop end-stage renal disease.50  This increased 
risk could be a direct effect of preeclampsia. However, preeclampsia 
itself is also associated with an increased risk of cardiovascular 
disease, and cardiovascular disease is in turn associated with kidney 
disease.51 Therefore, it is challenging to distinguish the precise role 
of preeclampsia in the development of kidney disease.  However, 
the risk of kidney disease and micro-albuminuria one decade after 
preeclampsia seems to be greater than the risk of cardiovascular 
disease,52, 53 which underscores the hypothesis that preeclampsia 
might induce a primary renal insult.
PATIENTS’ PERSPECTIVES 
No single factor can be held responsible for the development of 
kidney disease during and after preeclampsia. A variety of risk 
factors and mechanisms probably underlies this phenomenon. 
Regardless of which factors contribute, preeclampsia is an important 
risk factor for subsequent chronic kidney disease. This notion 
calls for early detection and intervention. To start with, early 
prediction of preeclampsia—for example by using podocyturia 
or urinary metabolomics analysis—could provide an opportunity 
for close surveillance and preventive strategies, such as early 
delivery. It lends credence to speculation that targeting factors that 
contribute to the pathogenesis of kidney disease in preeclampsia 
may have therapeutic value. For instance, murine models have 
shown reversal of proteinuria and of histologic changes typical 
of preeclampsia when treated with complement inhibitors.54 In 
humans, Eculizumab—a terminal complement inhibitor—has recently 
been administered in a woman with preeclampsia. This resulted 
in abrogation of preeclampsia manifestations and prolongation of 
pregnancy.55 Further research is warranted to validate these findings 
in a larger clinical study, especially regarding the potential side 
effects of the treatment. In addition, several studies showed that 
targeting the excessive proliferative response of parietal epithelial 
cells56 can be achieved by therapies, such as ACE-inhibitors57 
and inhibitors of the Notch-signaling pathway.58 Similarly to 
Eculizumab, ACE-inhibitors, and Notch-signaling pathway 
inhibitors should be further studied in randomised controlled trials, 
in particular regarding the side effects for the mother and the fetus. 
Furthermore, long-term follow-up is recommended after delivery, 
especially with respect to hypertension, obesity, and insulin 
resistance.51 Whether monitoring of these risk factors and usage 
of the abovementioned therapeutic options will improve the renal 
condition during and after preeclampsia and might decrease the risk 
of kidney disease later in life, should be subject of future studies. 
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Pre-eclampsie—in de volksmond zwangerschapsvergiftiging 
genoemd—is een ernstige zwangerschapscomplicatie, waarvan het 
beloop plotseling kan veranderen van een milde aandoening tot 
een levensbedreigende situatie. Pre-eclampsie wordt gekenmerkt 
door een hoge bloeddruk en eiwitverlies in de urine tijdens de 
zwangerschap.  Het eiwitverlies in de urine treedt op doordat 
de nier één van de organen is die beschadigd raakt tijdens pre-
eclampsie. Het is nog niet geheel duidelijk welke mechanismen deze 
schade precies veroorzaken. Bovendien lijkt de schade tijdens de 
zwangerschap tevens consequenties te hebben voor de gezondheid 
van de moeder in haar latere leven. Vrouwen die een zwangerschap 
met pre-eclampsie hebben doorgemaakt hebben namelijk een  licht 
verhoogd risico op het ontwikkelen van nierziekten. Dit lijkt erop te 
duiden dat pre-eclampsie een soort ‘ voetafdruk’ achterlaat in het 
lichaam van de moeder, hetgeen kan leiden tot chronische schade op 
de langere termijn. Gedacht wordt dat de oorzaak van pre-eclampsie 
een verkeerde aanleg en werking van de placenta is. De placenta 
produceert, met name tijdens pre-eclampsie, grote hoeveelheden 
anti-angiogenetische factoren. Deze anti-angiogenetische factoren 
remmen angiogenetische factoren. Angiogenetische factoren zijn 
belangrijk voor de aanmaak en groei van bloedvaten. Als  anti-
angiogentische factoren deze functies remmen, kan dat leiden tot 
schade aan het endotheel (de binnenbekleding van de bloedvaten) 
in het hele lichaam. Dit proefschrift beschrijft de schade —en de 
onderliggende mechanismen van deze schade—in de nieren tijdens 
pre-eclampsie en onderzoekt eveneens de mogelijkheden om pre-
eclampsie te voorspellen door gebruik te maken van specifieke 
moleculen in urine. 
HOOFDSTUK 2 gaat over één van de belangrijke anti-
angiogenetische factoren, sFlt-1. In dit hoofdstuk zijn de 
experimenten beschreven waarbij werd onderzocht waar deze 
factor wordt geproduceerd in de placenta en hoe deze factor in 
het lichaam van de moeder terechtkomt. Hoewel sFlt-1 ook tijdens 
normale zwangerschappen door de placenta gemaakt wordt, zijn 
de hoeveelheden sFlt-1 in het bloed van de moeder tijdens pre-
eclampsie veel hoger. In de placenta wordt sFlt-1 vooral gemaakt 
door de buitenste laag cellen, de zogenoemde syncytiotrofoblast. 
Met name tijdens pre-eclampsie vormt deze laag fragmenten, die 
grote hoeveelheden van sFlt-1 bevatten. De fragmenten laten 
los en komen in de bloedsomloop van de moeder terecht. In dit 
hoofdstuk hebben wij de fragmenten daadwerkelijk teruggevonden 
in de longen van de moeder .  In de longen van vrouwen met 
pre-eclampsie werden veel meer placenta fragmenten gevonden 
dan in longen van vrouwen die geen pre-eclampsie tijdens 
de zwangerschap hadden gehad. Het is goed mogelijk dat het 
circuleren van deze fragmenten van de placenta ervoor kan zorgen 
dat vrouwen met pre-eclampsie complicaties ontwikkelen na de 
bevalling. Het is zelfs mogelijk dat deze fragmenten van de placenta 
de gezondheid van de moeder nog jaren na de zwangerschap 
kunnen beïnvloeden.  
Zoals in het voorgaande is vermeld, is de nier een orgaan dat 
beschadigd raakt tijdens pre-eclampsie. Gedacht wordt dat de 
endotheelschade in de nier voor een groot deel veroorzaakt wordt 
door het effect van de anti-angiogenetische factoren. In de nier 
bevinden zich veel bloedvaatjes in de filterlichaampjes—glomeruli 
genaamd—waar het bloed wordt gefilterd tot urine. Voor de 
filtratiebarrière in de glomeruli is de angiogenetische factor, 
vasculaire endotheel groei factor-A (VEGF-A), erg belangrijk. 
Deze angiogenetische factor zorgt voor communicatie tussen de 
verschillende lagen cellen die samen de filtratiebarrière vormen 
om zo deze barrière goed te kunnen onderhouden.  Tijdens pre-
eclampsie zijn er in het bloed veel hogere concentraties van sFlt-1 
dan tijdens een gezonde zwangerschap. sFlt-1 bindt aan VEGF-A 
waardoor er veel minder ongebonden VEGF-A overblijft om te 
worden gebruikt voor de communicatie tussen de verschillende 
lagen van de filtratiebarrière. De mogelijke mechanismen die een 
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rol spelen bij het ontstaan van de nierschade bij pre-eclampsie 
werden onderzocht in de studies beschreven in HOOFDSTUK 3 
en HOOFDSTUK 4. Eerdere studies hebben laten zien dat schade 
van het endotheel in de nier kan leiden tot activatie van het 
complementsysteem. Het complementsysteem is een onderdeel van 
het immuunsysteem en speelt een belangrijke rol bij de afweer. 
Aangezien recente studies hebben laten zien dat tijdens pre-
eclampsie het complementsysteem geactiveerd is in bijvoorbeeld 
de placenta en het bloed van de moeder, werd de activatie van 
het complementsysteem in nieren van vrouwen met pre-eclampsie 
onderzocht in hoofdstuk 3.  
In de studies beschreven in dit hoofdstuk werd de activatie van 
het complementsysteem onderzocht in de nieren van vrouwen 
die waren overleden aan pre-eclampsie en in de nieren van 
vrouwen die tijdens de zwangerschap waren overleden, maar 
zonder pre-eclampsie. De laatste categorie vrouwen fungeerde 
als controlegroep. In de nieren van vrouwen met pre-eclampsie 
werd altijd complementactivatie gevonden, terwijl dit in een 
veel lager percentage bij de controlegroepen werd gezien. Het 
complementsysteem kan op verschillende manieren geactiveerd 
worden. Deze verschillende manieren worden onderverdeeld in 
drie verschillende ‘ routes’ die alle kunnen leiden tot activatie 
van het complementsysteem. Dit hoofdstuk beschrijft de 
onderzoeken die zijn verricht om uit te zoeken welke route van 
het complementsysteem geactiveerd is in de nieren van vrouwen 
met pre-eclampsie. De onderzoeken in hoofdstuk 3 wijzen erop 
dat de zogenoemde klassieke route  geactiveerd wordt, maar hoe 
deze route precies geactiveerd raakt, was nog niet geheel duidelijk. 
Omdat het onmogelijk is dit mechanisme in de mens te onderzoeken 
werden in dit hoofdstuk ook muizen onderzocht. Muizen die werden 
geïnjecteerd met sFlt-1 lieten meer complementactivatie in de nier 
zien dan muizen zonder sFlt-1. Samengevat, laten de onderzoeken 
in dit hoofdstuk zien dat pre-eclampsie gekenmerkt wordt door 
activatie van de klassieke route van het complementsysteem in de 
nieren. Deze bevinding suggereert dat complementactivatie zou 
kunnen leiden tot een lokale ontstekingsreactie en zo zou kunnen 
bijdragen aan de schade in de nieren bij pre-eclampsie. Bovendien 
zou naar aanleiding van deze resultaten gespeculeerd kunnen 
worden dat remming van complementactivatie een mogelijke 
therapeutische optie zou kunnen zijn om de schade tijdens pre-
eclampsie in de nier te beperken. 
De nierschade tijdens pre-eclampsie werd onderzocht in de studies 
beschreven in hoofdstuk 4. In dit hoofdstuk werden karakteristieke 
afwijkingen gevonden in de nieren van vrouwen met pre-eclampsie, 
namelijk zwelling van endotheelcellen (endotheliose genaamd), 
verdubbeling van de glomerulaire basaalmembraan en zwelling van 
podocyten. Podocyten zijn speciale cellen die deel uit maken van 
de filtratiebarrière. Zij hebben voet-achtige uitlopers, vandaar de 
naam podocyte, aangezien ‘ podo’  in het Latijn voet betekent. Een 
eerdere studie liet zien dat vrouwen met pre-eclampsie podocyten 
verliezen in de urine. Daarom beschrijft dit hoofdstuk of ook het 
aantal podocyten in de nieren van vrouwen met pre-eclampsie 
veranderd is. In andere studies is bovendien ook aangetoond dat 
verlies van podocyten kan leiden tot de aanmaak van ‘nieuwe 
podocyten’ vanuit andere cellen in de glomerulus.  Deze aanmaak 
van ‘nieuwe podocyten’  werd ook onderzocht in dit hoofdstuk 
met behulp van speciale technieken. De resultaten in het hoofdstuk 
laten zien dat het aantal podocyten in de nieren van vrouwen met 
pre-eclampsie niet verschilde met de controlegroepen. Wel werden 
er meer ‘nieuwe podocyten’ gevonden in de nieren van vrouwen 
met pre-eclampsie. Het is dus goed mogelijk dat door het verlies van 
podocyten in de urine, andere cellen uit de glomerulus de verloren 
podocyten vervangen en zo het verlies compenseren. Aan de andere 
kant zouden deze ‘nieuwe podocyten’ ook juist voor schade kunnen 
zorgen. Hoewel toekomstig onderzoek zou moeten uitwijzen welk 
van deze twee mogelijkheden—of beide—van toepassing zijn bij 
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pre-eclampsie, zouden de bevindingen in dit hoofdstuk wel een 
nieuw licht kunnen werpen op de ontstaansmechanismen van de 
nierschade later in het leven bij vrouwen met pre-eclampsie.  
In de hoofdstukken 3 en 4 is duidelijk geworden dat de nier—
en met name de glomerulus—beschadigd raakt tijdens pre-
eclampsie via verschillende mechanismen. Met name door de 
anti-angiogenetische factoren kunnen zowel de glomerulaire 
endotheelcellen als podocyten beschadigd raken. Podocyten die 
ernstig beschadigd zijn kunnen loslaten en op die manier in de 
urine terechtkomen. De toename van verlies van podocyten in de 
urine tijdens pre-eclampsie, ook wel podocyturie genoemd, werd 
onderzocht in de studies beschreven in HOOFDSTUK 5. Eerdere 
studies onderzochten de aanwezigheid van podocyten in urine 
door gebruik te maken van immunohistochemische kleuringen op 
gekweekte podocyten. Aangezien deze methode arbeidsintensief is 
en veel tijd kost, werd in hoofdstuk 5 onderzocht of het meten van 
podocyt-specifieke moleculen—met behulp van een quantitatieve 
polymerase chain reaction (qPCR)—in urine van vrouwen met 
pre-eclampsie en controle vrouwen een betere methode zou zijn. 
In de urine van vrouwen met pre-eclampsie werden veel hogere 
waarden van podocyt-specifieke moleculen gevonden dan in urine 
van gezonde zwangere controle vrouwen en niet-zwangere controle 
vrouwen. Aangezien ook podocyt-specifieke moleculen werden 
gevonden in de controle groepen, lijkt verlies van podocyten in 
urine fysiologisch te zijn. Het is dus goed mogelijk dat zowel 
een normale zwangerschap, als een zwangerschap met hoge 
bloeddruk en een zwangerschap met pre-eclampsie een continue 
spectrum vormen en zo in meer of mindere mate gepaard gaan 
met verlies van podocyten in de urine. Een recente studie laat zien 
dat podocyturie voorafging aan de klinische verschijnselen van 
pre-eclampsie, wat suggereert dat het meten van podocyturie zou 
kunnen voorspellen welke vrouwen een verhoogde kans hebben op 
het ontstaan van pre-eclampsie later tijdens de zwangerschap.
HOOFDSTUK 6 gaat over de mogelijkheden om pre-eclampsie al 
vroeg in de zwangerschap te voorspellen. In dit hoofdstuk werden 
urine-monsters, van vrouwen die elf tot dertien weken zwanger 
waren, onderzocht op de aanwezigheid van bepaalde ‘metabolieten’  
om zo pre-eclampsie te kunnen voorspellen. Metabolieten zijn de 
tussen- of eindproducten die ontstaan nadat een stof stofwisseling 
heeft ondergaan. De samenstelling van verschillende metabolieten 
in het lichaam wordt het ‘metaboloom’ genoemd. Het metaboloom 
is een resultaat van omgevings- en genetische factoren en  kan 
zo inzicht bieden in het ontstaan van bepaalde aandoeningen. 
In hoofdstuk 6 werden urine-monsters geanalyseerd met behulp 
van nuclear magnetic resonance en werd de concentratie van 
36 metabolieten vergeleken tussen zwangere vrouwen die later 
pre-eclampsie ontwikkelden en zwangere vrouwen die een 
ongecompliceerde zwangerschap doormaakten. De etnische afkomst 
van de vrouwen bleek de resultaten sterk te beïnvloeden. Binnen 
de grootste etnische subgroepen—Blanken en Afrikanen—kon 
een specifiek metabolietensamenstelling in de urine worden 
gevonden bij vrouwen die later in de zwangerschap pre-eclampsie 
ontwikkelden. De samenstelling van deze metabolieten in eerste 
trimester urine van vrouwen die later pre-eclampsie ontwikkelen 
zou in de toekomst wellicht gebruikt kunnen worden om pre-
eclampsie te kunnen voorspellen en  zou bovendien inzicht kunnen 
geven in het ontstaan van pre-eclampsie.
 
De bevindingen beschreven in dit proefschrift laten zien dat pre-
eclampsie een ernstige zwangerschapscomplicatie kan zijn, die de 
nodige effecten op de nier heeft.  
Toekomstig onderzoek moet uitwijzen of het behandelen met 
middelen die bijvoorbeeld complementactivatie tegengaan, een 
bijdrage zou kunnen leveren aan de gezondheid van vrouwen met 
pre-eclampsie en hun kinderen tijdens hun zwangerschap en in de 
navolgende jaren. Tevens hebben de studies in dit proefschrift de 
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mogelijkheden verkend om pre-eclampsie te voorspellen met behulp 
van verschillende markers in de urine. Ondanks de veelbelovende 
resultaten zouden deze onderzoeken eerst op uitgebreide schaal 
getest moeten worden voordat het kan worden toegepast in de 
dagelijkse praktijk. Het combineren van verschillende factoren 
in één model om pre-eclampsie te voorspellen, bijvoorbeeld de 
metabolieten in de urine, de leeftijd van de moeder, de Body Mass 
Index en boekingsbloeddruk, lijkt op dit moment de beste resultaten 
te geven. Vrouwen die hierbij een verhoogd risico laten zien op het 
ontwikkelen van pre-eclampsie, kunnen dan vaker worden gezien 
door een verloskundige of gynaecoloog tijdens de zwangerschap, 
om indien nodig, zo snel mogelijk actie te kunnen ondernemen. 
De beschadigingen van de nier tijdens de zwangerschap zouden 
mogelijk kunnen bijdragen aan het verhoogde risico dat vrouwen 
met pre-eclampsie hebben op nierziekten en hart- en vaatziekten. 
Het monitoren van de bloeddruk, glucosewaarden en overgewicht 
na de bevalling bij vrouwen die een zwangerschap met pre-
eclampsie doormaakten zou een eerste stap in de goede richting 
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